pmid,ArticleType,Substance,MeSH,Title,PubDate,Journal,nct_id,pub_source,start_date,primary_completion__date,study_type,brief_title,overall_status,phase,sponsor,why_stopped,days_since_update.x,pubmed_links,ctg_links,Abstract,Registry,Total_pubs,vaccine_trial_flag,Number_of_updates,US_site_flag,country,Has_Results,interventions_normalized
32251729,Clinical Trial Protocol|Journal Article,Antirheumatic Agents|Troponin|Colchicine|NA,"Antirheumatic Agents|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Colchicine|Coronavirus Infections|Heart Diseases|Humans|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Symptom Assessment|Troponin|NA",The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.,2020-07-24,Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese,NCT04326790,Abstract,2020-04-03,2020-08-31,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,Phase 2,National and Kapodistrian University of Athens,NA,332,https://pubmed.ncbi.nlm.nih.gov/32251729,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,0,4,0,Gibraltar,0,colchicine|standard treatment
32304640,Journal Article,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Drug Repositioning|Evidence-Based Medicine|Health Services Needs and Demand|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.,2020-06-29,The Lancet. Respiratory medicine,NCT04315948,Abstract,2020-03-22,2023-03-31,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,"Active, not recruiting",Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,61,https://pubmed.ncbi.nlm.nih.gov/32304640,https://clinicaltrials.gov/ct2/show/NCT04315948,3,0,3,0,7,0,Austria|Belgium|France|Luxembourg|Portugal,0,remdesivir|lopinavir/ritonavir|interferon beta-1a|hydroxychloroquine|standard of care|lopinavir|ritonavir
32330277,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anti-Bacterial Agents|Antiviral Agents|Oseltamivir|chloroquine diphosphate|Azithromycin|Chloroquine|NA,"Adult|Aged|Anti-Bacterial Agents|Antiviral Agents|Azithromycin|Betacoronavirus|Brazil|COVID-19|Chloroquine|Coronavirus Infections|Disease Outbreaks|Dose-Response Relationship, Drug|Double-Blind Method|Female|Humans|Male|Middle Aged|Oseltamivir|Pandemics|Pneumonia, Viral|SARS-CoV-2|Tertiary Care Centers|NA",Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.,2020-04-29,JAMA network open,NCT04323527,Abstract,2020-03-23,2020-05-07,Interventional,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,275,https://pubmed.ncbi.nlm.nih.gov/32330277,https://clinicaltrials.gov/ct2/show/NCT04323527,1,0,1,0,3,0,Brazil,0,chloroquine diphosphate
32356926,Journal Article,"Angiotensin II Type 1 Receptor Blockers|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|ACE2 protein, human|Angiotensin-Converting Enzyme 2|Telmisartan|NA","Angiotensin II Type 1 Receptor Blockers|Angiotensin-Converting Enzyme 2|COVID-19|Clinical Trials, Phase II as Topic|Humans|Lung|Pandemics|Protein Binding|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Telmisartan|Virus Internalization|NA",Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.,2020-12-04,Drug development research,NCT04355936,Abstract,2020-05-19,2020-11-02,Interventional,Telmisartan for Treatment of COVID-19 Patients,Completed,Phase 4,Laboratorio Elea Phoenix S.A.,NA,101,https://pubmed.ncbi.nlm.nih.gov/32356926,https://clinicaltrials.gov/ct2/show/NCT04355936,1,0,1,0,8,0,Argentina,0,telmisartan arm will receive 80 mg telmisartan twice daily/standard care.|telmisartan arm will receive 80 mg telmisartan twice daily|standard care.
32383125,Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|SARS-CoV-2|Severity of Illness Index|NA",Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.,2020-08-24,Canadian journal of anaesthesia = Journal canadien d'anesthesie,NCT04308668,Abstract,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,262,https://pubmed.ncbi.nlm.nih.gov/32383125,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,9,1,United States|Canada,0,hydroxychloroquine|placebo
32386744,Editorial,Antimalarials|NA,"Antimalarials|Betacoronavirus|COVID-19|Coronavirus Infections|Global Health|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?,2020-07-24,Medicina clinica,NCT04321278,Abstract,2020-03-28,2020-06-14,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,NA,78,https://pubmed.ncbi.nlm.nih.gov/32386744,https://clinicaltrials.gov/ct2/show/NCT04321278,2,0,2,0,6,0,Brazil,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin
32391667,Journal Article|Randomized Controlled Trial,"RNA, Viral|Hydroxychloroquine|NA","Betacoronavirus|COVID-19|China|Coronavirus Infections|Humans|Hydroxychloroquine|Pandemics|Pilot Projects|Pneumonia, Viral|RNA, Viral|SARS-CoV-2|Treatment Outcome|NA",[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].,2020-05-12,Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,NCT04261517,Abstract,2020-02-06,2020-02-25,Interventional,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Phase 3,Shanghai Public Health Clinical Center,NA,359,https://pubmed.ncbi.nlm.nih.gov/32391667,https://clinicaltrials.gov/ct2/show/NCT04261517,1,0,1,0,3,0,China,0,hydroxychloroquine
32401715,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Drug Combinations|lopinavir-ritonavir drug combination|Interferon beta-1b|Lopinavir|Ribavirin|Ritonavir|NA,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Drug Therapy, Combination|Female|Hong Kong|Hospitalization|Humans|Interferon beta-1b|Lopinavir|Male|Middle Aged|Pandemics|Pneumonia, Viral|Ribavirin|Ritonavir|SARS-CoV-2|NA","Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.",2020-06-02,"Lancet (London, England)",NCT04276688,Abstract,2020-02-10,2020-03-30,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,NA,355,https://pubmed.ncbi.nlm.nih.gov/32401715,https://clinicaltrials.gov/ct2/show/NCT04276688,2,0,2,0,2,0,Hong Kong,0,lopinavir/ritonavir|ribavirin|interferon beta-1b|lopinavir|ritonavir
32407672,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,NCT04366960,Abstract,2020-05-14,2021-08-31,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Phase 3,Niguarda Hospital,NA,82,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04366960,2,0,2,0,3,0,Italy,0,enoxaparin
32407672,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,NCT04345848,Abstract,2020-04-28,2021-03-31,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Phase 3,"University Hospital, Geneva",NA,103,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04345848,2,0,2,0,3,0,Switzerland,0,enoxaparin
32407672,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,NCT04372589,Abstract,2020-05-20,2021-01-31,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Active, not recruiting",Phase 2/Phase 3,University of Manitoba,NA,65,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04372589,3,0,3,1,4,1,United States|Brazil|Canada|Mexico,0,heparin
32407672,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,NCT04367831,Abstract,2020-05-02,2020-11-30,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Phase 4,Columbia University,NA,321,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04367831,2,0,2,0,2,1,United States,0,enoxaparin prophylactic dose|heparin infusion|heparin sc|enoxaparin/lovenox intermediate dose|enoxaparin|lovenox intermediate dose
32423584,Journal Article|Multicenter Study|Randomized Controlled Trial,Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|China|Coronavirus Infections|Double-Blind Method|Female|Humans|Infusions, Intravenous|Male|Middle Aged|Negative Results|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA","Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.",2020-05-29,"Lancet (London, England)",NCT04257656,Abstract,2020-02-06,2020-03-30,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",355,https://pubmed.ncbi.nlm.nih.gov/32423584,https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,0,3,0,China,0,remdesivir|remdesivir placebo
32425051,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Anti-Infective Agents|Hydroxychloroquine|Azithromycin|NA,"Adult|Anti-Infective Agents|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Monitoring|Female|Humans|Hydroxychloroquine|Male|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|Utah|NA","Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial.",2020-08-13,Annals of the American Thoracic Society,NCT04329832,Abstract,2020-03-30,2020-12-18,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",NA,215,https://pubmed.ncbi.nlm.nih.gov/32425051,https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,0,3,1,United States,0,hydroxychloroquine|azithromycin
32445440,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Adult|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Extracorporeal Membrane Oxygenation|Female|Humans|Kaplan-Meier Estimate|Male|Middle Aged|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Time Factors|Young Adult|NA",Remdesivir for the Treatment of Covid-19 - Final Report.,2020-12-01,The New England journal of medicine,NCT04280705,Abstract,2020-02-21,2020-05-21,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,119,https://pubmed.ncbi.nlm.nih.gov/32445440,https://clinicaltrials.gov/ct2/show/NCT04280705,3,0,3,0,24,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir
32448345,Clinical Trial Protocol|Journal Article,Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|China|Clinical Trials, Phase III as Topic|Coronavirus Infections|Double-Blind Method|Equivalence Trials as Topic|Female|Humans|Infusions, Intravenous|Male|Multicenter Studies as Topic|Pandemics|Patient Safety|Pneumonia, Viral|Risk Assessment|Risk Factors|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA","Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.",2020-05-27,Trials,NCT04257656,Abstract,2020-02-06,2020-03-30,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",355,https://pubmed.ncbi.nlm.nih.gov/32448345,https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,0,3,0,China,0,remdesivir|remdesivir placebo
32450106,"Clinical Trial, Phase I|Journal Article","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Vaccines, Synthetic|Viral Vaccines|NA","Adenoviridae|Adolescent|Adult|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|China|Coronavirus Infections|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunity, Cellular|Immunity, Humoral|Injections, Intramuscular|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|T-Lymphocytes|Vaccines, Synthetic|Viral Vaccines|Young Adult|NA","Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.",2020-06-17,"Lancet (London, England)",NCT04313127,Abstract,2020-03-16,2020-12-30,Interventional,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Phase 1,CanSino Biologics Inc.,NA,322,https://pubmed.ncbi.nlm.nih.gov/32450106,https://clinicaltrials.gov/ct2/show/NCT04313127,1,0,1,1,4,0,China,0,recombinant novel coronavirus vaccine (adenovirus type 5 vector)
32459919,"Clinical Trial, Phase III|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Adult|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Hospitalization|Humans|Male|Middle Aged|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.,2020-12-01,The New England journal of medicine,NCT04292899,Abstract,2020-03-06,2020-04-09,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Phase 3,Gilead Sciences,NA,109,https://pubmed.ncbi.nlm.nih.gov/32459919,https://clinicaltrials.gov/ct2/show/NCT04292899,1,0,1,0,20,1,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard of care
32468508,Clinical Trial Protocol|Journal Article|Multicenter Study, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Immunization, Passive|Pandemics|Plasma|Pneumonia, Viral|SARS-CoV-2|NA",Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.,2020-08-28,Internal and emergency medicine,NCT04321421,Abstract,2020-03-17,2020-04-28,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,NA,311,https://pubmed.ncbi.nlm.nih.gov/32468508,https://clinicaltrials.gov/ct2/show/NCT04321421,3,0,3,0,2,0,Italy,0,hyperimmune plasma
32492293,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Hydroxychloroquine|NA,"Adult|Betacoronavirus|COVID-19|Canada|Coronavirus Infections|Double-Blind Method|Female|Humans|Hydroxychloroquine|Inhalation Exposure|Male|Middle Aged|Occupational Exposure|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|SARS-CoV-2|Treatment Failure|United States|NA",A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,2020-08-12,The New England journal of medicine,NCT04308668,Abstract,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,262,https://pubmed.ncbi.nlm.nih.gov/32492293,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,9,1,United States|Canada,0,hydroxychloroquine|placebo
32492354,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural",Antimalarials|Hydroxychloroquine|NA,"Adult|Antimalarials|Betacoronavirus|COVID-19|Coronavirus Infections|Dose-Response Relationship, Drug|Hospitalization|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|SARS-CoV-2|Single-Blind Method|Treatment Outcome|NA",Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.,2020-09-21,Annals of the American Thoracic Society,NCT04332991,Abstract,2020-04-02,2020-06-19,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,NA,22,https://pubmed.ncbi.nlm.nih.gov/32492354,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,0,9,1,United States,1,hydroxychloroquine|placebo
32493441,Clinical Trial Protocol|Letter,"Anti-Inflammatory Agents|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|IL6 protein, human|IL6R protein, human|Interleukin 1 Receptor Antagonist Protein|Interleukin-1|Interleukin-6|Receptors, Interleukin-6|tocilizumab|siltuximab|NA","Anti-Inflammatory Agents|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Belgium|Betacoronavirus|COVID-19|Clinical Trials, Phase III as Topic|Coronavirus Infections|Drug Therapy, Combination|Host-Pathogen Interactions|Humans|Interleukin 1 Receptor Antagonist Protein|Interleukin-1|Interleukin-6|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Receptors, Interleukin-6|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA",Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.,2020-06-10,Trials,NCT04330638,Abstract,2020-04-03,2020-12-18,Interventional,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Phase 3,"University Hospital, Ghent",NA,33,https://pubmed.ncbi.nlm.nih.gov/32493441,https://clinicaltrials.gov/ct2/show/NCT04330638,1,0,1,0,7,0,Belgium,0,usual care|anakinra|siltuximab|tocilizumab
32493468,Clinical Trial Protocol|Letter,Antiviral Agents|Drug Combinations|lopinavir-ritonavir drug combination|Interferon beta-1b|Lopinavir|Hydroxychloroquine|Ritonavir|Interferon beta-1a|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Drug Therapy, Combination|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Interferon beta-1a|Interferon beta-1b|Iran|Lopinavir|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA","Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.",2020-06-10,Trials,NCT04343768,Abstract,2020-04-09,2020-04-27,Interventional,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Phase 2,Shahid Beheshti University of Medical Sciences,NA,336,https://pubmed.ncbi.nlm.nih.gov/32493468,https://clinicaltrials.gov/ct2/show/NCT04343768,1,0,1,0,3,0,"Iran, Islamic Republic of",0,hydroxychloroquine|lopinavir / ritonavir|interferon beta-1a|interferon beta-1b|lopinavir|ritonavir
32493478,Clinical Trial Protocol|Letter,Antiviral Agents|Hydroxychloroquine|Ascorbic Acid|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Antiviral Agents|Ascorbic Acid|Betacoronavirus|COVID-19|Contact Tracing|Coronavirus Infections|Drug Administration Schedule|Female|Humans|Hydroxychloroquine|Incidence|Male|Middle Aged|Multicenter Studies as Topic|Occupational Exposure|Occupational Health|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|Randomized Controlled Trials as Topic|Risk Assessment|Risk Factors|SARS-CoV-2|Time Factors|Treatment Outcome|United States|Virus Shedding|Young Adult|NA",Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.,2020-06-10,Trials,NCT04328961,Abstract,2020-03-31,2020-09-24,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,NA,158,https://pubmed.ncbi.nlm.nih.gov/32493478,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,0,5,1,United States,0,hydroxychloroquine sulfate|ascorbic acid
32503602,Clinical Trial Protocol|Letter,BCG Vaccine|NA,"Absenteeism|Adult|Aged|Aged, 80 and over|BCG Vaccine|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Health Personnel|Hospitalization|Humans|Male|Middle Aged|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Vaccination|NA",Two Randomized Controlled Trials of Bacillus Calmette-GuÃ©rin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.,2020-06-30,Trials,NCT04328441,Abstract,2020-03-25,2021-03-31,Interventional,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Phase 3,UMC Utrecht,NA,231,https://pubmed.ncbi.nlm.nih.gov/32503602,https://clinicaltrials.gov/ct2/show/NCT04328441,1,0,1,1,3,0,Netherlands,0,bcg vaccine|placebo
32503620,Clinical Trial Protocol|Letter,Drug Combinations|lopinavir-ritonavir drug combination|Lopinavir|Ritonavir|Colchicine|NA,"Betacoronavirus|COVID-19|Colchicine|Coronavirus Infections|Double-Blind Method|Drug Combinations|Hospitalization|Humans|Lopinavir|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|NA",Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.,2020-06-30,Trials,NCT04360980,Abstract,2020-03-20,2021-09-01,Interventional,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Phase 2,Shahid Beheshti University of Medical Sciences,NA,94,https://pubmed.ncbi.nlm.nih.gov/32503620,https://clinicaltrials.gov/ct2/show/NCT04360980,1,0,1,0,3,0,"Iran, Islamic Republic of",0,colchicine tablets
32503657,Clinical Trial Protocol|Letter,"Amides|Antiviral Agents|Pyrazines|RNA, Viral|favipiravir|NA","Adolescent|Adult|Aged|Aged, 80 and over|Amides|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Pyrazines|RNA, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|Young Adult|NA","The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.",2020-06-30,Trials,NCT04333589,Abstract,2020-04-01,2020-06-01,Interventional,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,N/A,Peking University First Hospital,NA,346,https://pubmed.ncbi.nlm.nih.gov/32503657,https://clinicaltrials.gov/ct2/show/NCT04333589,1,0,1,0,2,0,China,0,favipiravir
32503662,Clinical Trial Protocol|Letter,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Norway|Pandemics|Pneumonia, Viral|Pragmatic Clinical Trials as Topic|Research Design|SARS-CoV-2|Viral Load|NA",Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.,2020-06-30,Trials,NCT04316377,Abstract,2020-03-25,2020-05-25,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",NA,303,https://pubmed.ncbi.nlm.nih.gov/32503662,https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,0,3,0,Norway,0,hydroxychloroquine sulfate
32503663,Clinical Trial Protocol|Letter,Recombinant Proteins|sargramostim|Granulocyte-Macrophage Colony-Stimulating Factor|Oxygen|NA,"Acute Disease|Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|Clinical Trials, Phase IV as Topic|Coronavirus Infections|Female|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Male|Middle Aged|Oxygen|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Recombinant Proteins|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Young Adult|NA",Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.,2020-06-30,Trials,NCT04326920,Abstract,2020-03-24,2020-09-28,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),Completed,Phase 4,"University Hospital, Ghent",NA,33,https://pubmed.ncbi.nlm.nih.gov/32503663,https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,0,5,0,Belgium,0,sargramostim|control
32511534,Preprint, , ,Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2).,2020-09-28,medRxiv : the preprint server for health sciences,NCT04306393,Abstract,2020-03-21,2021-03-21,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Phase 2,Massachusetts General Hospital,NA,267,https://pubmed.ncbi.nlm.nih.gov/32511534,https://clinicaltrials.gov/ct2/show/NCT04306393,2,0,2,0,7,1,United States,0,nitric oxide gas
32512291,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't",Angiotensin II Type 1 Receptor Blockers|Placebos|Valsartan|NA,"Adult|Angiotensin II Type 1 Receptor Blockers|Betacoronavirus|COVID-19|Coronary Care Units|Coronavirus Infections|Double-Blind Method|Drug Administration Schedule|Humans|Inpatients|Multicenter Studies as Topic|Netherlands|Pandemics|Placebos|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Time Factors|Valsartan|NA","Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.",2020-08-26,American heart journal,NCT04335786,Abstract,2020-04-17,2020-12-31,Interventional,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Phase 4,Radboud University,NA,299,https://pubmed.ncbi.nlm.nih.gov/32512291,https://clinicaltrials.gov/ct2/show/NCT04335786,1,0,1,0,6,0,Netherlands,0,valsartan (diovan)|placebo oral tablet
32513231,Clinical Trial Protocol|Letter,Thiazoles|Hydroxychloroquine|nitazoxanide|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|Prognosis|Randomized Controlled Trials as Topic|Respiration, Artificial|Risk Factors|SARS-CoV-2|Single-Blind Method|Thiazoles|NA",Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial.,2020-06-30,Trials,NCT04341493,Abstract,2020-04-06,2020-08-30,Interventional,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Recruiting,Phase 4,Materno-Perinatal Hospital of the State of Mexico,NA,346,https://pubmed.ncbi.nlm.nih.gov/32513231,https://clinicaltrials.gov/ct2/show/NCT04341493,1,0,1,0,3,0,Mexico,0,nitazoxanide 500 mg|hydroxychloroquine
32513299,Clinical Trial Protocol|Letter,"Antiviral Agents|Drugs, Chinese Herbal|anluohuaxian|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drugs, Chinese Herbal|Female|Humans|Lung|Male|Middle Aged|Multicenter Studies as Topic|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|Walking|Young Adult|NA","Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.",2020-06-30,Trials,NCT04334265,Abstract,2020-04-01,2020-06-01,Interventional,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,346,https://pubmed.ncbi.nlm.nih.gov/32513299,https://clinicaltrials.gov/ct2/show/NCT04334265,1,0,1,0,1,0,China,0,anluohuaxian
32513308,Clinical Trial Protocol|Letter,"Antibodies, Viral|NA","Adult|Antibodies, Viral|Betacoronavirus|COVID-19|Clinical Trials, Phase II as Topic|Coronavirus Infections|Humans|Immunization, Passive|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|NA",Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.,2020-06-30,Trials,NCT04359810,Abstract,2020-04-21,2020-12-31,Interventional,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Phase 2,Columbia University,NA,142,https://pubmed.ncbi.nlm.nih.gov/32513308,https://clinicaltrials.gov/ct2/show/NCT04359810,1,0,1,0,3,1,United States|Brazil,0,convalescent plasma (anti-sars-cov-2 plasma)|non-convalescent plasma (control plasma)
32518419,"Journal Article|Research Support, Non-U.S. Gov't","Anti-Inflammatory Agents|Cytokines|INCB018424|Protein Kinase Inhibitors|Pyrazoles|JAK1 protein, human|JAK2 protein, human|Janus Kinase 1|Janus Kinase 2|NA","Adult|Aged|Aged, 80 and over|Anti-Inflammatory Agents|Betacoronavirus|COVID-19|Clinical Trials as Topic|Coronavirus Infections|Cytokine Release Syndrome|Cytokines|Drug Administration Schedule|Female|Gene Expression Regulation|Humans|Immunity, Innate|Inflammation|Janus Kinase 1|Janus Kinase 2|Male|Middle Aged|Pandemics|Patient Safety|Pneumonia, Viral|Protein Kinase Inhibitors|Pyrazoles|Retrospective Studies|SARS-CoV-2|Severe Acute Respiratory Syndrome|T-Lymphocytes|Treatment Outcome|NA",The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.,2020-07-14,Leukemia,NCT04338958,Abstract,2020-04-22,2021-07-31,Interventional,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Phase 2,University of Jena,NA,66,https://pubmed.ncbi.nlm.nih.gov/32518419,https://clinicaltrials.gov/ct2/show/NCT04338958,1,0,1,0,4,0,Germany,0,ruxolitinib
32522282,Clinical Trial Protocol|Letter,Antiviral Agents|Hydroxychloroquine|Azithromycin|NA,"Antiviral Agents|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Care|Denmark|Double-Blind Method|Drug Administration Schedule|Hospital Mortality|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Inpatients|Length of Stay|Multicenter Studies as Topic|Noninvasive Ventilation|Pandemics|Patient Admission|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA",Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.,2020-06-17,Trials,NCT04322396,Abstract,2020-04-06,2021-02-02,Interventional,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Completed,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",NA,52,https://pubmed.ncbi.nlm.nih.gov/32522282,https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,0,4,0,Denmark,0,azithromycin|hydroxychloroquine|placebo oral tablet
32532356,"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter", ,"Adolescent|Adult|Aged|Betacoronavirus|COVID-19|Coronavirus Infections|Dental Pulp|Female|Humans|Male|Middle Aged|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Stem Cell Transplantation|Transplantation, Homologous|Young Adult|NA",Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).,2020-06-22,Trials,NCT04336254,Abstract,2020-05-06,2021-11-30,Interventional,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Phase 1/Phase 2,Renmin Hospital of Wuhan University,NA,26,https://pubmed.ncbi.nlm.nih.gov/32532356,https://clinicaltrials.gov/ct2/show/NCT04336254,1,0,1,0,1,0,China,0,allogeneic human dental pulp stem cells (bsh btc/utooth btc)|intravenous saline injection (placebo)|allogeneic human dental pulp stem cells (bsh btc|utooth btc)
32554923,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review", ,"Betacoronavirus|Blood Coagulation|COVID-19|Complement Activation|Coronavirus Infections|Endothelial Cells|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",The complement system in COVID-19: friend and foe?,2020-08-17,JCI insight,NCT04369469,Abstract,2020-05-11,2021-05-31,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"Active, not recruiting",Phase 3,Alexion Pharmaceuticals,NA,60,https://pubmed.ncbi.nlm.nih.gov/32554923,https://clinicaltrials.gov/ct2/show/NCT04369469,2,0,2,0,8,1,United States|France|Japan|Spain|United Kingdom,0,ravulizumab|best supportive care
32555385,Journal Article|Review, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Immunity, Mucosal|Inflammatory Bowel Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",IBD in the time of corona - vigilance for immune-mediated diseases.,2020-09-08,Nature reviews. Gastroenterology &amp; hepatology,NCT04276688,Abstract,2020-02-10,2020-03-30,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,NA,355,https://pubmed.ncbi.nlm.nih.gov/32555385,https://clinicaltrials.gov/ct2/show/NCT04276688,2,0,2,0,2,0,Hong Kong,0,lopinavir/ritonavir|ribavirin|interferon beta-1b|lopinavir|ritonavir
32555385,Journal Article|Review, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Immunity, Mucosal|Inflammatory Bowel Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",IBD in the time of corona - vigilance for immune-mediated diseases.,2020-09-08,Nature reviews. Gastroenterology &amp; hepatology,NCT04354259,Abstract,2020-05-13,2020-08-01,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,325,https://pubmed.ncbi.nlm.nih.gov/32555385,https://clinicaltrials.gov/ct2/show/NCT04354259,3,0,3,0,1,0,Canada,0,peginterferon lambda-1a|placebo
32559419,"Journal Article|Research Support, Non-U.S. Gov't|Review",Immunologic Factors|Granulocyte-Macrophage Colony-Stimulating Factor|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Disease Progression|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Immunologic Factors|Immunomodulation|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA",Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.,2020-08-31,The Lancet. Respiratory medicine,NCT04326920,Abstract,2020-03-24,2020-09-28,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),Completed,Phase 4,"University Hospital, Ghent",NA,33,https://pubmed.ncbi.nlm.nih.gov/32559419,https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,0,5,0,Belgium,0,sargramostim|control
32560746,Clinical Trial Protocol|Letter|Multicenter Study,Aerosols|Recombinant Proteins|Deoxyribonuclease I|dornase alfa|NA,"Adult|Aerosols|Betacoronavirus|COVID-19|Coronavirus Infections|Deoxyribonuclease I|Humans|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Recombinant Proteins|Respiratory Distress Syndrome|SARS-CoV-2|Trachea|NA",Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial.,2020-07-07,Trials,NCT04355364,Abstract,2020-04-21,2020-11-21,Interventional,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,122,https://pubmed.ncbi.nlm.nih.gov/32560746,https://clinicaltrials.gov/ct2/show/NCT04355364,1,0,1,0,7,0,France,0,dornase alfa inhalation solution [pulmozyme]|standard procedure
32579195,Journal Article|Randomized Controlled Trial,Fibrin Fibrinogen Degradation Products|Troponin|Tubulin Modulators|fibrin fragment D|C-Reactive Protein|Colchicine|NA,"Aged|Aged, 80 and over|Betacoronavirus|C-Reactive Protein|COVID-19|Cause of Death|Colchicine|Coronavirus Infections|Diarrhea|Disease Progression|Female|Fibrin Fibrinogen Degradation Products|Greece|Hospitalization|Humans|Inflammation|Kaplan-Meier Estimate|Male|Middle Aged|Mortality|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Time Factors|Treatment Outcome|Troponin|Tubulin Modulators|NA",Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.,2020-07-02,JAMA network open,NCT04326790,Abstract,2020-04-03,2020-08-31,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,Phase 2,National and Kapodistrian University of Athens,NA,332,https://pubmed.ncbi.nlm.nih.gov/32579195,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,0,4,0,Gibraltar,0,colchicine|standard treatment
32586395,Clinical Trial Protocol|Letter, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Intensive Care Units|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Vagus Nerve Stimulation|NA","A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCoreÂ®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial&quot;.",2020-07-07,Trials,NCT04368156,Abstract,2020-04-20,2021-02-23,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"Active, not recruiting",N/A,Hospital ClÃ­nico Universitario de Valencia,NA,50,https://pubmed.ncbi.nlm.nih.gov/32586395,https://clinicaltrials.gov/ct2/show/NCT04368156,1,0,1,0,1,0,Spain,0,gammacoreâ® (vagus nerve stimulation)|gammacoreâ® (vagus nerve stimulation)
32586399,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter|Multicenter Study",Triiodothyronine|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Double-Blind Method|Extracorporeal Membrane Oxygenation|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Triiodothyronine|Young Adult|NA",Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.,2020-07-07,Trials,NCT04348513,Abstract,2020-05-29,2021-05-02,Interventional,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,309,https://pubmed.ncbi.nlm.nih.gov/32586399,https://clinicaltrials.gov/ct2/show/NCT04348513,1,0,1,0,1,0,Greece,0,t3 solution for injection|placebo
32613089,Journal Article, , ,Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.,2020-09-28,Clinical and translational radiation oncology,NCT04380818,Abstract,2020-06-05,2021-05-04,Interventional,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,N/A,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,NA,290,https://pubmed.ncbi.nlm.nih.gov/32613089,https://clinicaltrials.gov/ct2/show/NCT04380818,1,0,1,0,2,0,Spain,0,low-dose radiotherapy|hydroxychloroquine sulfate|ritonavir/lopinavir|tocilizumab injection [actemra]|azithromycin|corticosteroid|low molecular weight heparin|oxygen supply|ritonavir|lopinavir
32616063,Clinical Trial Protocol|Letter,Antiviral Agents|Hydroxychloroquine|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Chemoprevention|Coronavirus Infections|Double-Blind Method|Drug Administration Schedule|Female|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Pregnancy|Pregnancy Complications, Infectious|Protective Factors|Randomized Controlled Trials as Topic|Risk Assessment|Risk Factors|SARS-CoV-2|Severity of Illness Index|Spain|Time Factors|Treatment Outcome|Virus Shedding|NA",Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.,2020-07-10,Trials,NCT04410562,Abstract,2020-05-13,2021-05-13,Interventional,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,Phase 3,Barcelona Institute for Global Health,NA,73,https://pubmed.ncbi.nlm.nih.gov/32616063,https://clinicaltrials.gov/ct2/show/NCT04410562,1,0,1,0,1,0,Spain,0,hydroxychloroquine|placebo
32618282,Journal Article|Comment, ,"Betacoronavirus|COVID-19|Humans|Pandemics|Pneumonia, Viral|NA",Testing COVID-19 therapies to prevent progression of mild disease.,2020-12-04,The Lancet. Infectious diseases,NCT04307693,Abstract,2020-03-11,2020-04-30,Interventional,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Phase 2,Asan Medical Center,Terminated early because no patients were further enrolled since mid-Apr 2020.,313,https://pubmed.ncbi.nlm.nih.gov/32618282,https://clinicaltrials.gov/ct2/show/NCT04307693,1,0,1,0,2,0,"Korea, Republic of",0,lopinavir/ritonavir|hydroxychloroquine sulfate|lopinavir|ritonavir
32627860,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Adult|Allied Health Personnel|Cognitive Behavioral Therapy|Female|Health Personnel|Humans|Male|Middle Aged|Mindfulness|Occupational Diseases|Randomized Controlled Trials as Topic|Resilience, Psychological|Stress, Psychological|NA",Psychological interventions to foster resilience in healthcare professionals.,2020-09-25,The Cochrane database of systematic reviews,NCT04368676,Abstract,2020-06-25,2022-06-30,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,"Active, not recruiting",Early Phase 1,Lawson Health Research Institute,NA,10,https://pubmed.ncbi.nlm.nih.gov/32627860,https://clinicaltrials.gov/ct2/show/NCT04368676,2,0,2,0,3,0,Canada,0,sudarshan kriya yoga (sky)|health enhancement program
32641154,"Clinical Trial Protocol|Clinical Trial, Phase IV|Letter","Antibodies, Monoclonal, Humanized|Azetidines|Immunologic Factors|Sulfonamides|ravulizumab|baricitinib|NA","Antibodies, Monoclonal, Humanized|Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Repositioning|Humans|Immunologic Factors|Intensive Care Units|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Sulfonamides|NA",Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.,2020-07-14,Trials,NCT04390464,Abstract,2020-05-08,2021-05-07,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Phase 4,Cambridge University Hospitals NHS Foundation Trust,NA,324,https://pubmed.ncbi.nlm.nih.gov/32641154,https://clinicaltrials.gov/ct2/show/NCT04390464,1,0,1,0,1,0,United Kingdom,0,ravulizumab|baricitinib|standard of care
32641163,Clinical Trial Protocol|Journal Article|Multicenter Study,Hydroxychloroquine|Azithromycin|NA,"Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Drug Therapy, Combination|Humans|Hydroxychloroquine|Intensive Care Units|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|NA",Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.,2020-07-14,Trials,NCT04339816,Abstract,2020-05-13,2020-11-04,Interventional,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Phase 3,"Charles University, Czech Republic",Steering Committee decision in accordance with stopping rule 1: Emergence of new data,149,https://pubmed.ncbi.nlm.nih.gov/32641163,https://clinicaltrials.gov/ct2/show/NCT04339816,1,0,1,0,3,0,Czechia,0,azithromycin|hydroxychloroquine|placebo
32641343,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Vitamins|Ascorbic Acid|NA,"Administration, Intravenous|Ascorbic Acid|Betacoronavirus|COVID-19|China|Coronavirus Infections|Cytokine Release Syndrome|Hospital Mortality|Humans|Intensive Care Units|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|Vitamins|NA",Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial.,2020-07-17,BMJ open,NCT04264533,Abstract,2020-02-14,2020-03-02,Interventional,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Phase 2,Zhongnan Hospital,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19
    patients decreased with the control of the epidemic so that we had to stop our trial before
    reaching the predefined sample size.",177,https://pubmed.ncbi.nlm.nih.gov/32641343,https://clinicaltrials.gov/ct2/show/NCT04264533,1,0,1,0,2,0,China,0,vc|sterile water for injection
32648959,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Betacoronavirus|COVID-19|Cause of Death|Coronavirus Infections|Early Termination of Clinical Trials|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Selection Bias|Severity of Illness Index|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-07-22,The Cochrane database of systematic reviews,NCT04321421,Abstract,2020-03-17,2020-04-28,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,NA,311,https://pubmed.ncbi.nlm.nih.gov/32648959,https://clinicaltrials.gov/ct2/show/NCT04321421,3,0,3,0,2,0,Italy,0,hyperimmune plasma
32658300,Journal Article, ,"Acute Kidney Injury|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",[COVID-19 and kidney disease].,2020-07-20,Lakartidningen,NCT04335123,Abstract,2020-04-04,2020-06-21,Interventional,Study of Open Label Losartan in COVID-19,Completed,Phase 1,University of Kansas Medical Center,NA,152,https://pubmed.ncbi.nlm.nih.gov/32658300,https://clinicaltrials.gov/ct2/show/NCT04335123,1,0,1,0,3,1,United States,0,losartan
32658300,Journal Article, ,"Acute Kidney Injury|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",[COVID-19 and kidney disease].,2020-07-20,Lakartidningen,NCT04312009,Abstract,2020-04-13,2021-02-01,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,50,https://pubmed.ncbi.nlm.nih.gov/32658300,https://clinicaltrials.gov/ct2/show/NCT04312009,1,0,1,0,13,1,United States,0,losartan|placebo
32658300,Journal Article, ,"Acute Kidney Injury|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",[COVID-19 and kidney disease].,2020-07-20,Lakartidningen,NCT04311177,Abstract,2020-04-09,2021-02-01,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,50,https://pubmed.ncbi.nlm.nih.gov/32658300,https://clinicaltrials.gov/ct2/show/NCT04311177,1,0,1,0,10,1,United States,0,losartan|placebo
32660611,Clinical Trial Protocol|Letter,"Antibodies, Monoclonal, Humanized|Antiviral Agents|Complement Inactivating Agents|ravulizumab|NA","Administration, Intravenous|Antibodies, Monoclonal, Humanized|Antiviral Agents|Betacoronavirus|COVID-19|Clinical Trials, Phase III as Topic|Complement Inactivating Agents|Coronavirus Infections|Female|Host-Pathogen Interactions|Humans|Male|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Time Factors|Treatment Outcome|NA","A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.",2020-07-15,Trials,NCT04369469,Abstract,2020-05-11,2021-05-31,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"Active, not recruiting",Phase 3,Alexion Pharmaceuticals,NA,60,https://pubmed.ncbi.nlm.nih.gov/32660611,https://clinicaltrials.gov/ct2/show/NCT04369469,2,0,2,0,8,1,United States|France|Japan|Spain|United Kingdom,0,ravulizumab|best supportive care
32663912,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|RNA, Messenger|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|mRNA-1273 vaccine|NA","Adult|Antibodies, Neutralizing|Antibodies, Viral|Antibody Formation|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunization, Secondary|Male|Pandemics|Pneumonia, Viral|RNA, Messenger|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|Viral Vaccines|Young Adult|NA",An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.,2020-11-16,The New England journal of medicine,NCT04283461,Abstract,2020-03-16,2022-11-22,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,9,https://pubmed.ncbi.nlm.nih.gov/32663912,https://clinicaltrials.gov/ct2/show/NCT04283461,2,0,2,1,19,1,United States,0,mrna-1273
32665041,"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter", ,"Betacoronavirus|COVID-19|Coronavirus Infections|Education, Distance|Feasibility Studies|Humans|Long-Term Care|Mind-Body Therapies|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiration|SARS-CoV-2|Yoga|NA",Breath Regulation and yogic Exercise An online Therapy for calm and Happiness (BREATH) for frontline hospital and long-term care home staff managing the COVID-19 pandemic: A structured summary of a study protocol for a feasibility study for a randomised controlled trial.,2020-08-18,Trials,NCT04368676,Abstract,2020-06-25,2022-06-30,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,"Active, not recruiting",Early Phase 1,Lawson Health Research Institute,NA,10,https://pubmed.ncbi.nlm.nih.gov/32665041,https://clinicaltrials.gov/ct2/show/NCT04368676,2,0,2,0,3,0,Canada,0,sudarshan kriya yoga (sky)|health enhancement program
32671131,Journal Article, , ,Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.,2020-09-28,Open forum infectious diseases,NCT04252274,Abstract,2020-01-30,2020-08-31,Interventional,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Phase 3,Shanghai Public Health Clinical Center,NA,359,https://pubmed.ncbi.nlm.nih.gov/32671131,https://clinicaltrials.gov/ct2/show/NCT04252274,1,0,1,0,2,0,China,0,darunavir/cobicistat|darunavir|cobicistat
32673060,Journal Article|Multicenter Study|Randomized Controlled Trial,Antimalarials|Hydroxychloroquine|NA,"Adult|Antimalarials|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Female|Follow-Up Studies|Humans|Hydroxychloroquine|Male|Middle Aged|Outpatients|Pandemics|Pneumonia, Viral|Retrospective Studies|Risk Factors|SARS-CoV-2|Time Factors|NA",Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.,2020-10-27,Annals of internal medicine,NCT04308668,Abstract,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,262,https://pubmed.ncbi.nlm.nih.gov/32673060,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,9,1,United States|Canada,0,hydroxychloroquine|placebo
32676976,Journal Article|Randomized Controlled Trial,"Drugs, Chinese Herbal|Interferon-alpha|Lopinavir|NA","Administration, Inhalation|Adult|COVID-19|China|Coronavirus Infections|Dose-Response Relationship, Drug|Drug Administration Schedule|Drugs, Chinese Herbal|Female|Follow-Up Studies|Humans|Integrative Medicine|Interferon-alpha|Lopinavir|Male|Middle Aged|Pandemics|Pneumonia, Viral|Risk Assessment|Severe Acute Respiratory Syndrome|Severity of Illness Index|Survival Rate|NA",Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.,2020-09-08,Chinese journal of integrative medicine,NCT04251871,Abstract,2020-01-22,2021-01-22,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,N/A,Beijing 302 Hospital,NA,334,https://pubmed.ncbi.nlm.nih.gov/32676976,https://clinicaltrials.gov/ct2/show/NCT04251871,2,0,2,0,1,0,China,0,"conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,|lopinavir|ritonavir)|traditional chinese medicines (tcms) granules"
32678530,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial,Anti-Infective Agents|Glucocorticoids|Dexamethasone|NA,"Administration, Oral|Aged|Aged, 80 and over|Anti-Infective Agents|COVID-19|Dexamethasone|Drug Therapy, Combination|Female|Glucocorticoids|Hospitalization|Humans|Injections, Intravenous|Kaplan-Meier Estimate|Length of Stay|Male|Odds Ratio|Oxygen Inhalation Therapy|Respiration, Artificial|United Kingdom|NA",Dexamethasone in Hospitalized Patients with Covid-19.,2021-03-01,The New England journal of medicine,NCT04381936,Abstract,2020-03-19,2021-12-31,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,37,https://pubmed.ncbi.nlm.nih.gov/32678530,https://clinicaltrials.gov/ct2/show/NCT04381936,2,2,4,0,8,0,Indonesia|Nepal|United Kingdom,0,lopinavir-ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine|baricitinib|anakinra|dimethyl fumarate
32690074,Clinical Trial Protocol|Letter|Multicenter Study,Budesonide|NA,"Betacoronavirus|Budesonide|COVID-19|Coronavirus Infections|Humans|Olfaction Disorders|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|NA",Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.,2020-08-18,Trials,NCT04361474,Abstract,2020-05-18,2020-11-24,Interventional,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,130,https://pubmed.ncbi.nlm.nih.gov/32690074,https://clinicaltrials.gov/ct2/show/NCT04361474,1,0,1,0,4,0,France,0,budesonide nasal|physiological serum
32702298,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Analgesics, Non-Narcotic|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|Acetaminophen|NA","Acetaminophen|Adenoviruses, Simian|Adult|Analgesics, Non-Narcotic|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Genetic Vectors|Humans|Immunization, Secondary|Immunoglobulin G|Male|Pandemics|Pneumonia, Viral|SARS-CoV-2|Single-Blind Method|Spike Glycoprotein, Coronavirus|T-Lymphocytes|United Kingdom|Viral Vaccines|NA","Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.",2020-08-24,"Lancet (London, England)",NCT04324606,Abstract,2020-04-23,2021-10-31,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,12,https://pubmed.ncbi.nlm.nih.gov/32702298,https://clinicaltrials.gov/ct2/show/NCT04324606,4,0,4,1,13,0,United Kingdom,0,chadox1 ncov-19|menacwy|chadox1 ncov-19 full boost|chadox1 ncov-19 half boost|menacwy boost|paracetamol|chadox1 ncov-19 0.5ml boost|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine (lv)|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine two (lvt)
32702299,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|NA","Adenoviridae|Adolescent|Adult|Age Factors|Aged|Aged, 80 and over|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|China|Coronavirus Infections|Double-Blind Method|Female|Genetic Vectors|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|Viral Vaccines|Young Adult|NA","Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.",2020-08-24,"Lancet (London, England)",NCT04341389,Abstract,2020-04-12,2021-01-31,Interventional,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,324,https://pubmed.ncbi.nlm.nih.gov/32702299,https://clinicaltrials.gov/ct2/show/NCT04341389,1,0,1,1,3,0,China,0,recombinant novel coronavirus vaccine (adenovirus type 5 vector)|placebo
32706953,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|Azithromycin|NA,"Adult|Aged|Aged, 80 and over|Antiviral Agents|Azithromycin|Betacoronavirus|Brazil|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Treatment Failure|NA",Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.,2020-12-01,The New England journal of medicine,NCT04322123,Abstract,2020-04-01,2020-08-30,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Phase 3,Hospital do Coracao,NA,310,https://pubmed.ncbi.nlm.nih.gov/32706953,https://clinicaltrials.gov/ct2/show/NCT04322123,1,0,1,0,6,0,Brazil,0,hydroxychloroquine oral product|hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin
32727613,Clinical Trial Protocol|Letter|Multicenter Study,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Health Personnel|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|Pre-Exposure Prophylaxis|Randomized Controlled Trials as Topic|SARS-CoV-2|NA","Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.",2020-08-18,Trials,NCT04331834,Abstract,2020-04-03,2020-06-25,Interventional,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,Completed,Phase 3,Barcelona Institute for Global Health,NA,47,https://pubmed.ncbi.nlm.nih.gov/32727613,https://clinicaltrials.gov/ct2/show/NCT04331834,1,0,1,0,3,0,Spain,0,hydroxychloroquine|placebos
32736592,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Letter","2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol|Benzhydryl Compounds|Glucosides|Immunologic Factors|Phenylpropionates|Pyridazines|ambrisentan|NA","Benzhydryl Compounds|Betacoronavirus|COVID-19|Coronavirus Infections|Glucosides|Humans|Immunologic Factors|Intensive Care Units|Pandemics|Phenylpropionates|Pneumonia, Viral|Pyridazines|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Standard of Care|NA",muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.,2020-08-18,Trials,NCT04393246,Abstract,2020-07-03,2022-02-15,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,16,https://pubmed.ncbi.nlm.nih.gov/32736592,https://clinicaltrials.gov/ct2/show/NCT04393246,1,0,1,0,3,0,United Kingdom,0,edp1815|dapagliflozin|ambrisentan|standard of care
32736597,Clinical Trial Protocol|Comparative Study|Journal Article|Observational Study,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Cluster Analysis|Coronavirus Infections|Female|Humans|Hydroxychloroquine|Male|Pandemics|Patient Reported Outcome Measures|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Telemedicine|NA",PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.,2020-08-18,Trials,NCT04363827,Abstract,2020-05-14,2021-06-30,Interventional,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,51,https://pubmed.ncbi.nlm.nih.gov/32736597,https://clinicaltrials.gov/ct2/show/NCT04363827,1,0,1,0,3,0,Italy,0,hydroxychloroquine
32738255,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Viral|Spike Glycoprotein, Coronavirus|NA","Animals|Antibodies, Viral|Betacoronavirus|COVID-19|Chlorocebus aethiops|Coronavirus Infections|Enzyme-Linked Immunosorbent Assay|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|Spike Glycoprotein, Coronavirus|Vero Cells|Viral Plaque Assay|NA",An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.,2020-09-07,Antiviral research,NCT04433910,Abstract,2020-08-30,2021-01-21,Interventional,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,Completed,Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,18,https://pubmed.ncbi.nlm.nih.gov/32738255,https://clinicaltrials.gov/ct2/show/NCT04433910,1,0,1,0,4,0,Germany,0,convalesscent plasma
32738928,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,NCT04377711,Abstract,2020-06-08,2020-09-01,Interventional,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Recruiting,Phase 3,Covis Pharma S.Ã .r.l.,NA,298,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04377711,1,0,1,0,2,1,United States,0,ciclesonide|placebo
32738928,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,NCT04330586,Abstract,2020-04-01,2021-03-31,Interventional,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Phase 2,Korea University Guro Hospital,NA,58,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04330586,1,0,1,0,2,0,"Korea, Republic of",0,ciclesonide metered dose inhaler [alvesco]
32738928,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,NCT04416399,Abstract,2020-07-16,2021-01-12,Interventional,STerOids in COVID-19 Study,Terminated,Phase 2,University of Oxford,Independent statistical review advice,59,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04416399,1,0,1,0,4,0,United Kingdom,0,budesonide dry powder inhaler
32738928,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,NCT04331470,Abstract,2020-04-04,2020-04-20,Interventional,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Fasa University of Medical Sciences,NA,359,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04331470,1,0,1,0,2,0,"Iran, Islamic Republic of",0,levamisole pill / budesonide/formoterol inhaler|lopinavir/ritonavir / hydoxychloroquine|levamisole pill|budesonide|formoterol inhaler|lopinavir|ritonavir|hydoxychloroquine
32738928,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,NCT04355637,Abstract,2020-04-21,2021-08-31,Interventional,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Phase 4,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,82,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04355637,1,0,1,0,4,0,Argentina|Spain,0,inhaled budesonide
32758441,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Disease Transmission, Infectious|Humans|Masks|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Use of facemasks during the COVID-19 pandemic.,2020-10-13,The Lancet. Respiratory medicine,NCT04296643,Abstract,2020-04-01,2021-02-01,Interventional,Medical Masks vs N95 Respirators for COVID-19,Recruiting,N/A,McMaster University,NA,53,https://pubmed.ncbi.nlm.nih.gov/32758441,https://clinicaltrials.gov/ct2/show/NCT04296643,1,0,1,0,2,0,Canada|Israel,0,medical mask|n95 respirator
32771032,Clinical Trial Protocol|Letter|Multicenter Study|Observational Study|Randomized Controlled Trial,Oseltamivir|Hydroxychloroquine|Azithromycin|NA,"Azithromycin|Betacoronavirus|COVID-19|Comorbidity|Coronavirus Infections|Humans|Hydroxychloroquine|Oseltamivir|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Research Design|SARS-CoV-2|NA","Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.",2020-08-17,Trials,NCT04338698,Abstract,2020-04-22,2020-09-01,Interventional,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Phase 3,University of Health Sciences Lahore,NA,265,https://pubmed.ncbi.nlm.nih.gov/32771032,https://clinicaltrials.gov/ct2/show/NCT04338698,1,0,1,0,2,0,Pakistan,0,hydroxychloroquine|oseltamivir|azithromycin
32771034,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter", ,"Adolescent|Adult|Aged|Betacoronavirus|COVID-19|Coronavirus Infections|Dietary Supplements|Humans|Middle Aged|Nigella sativa|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|Standard of Care|Young Adult|NA","Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial.",2020-08-17,Trials,NCT04401202,Abstract,2020-05-21,2020-12-31,Interventional,Nigella Sativa in COVID-19,Recruiting,Phase 2,King Abdulaziz University,NA,316,https://pubmed.ncbi.nlm.nih.gov/32771034,https://clinicaltrials.gov/ct2/show/NCT04401202,1,0,1,0,0,0,Saudi Arabia,0,nigella sativa
32779705,Clinical Trial|Journal Article,"Antibodies, Neutralizing|Antibodies, Viral|Immunoglobulin G|RNA, Viral|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|NA","Adult|Aged|Aged, 80 and over|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|Blood Donors|COVID-19|Cohort Studies|Coronavirus Infections|Female|Humans|Immunization, Passive|Immunoglobulin G|Male|Middle Aged|New Mexico|Pandemics|Pneumonia, Viral|RNA, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Treatment Outcome|NA",Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.,2020-11-02,The Journal of infectious diseases,NCT04434131,Abstract,2020-04-28,2021-04-28,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,NA,293,https://pubmed.ncbi.nlm.nih.gov/32779705,https://clinicaltrials.gov/ct2/show/NCT04434131,2,0,2,0,1,1,United States,0,convalescent plasma
32785213,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|NA","Adult|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunization, Passive|Immunoglobulin G|Male|Middle Aged|Pandemics|Pneumonia, Viral|Spike Glycoprotein, Coronavirus|Time Factors|Viral Vaccines|Young Adult|NA",PhaseÂ I/II study of COVID-19 RNA vaccine BNT162b1 in adults.,2020-10-29,Nature,NCT04368728,Abstract,2020-04-29,2021-08-03,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","Active, not recruiting",Phase 2/Phase 3,BioNTech SE,NA,17,https://pubmed.ncbi.nlm.nih.gov/32785213,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,26,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo
32785710,Journal Article, , ,"Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.",2020-09-01,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,NCT04343729,Abstract,2020-04-18,2020-06-16,Interventional,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,28,https://pubmed.ncbi.nlm.nih.gov/32785710,https://clinicaltrials.gov/ct2/show/NCT04343729,1,0,1,0,7,0,Brazil,0,methylprednisolone sodium succinate|placebo solution
32788708,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,NCT04354259,Abstract,2020-05-13,2020-08-01,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,325,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04354259,3,0,3,0,1,0,Canada,0,peginterferon lambda-1a|placebo
32788708,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,NCT04385095,Abstract,2020-03-16,2021-02-17,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,"Active, not recruiting",Phase 2,Synairgen Research Ltd.,NA,15,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04385095,2,0,2,0,3,0,United Kingdom,0,sng001|placebo
32788708,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,NCT04344600,Abstract,2020-05-29,2021-06-30,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Johns Hopkins University,NA,228,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04344600,1,0,1,0,3,1,United States,0,peginterferon lambda alfa-1a subcutaneous injection|saline
32788708,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,NCT04343976,Abstract,2020-06-22,2021-04-01,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Phase 2,Massachusetts General Hospital,NA,115,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04343976,1,0,1,0,3,1,United States,0,pegylated interferon lambda
32795330,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Calcium Release Activated Calcium Channels|NA,"Aged|COVID-19|Calcium Release Activated Calcium Channels|Coronavirus Infections|Critical Care|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Severity of Illness Index|Standard of Care|Treatment Outcome|NA",Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial.,2020-08-20,"Critical care (London, England)",NCT04345614,Abstract,2020-04-08,2021-04-30,Interventional,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,33,https://pubmed.ncbi.nlm.nih.gov/32795330,https://clinicaltrials.gov/ct2/show/NCT04345614,1,0,1,0,17,1,United States|Puerto Rico,0,auxora|placebo
32799933,Clinical Trial Protocol|Journal Article|Multicenter Study,Dexamethasone|NA,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Dexamethasone|Humans|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiratory Distress Syndrome|SARS-CoV-2|Sample Size|NA",Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.,2020-08-25,Trials,NCT04325061,Abstract,2020-04-03,2020-06-19,Interventional,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,Phase 4,Dr. Negrin University Hospital,Lack of enrollment,60,https://pubmed.ncbi.nlm.nih.gov/32799933,https://clinicaltrials.gov/ct2/show/NCT04325061,1,2,3,0,8,0,Spain,0,dexamethasone
32807209,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study",Anti-Bacterial Agents|Azithromycin|NA,"Anti-Bacterial Agents|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Research Design|SARS-CoV-2|Severity of Illness Index|NA",A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial.,2020-08-25,Trials,NCT04381962,Abstract,2020-05-29,2020-09-13,Interventional,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Recruiting,Phase 3,University of Oxford,NA,303,https://pubmed.ncbi.nlm.nih.gov/32807209,https://clinicaltrials.gov/ct2/show/NCT04381962,1,0,1,0,1,0,United Kingdom,0,azithromycin capsule
32815416,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anticoagulants|Antiviral Agents|Heparin|NA,"Adolescent|Adult|Anticoagulants|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Dose-Response Relationship, Drug|Female|Heparin|Humans|Male|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombosis|Treatment Outcome|Young Adult|NA","Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.",2020-10-15,"Clinical trials (London, England)",NCT04372589,Abstract,2020-05-20,2021-01-31,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Active, not recruiting",Phase 2/Phase 3,University of Manitoba,NA,65,https://pubmed.ncbi.nlm.nih.gov/32815416,https://clinicaltrials.gov/ct2/show/NCT04372589,3,0,3,1,4,1,United States|Brazil|Canada|Mexico,0,heparin
32817460,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal|IL6 protein, human|Interleukin-6|TNFSF14 protein, human|Tumor Necrosis Factor Ligand Superfamily Member 14|NA","Adult|Age Factors|Aged|Antibodies, Monoclonal|Betacoronavirus|COVID-19|Clinical Trials as Topic|Coronavirus Infections|Cytokine Release Syndrome|Hospitalization|Humans|Interleukin-6|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Tumor Necrosis Factor Ligand Superfamily Member 14|NA",Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS.,2020-09-04,mSphere,NCT04412057,Abstract,2020-06-09,2020-12-02,Interventional,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Completed,Phase 2,Cerecor Inc,NA,33,https://pubmed.ncbi.nlm.nih.gov/32817460,https://clinicaltrials.gov/ct2/show/NCT04412057,1,0,1,0,6,1,United States,0,cerc-002|placebo
32821939,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Hospitalization|Humans|Male|Middle Aged|Odds Ratio|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.,2020-09-29,JAMA,NCT04292730,Abstract,2020-03-15,2020-04-29,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,NA,72,https://pubmed.ncbi.nlm.nih.gov/32821939,https://clinicaltrials.gov/ct2/show/NCT04292730,1,1,2,0,20,1,"Japan|United States|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard of care
32828741,Case Reports|Journal Article,Ascorbic Acid|Methylene Blue|Acetylcysteine|NA,"Acetylcysteine|Ascorbic Acid|COVID-19|Clinical Trials, Phase I as Topic|Compassionate Use Trials|Coronavirus Infections|Critical Illness|Female|Humans|Hypoxia|Male|Methylene Blue|Middle Aged|Pandemics|Pneumonia, Viral|NA","Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.",2020-10-13,European journal of pharmacology,NCT04370288,Abstract,2020-04-19,2020-09-20,Interventional,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,Phase 1,Mashhad University of Medical Sciences,NA,338,https://pubmed.ncbi.nlm.nih.gov/32828741,https://clinicaltrials.gov/ct2/show/NCT04370288,1,0,1,0,1,0,"Iran, Islamic Republic of",0,"mcn (methylene blue, vitamin c, n-acetyl cysteine)"
32829745,Journal Article|Randomized Controlled Trial, ,"Adult|Aged|COVID-19|Communicable Disease Control|Coronavirus Infections|Denmark|Female|Humans|Incidence|Infectious Disease Transmission, Vertical|Male|Masks|Middle Aged|Pandemics|Pneumonia, Viral|Primary Prevention|Public Health|Risk Assessment|World Health Organization|NA",Face masks for the prevention of COVID-19 - Rationale and design of the randomised controlled trial DANMASK-19.,2020-08-31,Danish medical journal,NCT04337541,Abstract,2020-04-02,2020-06-02,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,N/A,"Rigshospitalet, Denmark",NA,248,https://pubmed.ncbi.nlm.nih.gov/32829745,https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,0,1,0,Denmark,0,surgical facial mask
32838109,Journal Article, , ,STudy of Alteplase for Respiratory failure in SARS-Cov2/COVID-19: Study Design of the Phase IIa STARS Trial.,2020-09-28,Research and practice in thrombosis and haemostasis,NCT04357730,Abstract,2020-05-14,2021-03-22,Interventional,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,"Active, not recruiting",Phase 2,Denver Health and Hospital Authority,NA,31,https://pubmed.ncbi.nlm.nih.gov/32838109,https://clinicaltrials.gov/ct2/show/NCT04357730,1,0,1,0,9,1,United States,0,alteplase 50 mg [activase]
32838353,Journal Article, , ,Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.,2021-01-10,"Med (New York, N.Y.)",NCT04252885,Abstract,2020-01-28,2020-04-30,Interventional,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Completed,Phase 4,Guangzhou 8th People's Hospital,NA,278,https://pubmed.ncbi.nlm.nih.gov/32838353,https://clinicaltrials.gov/ct2/show/NCT04252885,1,0,1,0,1,0,China,0,lopinavir/ritonavir tablets|arbidol|lopinavir|ritonavir tablets
32843098,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial,Glucocorticoids|Dexamethasone|NA,"Argentina|Betacoronavirus|COVID-19|Coronavirus Infections|Cross Infection|Delirium|Dexamethasone|Glucocorticoids|Humans|Mortality|Organ Dysfunction Scores|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Virus Shedding|NA",High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.,2020-09-03,Trials,NCT04395105,Abstract,2020-05-21,2020-12-31,Interventional,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,261,https://pubmed.ncbi.nlm.nih.gov/32843098,https://clinicaltrials.gov/ct2/show/NCT04395105,1,0,1,0,3,0,Argentina,0,dexamethasone (high dose)
32847626,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial,"THBD protein, human|Thrombomodulin|Vasodilator Agents|Iloprost|NA","Betacoronavirus|COVID-19|Coronavirus Infections|Denmark|Endothelium, Vascular|Humans|Iloprost|Infusions, Intravenous|Intensive Care Units|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Thrombomodulin|Vasodilator Agents|NA",The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.,2020-09-03,Trials,NCT04420741,Abstract,2020-06-15,2021-02-23,Interventional,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,"Active, not recruiting",Phase 2,"Rigshospitalet, Denmark",NA,25,https://pubmed.ncbi.nlm.nih.gov/32847626,https://clinicaltrials.gov/ct2/show/NCT04420741,1,0,1,0,6,0,Denmark,0,iloprost|isotonic saline
32876695,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anti-Inflammatory Agents|Dexamethasone|NA,"Administration, Intravenous|Aged|Anti-Inflammatory Agents|Betacoronavirus|Brazil|COVID-19|Catheter-Related Infections|Coronavirus Infections|Dexamethasone|Early Termination of Clinical Trials|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|NA",Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.,2020-11-04,JAMA,NCT04327401,Abstract,2020-04-13,2020-07-22,Interventional,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Phase 3,Hospital Sirio-Libanes,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial
    results, which was accepted by the CoDEX Steering Committee.",241,https://pubmed.ncbi.nlm.nih.gov/32876695,https://clinicaltrials.gov/ct2/show/NCT04327401,1,0,1,0,5,0,Brazil,0,dexamethasone
32877576,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Adjuvants, Immunologic|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Matrix-M|Saponins|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|spike glycoprotein, SARS-CoV|NA","Adjuvants, Immunologic|Adolescent|Adult|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunization Schedule|Immunogenicity, Vaccine|Immunoglobulin G|Male|Middle Aged|Nanoparticles|Pandemics|Saponins|Spike Glycoprotein, Coronavirus|Th1 Cells|Vaccines, Synthetic|Young Adult|NA",Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.,2020-12-17,The New England journal of medicine,NCT04368988,Abstract,2020-05-25,2020-12-01,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,177,https://pubmed.ncbi.nlm.nih.gov/32877576,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,United States|Australia,0,"sars-cov-2 rs - phase 1|sars-cov-2 rs/matrix-m adjuvant - phase 1|normal saline solution (nss), placebo - phase 1|normal saline solution (nss), placebo - phase 2|sars-cov-2 rs/matrix-m adjuvant, day 0 - phase 1|normal saline solution (nss), placebo, day 21 - phase 1|sars-cov-2 rs/matrix-m adjuvant, days 0/21 - phase 2|normal saline solution (nss), placebo, day 189 - phase 2|sars-cov-2 rs/matrix-m adjuvant, day 0 - phase 2|normal saline solution (nss), placebo, day 21 - phase 2|sars-cov-2 rs/matrix-m adjuvant - day 189 - phase 2|sars-cov-2 rs|matrix-m adjuvant - phase 1|matrix-m adjuvant, day 0 - phase 1|matrix-m adjuvant, days 0|21 - phase 2|matrix-m adjuvant, day 0 - phase 2|matrix-m adjuvant - day 189 - phase 2"
32888112,Journal Article, ,"Aged|Ambulatory Care|COVID-19|Coronavirus Infections|Delphi Technique|Hospitalization|Humans|Male|Middle Aged|Outpatients|Pandemics|Pneumonia, Viral|Risk Factors|Surveys and Questionnaires|NA",Outpatient management or hospitalization of patients with proven or suspected SARS-CoV-2 infection: the HOME-CoV rule.,2020-11-24,Internal and emergency medicine,NCT04338841,Abstract,2020-04-09,2020-06-17,Interventional,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,N/A,"University Hospital, Angers",NA,193,https://pubmed.ncbi.nlm.nih.gov/32888112,https://clinicaltrials.gov/ct2/show/NCT04338841,1,0,1,0,2,0,Belgium|France|Monaco,0,home-cov rule implementation
32895056,Clinical Trial Protocol|Equivalence Trial|Letter,"Anticoagulants|Antithrombins|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Hirudins|Peptide Fragments|Recombinant Proteins|fibrin fragment D|Heparin|bivalirudin|NA","Anticoagulants|Antithrombins|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Fibrin Fibrinogen Degradation Products|Heparin|Heparin, Low-Molecular-Weight|Hirudins|Humans|Pandemics|Partial Thromboplastin Time|Peptide Fragments|Pneumonia, Viral|Qatar|Recombinant Proteins|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|NA","Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial.",2020-09-10,Trials,NCT04445935,Abstract,2020-06-28,2020-09-28,Interventional,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Phase 4,Hamad Medical Corporation,NA,284,https://pubmed.ncbi.nlm.nih.gov/32895056,https://clinicaltrials.gov/ct2/show/NCT04445935,1,0,1,0,0,0,Qatar,0,bivalirudin injection|standard treatment
32896291,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Viral Vaccines|NA","Adenoviridae|Adult|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunity, Cellular|Immunity, Humoral|Immunization, Secondary|Immunoglobulin G|Injections, Intramuscular|Male|Pandemics|Pneumonia, Viral|Russia|SARS-CoV-2|Viral Vaccines|Young Adult|NA","Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.",2020-10-05,"Lancet (London, England)",NCT04436471,Abstract,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,235,https://pubmed.ncbi.nlm.nih.gov/32896291,https://clinicaltrials.gov/ct2/show/NCT04436471,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac
32896291,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Viral Vaccines|NA","Adenoviridae|Adult|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunity, Cellular|Immunity, Humoral|Immunization, Secondary|Immunoglobulin G|Injections, Intramuscular|Male|Pandemics|Pneumonia, Viral|Russia|SARS-CoV-2|Viral Vaccines|Young Adult|NA","Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.",2020-10-05,"Lancet (London, England)",NCT04437875,Abstract,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,235,https://pubmed.ncbi.nlm.nih.gov/32896291,https://clinicaltrials.gov/ct2/show/NCT04437875,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac lyo
32896292,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|Azithromycin|NA,"Aged|Antiviral Agents|Azithromycin|Betacoronavirus|Brazil|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Length of Stay|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiratory Therapy|SARS-CoV-2|Standard of Care|Treatment Outcome|NA",Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.,2020-10-14,"Lancet (London, England)",NCT04321278,Abstract,2020-03-28,2020-06-14,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,NA,78,https://pubmed.ncbi.nlm.nih.gov/32896292,https://clinicaltrials.gov/ct2/show/NCT04321278,2,0,2,0,6,0,Brazil,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin
32903199,Journal Article, , ,Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study.,2020-10-23,JMIR research protocols,NCT04347681,Abstract,2020-04-18,2020-12-31,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Phase 2,King Fahad Specialist Hospital Dammam,NA,237,https://pubmed.ncbi.nlm.nih.gov/32903199,https://clinicaltrials.gov/ct2/show/NCT04347681,2,0,2,0,3,0,Saudi Arabia,0,convalescent plasma from recovered covid 19 donor
32907635,Clinical Trial Protocol|Letter,Anticoagulants|Enoxaparin|NA,"Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Enoxaparin|Equivalence Trials as Topic|Host-Pathogen Interactions|Humans|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombosis|Time Factors|Treatment Outcome|NA",Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.,2020-09-16,Trials,NCT04400799,Abstract,2020-06-15,2021-03-14,Interventional,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Phase 3,University of Zurich,NA,263,https://pubmed.ncbi.nlm.nih.gov/32907635,https://clinicaltrials.gov/ct2/show/NCT04400799,1,0,1,0,1,0,Switzerland,0,enoxaparin 40mg/0.4ml inj syringe 0.4ml|enoxaparin 40mg|0.4ml inj syringe 0.4ml
32907638,Clinical Trial Protocol|Letter,"Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|sarilumab|NA","Adult|Aged|Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Host-Pathogen Interactions|Humans|Male|Middle Aged|Pandemics|Patient Admission|Pneumonia, Viral|Proof of Concept Study|Randomized Controlled Trials as Topic|SARS-CoV-2|Spain|Time Factors|Treatment Outcome|Young Adult|NA",Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.,2020-09-16,Trials,NCT04357808,Abstract,2020-04-13,2020-11-30,Interventional,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Completed,Phase 2,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,52,https://pubmed.ncbi.nlm.nih.gov/32907638,https://clinicaltrials.gov/ct2/show/NCT04357808,1,0,1,0,3,0,Spain,0,sarilumab|standar of care
32917259,Clinical Trial Protocol|Letter, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Feasibility Studies|Host-Pathogen Interactions|Humans|Lung|Pandemics|Pneumonia, Viral|Prospective Studies|Qatar|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Time Factors|Treatment Outcome|NA",Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial.,2020-09-16,Trials,NCT04399317,Abstract,2020-05-28,2020-07-31,Interventional,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,N/A,Hamad Medical Corporation,NA,284,https://pubmed.ncbi.nlm.nih.gov/32917259,https://clinicaltrials.gov/ct2/show/NCT04399317,1,0,1,0,1,0,Qatar,0,flow controlled ventilation (evone-ventilator)
32934758,"Journal Article|Research Support, Non-U.S. Gov't|Review",BCG Vaccine|Cytokines|NA,"BCG Vaccine|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coinfection|Coronavirus Infections|Cytokines|Diagnostic Errors|Disease Outbreaks|Humans|Influenza, Human|Middle East Respiratory Syndrome Coronavirus|Pandemics|Pneumonia, Viral|SARS Virus|SARS-CoV-2|Severe Acute Respiratory Syndrome|Severity of Illness Index|Tuberculosis|NA",Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.,2020-09-24,Canadian respiratory journal,NCT04327206,Abstract,2020-03-30,2021-06-30,Interventional,BCG Vaccination to Protect Healthcare Workers Against COVID-19,Recruiting,Phase 3,Murdoch Childrens Research Institute,NA,60,https://pubmed.ncbi.nlm.nih.gov/32934758,https://clinicaltrials.gov/ct2/show/NCT04327206,1,0,1,1,10,0,Australia|Brazil|Netherlands|Spain|United Kingdom,0,bcg vaccine|0.9%nacl
32936948,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anti-Infective Agents|Mouthwashes|Nasal Sprays|NA,"Anti-Infective Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Health Personnel|Humans|Infectious Disease Transmission, Patient-to-Professional|Mouth|Mouthwashes|Nasal Sprays|Nose|Occupational Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|Therapeutic Irrigation|NA",Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them.,2020-09-30,The Cochrane database of systematic reviews,NCT04352959,Abstract,2020-04-27,2020-12-11,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Completed,N/A,Claude Bernard University,NA,52,https://pubmed.ncbi.nlm.nih.gov/32936948,https://clinicaltrials.gov/ct2/show/NCT04352959,2,0,2,0,4,0,France,0,mouthrinse with bãªta-cyclodextrin/citrox|mouthrinse without bãªta-cyclodextrin/citrox|mouthrinse with bãªta-cyclodextrin|citrox|mouthrinse without bãªta-cyclodextrin
32936949,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anti-Infective Agents|Mouthwashes|Nasal Sprays|NA,"Anti-Infective Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Health Personnel|Humans|Infectious Disease Transmission, Patient-to-Professional|Mouth|Mouthwashes|Nasal Sprays|Nose|Occupational Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|Therapeutic Irrigation|NA",Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection.,2020-09-30,The Cochrane database of systematic reviews,NCT04364802,Abstract,2020-04-29,2021-05-31,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Phase 2,University of Kentucky,NA,132,https://pubmed.ncbi.nlm.nih.gov/32936949,https://clinicaltrials.gov/ct2/show/NCT04364802,1,0,1,0,2,1,United States,0,povidone-iodine nasal spray/gargle|povidone-iodine nasal spray|gargle
32943115,Clinical Trial Protocol|Letter,BCG Vaccine|NA,"Absenteeism|BCG Vaccine|Betacoronavirus|COVID-19|Coronavirus Infections|Denmark|Female|Health Personnel|Humans|Male|Multicenter Studies as Topic|Occupational Health|Pandemics|Patient Admission|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Sick Leave|Single-Blind Method|Time Factors|Treatment Outcome|Vaccination|NA",Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.,2020-09-23,Trials,NCT04373291,Abstract,2020-05-18,2021-07-31,Interventional,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,"Active, not recruiting",Phase 3,Bandim Health Project,NA,62,https://pubmed.ncbi.nlm.nih.gov/32943115,https://clinicaltrials.gov/ct2/show/NCT04373291,1,0,1,1,4,0,Denmark,0,bcg-denmark|saline
32951151,Journal Article, , ,Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective PhaseÂ II Clinical Trial.,2021-01-29,Infectious diseases and therapy,NCT04343261,Abstract,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,193,https://pubmed.ncbi.nlm.nih.gov/32951151,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma
32958495,"Adaptive Clinical Trial|Clinical Trial Protocol|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Drug Combinations|lopinavir-ritonavir drug combination|Lopinavir|remdesivir|Adenosine Monophosphate|Hydroxychloroquine|Ritonavir|Alanine|Interferon beta-1a|NA,"Adenosine Monophosphate|Adult|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Drug Therapy, Combination|Early Warning Score|Extracorporeal Membrane Oxygenation|Hospital Mortality|Hospitalization|Humans|Hydroxychloroquine|Interferon beta-1a|Length of Stay|Lopinavir|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|Respiration, Artificial|Ritonavir|SARS-CoV-2|Standard of Care|Treatment Outcome|NA","Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.",2020-10-05,BMJ open,NCT04315948,Abstract,2020-03-22,2023-03-31,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,"Active, not recruiting",Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,61,https://pubmed.ncbi.nlm.nih.gov/32958495,https://clinicaltrials.gov/ct2/show/NCT04315948,3,0,3,0,7,0,Austria|Belgium|France|Luxembourg|Portugal,0,remdesivir|lopinavir/ritonavir|interferon beta-1a|hydroxychloroquine|standard of care|lopinavir|ritonavir
32969710,"Journal Article|Research Support, Non-U.S. Gov't", , ,Urgent Need for Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System.,2021-03-31,Circulation,NCT04280705,Abstract,2020-02-21,2020-05-21,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,119,https://pubmed.ncbi.nlm.nih.gov/32969710,https://clinicaltrials.gov/ct2/show/NCT04280705,3,0,3,0,24,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir
32983830,Journal Article, , ,Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective PhaseÂ II Clinical Trial.,2020-11-23,Infectious diseases and therapy,NCT04343261,Abstract,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,193,https://pubmed.ncbi.nlm.nih.gov/32983830,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma
32991794,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|mRNA-1273 vaccine|NA","Aged|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Dose-Response Relationship, Drug|Female|Humans|Male|Middle Aged|Neutralization Tests|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|NA",Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.,2020-12-23,The New England journal of medicine,NCT04283461,Abstract,2020-03-16,2022-11-22,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,9,https://pubmed.ncbi.nlm.nih.gov/32991794,https://clinicaltrials.gov/ct2/show/NCT04283461,2,0,2,1,19,1,United States,0,mrna-1273
32993779,Clinical Trial Protocol|Journal Article, ,"Adaptive Clinical Trials as Topic|Age Factors|Aged|Aged, 80 and over|Alcohol Drinking|Betacoronavirus|COVID-19|Coronavirus Infections|Exercise|Feeding Behavior|Female|Health Education|Health Knowledge, Attitudes, Practice|Health Status|Host-Pathogen Interactions|Humans|Hungary|Male|Mental Health|Middle Aged|Pandemics|Pneumonia, Viral|Pragmatic Clinical Trials as Topic|Protective Factors|Risk Assessment|Risk Factors|Risk Reduction Behavior|SARS-CoV-2|Smoking|NA",Personalised health education against health damage of COVID-19 epidemic in the elderly Hungarian population (PROACTIVE-19): protocol of an adaptive randomised controlled clinical trial.,2020-10-13,Trials,NCT04321928,Abstract,2020-04-01,2021-04-21,Interventional,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,N/A,University of Pecs,NA,302,https://pubmed.ncbi.nlm.nih.gov/32993779,https://clinicaltrials.gov/ct2/show/NCT04321928,1,0,1,0,2,0,Hungary,0,personalized health education|general health education
32999432,"Letter|Research Support, N.I.H., Extramural",Antiviral Agents|Protein Kinase Inhibitors|Pyrazoles|asciminib|Niacinamide|Imatinib Mesylate|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Caco-2 Cells|Coronavirus Infections|Drug Repositioning|Humans|Imatinib Mesylate|Inhibitory Concentration 50|Niacinamide|Pandemics|Pneumonia, Viral|Protein Kinase Inhibitors|Pyrazoles|Randomized Controlled Trials as Topic|SARS-CoV-2|Virus Internalization|Virus Replication|NA",Imatinib is not a potent anti-SARS-CoV-2 drug.,2020-11-05,Leukemia,NCT04394416,Abstract,2020-06-02,2022-06-01,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",NA,305,https://pubmed.ncbi.nlm.nih.gov/32999432,https://clinicaltrials.gov/ct2/show/NCT04394416,2,0,2,0,1,1,United States,0,imatinib|placebo oral tablet
33001138,Journal Article|Multicenter Study|Randomized Controlled Trial,Hydroxychloroquine|NA,"Adult|COVID-19|Cross Infection|Double-Blind Method|Female|Hospitals, Urban|Humans|Hydroxychloroquine|Incidence|Male|Pennsylvania|Personnel, Hospital|Pre-Exposure Prophylaxis|SARS-CoV-2|NA",Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.,2021-02-05,JAMA internal medicine,NCT04329923,Abstract,2020-04-09,2020-11-11,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,"Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
    pre-specificied futility analysis at planned second interim analysis",116,https://pubmed.ncbi.nlm.nih.gov/33001138,https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,0,7,1,United States,1,hydroxychloroquine sulfate 400 mg twice a day|hydroxychloroquine sulfate 600 mg twice a day|hydroxychloroquine sulfate 600 mg once a day|placebo oral tablet
33015643,Journal Article, , ,"Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.",2020-11-27,The Lancet. Rheumatology,NCT04333420,Abstract,2020-03-31,2021-05-31,Interventional,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,InflaRx GmbH,NA,120,https://pubmed.ncbi.nlm.nih.gov/33015643,https://clinicaltrials.gov/ct2/show/NCT04333420,1,0,1,0,5,0,Germany|Netherlands,0,soc / ifx-1|soc / placebo|soc|ifx-1|placebo
33031652,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial,Antiviral Agents|Hydroxychloroquine|NA,"Aged|Aged, 80 and over|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Treatment Failure|NA",Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.,2020-12-01,The New England journal of medicine,NCT04381936,Abstract,2020-03-19,2021-12-31,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,37,https://pubmed.ncbi.nlm.nih.gov/33031652,https://clinicaltrials.gov/ct2/show/NCT04381936,2,2,4,0,8,0,Indonesia|Nepal|United Kingdom,0,lopinavir-ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine|baricitinib|anakinra|dimethyl fumarate
33031955,Clinical Trial Protocol|Journal Article,"Antibodies, Monoclonal, Humanized|Immunologic Factors|Receptors, Interleukin-6|tocilizumab|NA","Administration, Intravenous|Adult|Antibodies, Monoclonal, Humanized|COVID-19|Clinical Trials, Phase II as Topic|Cytokine Release Syndrome|Drug Administration Schedule|Drug Monitoring|Female|Humans|Immunologic Factors|Male|Multicenter Studies as Topic|Pneumonia, Viral|Receptors, Interleukin-6|Treatment Outcome|NA",TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol.,2020-12-11,Contemporary clinical trials,NCT04317092,Abstract,2020-03-19,2021-12-19,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,32,https://pubmed.ncbi.nlm.nih.gov/33031955,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,4,0,Italy,0,tocilizumab injection
33043164,Journal Article, , ,"A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan.",2020-12-22,Contemporary clinical trials communications,NCT04317092,Abstract,2020-03-19,2021-12-19,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,32,https://pubmed.ncbi.nlm.nih.gov/33043164,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,4,0,Italy,0,tocilizumab injection
33044747,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,NCT04357106,Abstract,2020-04-13,2020-07-31,Interventional,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Phase 2,Centro de HematologÃ­a y Medicina Interna,NA,347,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04357106,1,0,1,0,0,0,Mexico,0,convalescent plasma
33044747,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,NCT04340050,Abstract,2020-04-10,2020-12-23,Interventional,COVID-19 Convalescent Plasma,Completed,Early Phase 1,University of Chicago,NA,101,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04340050,1,0,1,0,4,1,United States,0,anti-sars-cov-2 convalescent plasma
33044747,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,NCT04343261,Abstract,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,193,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma
33044747,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,NCT04441424,Abstract,2020-04-03,2020-06-01,Interventional,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,N/A,Alkarkh Health Directorate-Baghdad,NA,287,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04441424,1,0,1,0,1,0,Iraq,0,convalescent plasma|hydroxychloroquin with azithromycin
33044747,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,NCT04342182,Abstract,2020-04-08,2021-07-01,Interventional,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Phase 2/Phase 3,Erasmus Medical Center,NA,141,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04342182,1,0,1,0,11,0,Netherlands,0,convalescent plasma
33044747,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,NCT04321421,Abstract,2020-03-17,2020-04-28,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,NA,311,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04321421,3,0,3,0,2,0,Italy,0,hyperimmune plasma
33044747,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,NCT04434131,Abstract,2020-04-28,2021-04-28,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,NA,293,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04434131,2,0,2,0,1,1,United States,0,convalescent plasma
33050459,Journal Article, , ,May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?,2020-11-03,"Antioxidants (Basel, Switzerland)",NCT04555096,Abstract,2020-09-09,2021-11-30,Interventional,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Phase 2,"Galera Therapeutics, Inc.",NA,33,https://pubmed.ncbi.nlm.nih.gov/33050459,https://clinicaltrials.gov/ct2/show/NCT04555096,1,0,1,0,4,1,United States,0,gc4419|placebo
33050924,"Clinical Trial, Phase III|Letter|Randomized Controlled Trial",Amides|Antihypertensive Agents|Antimalarials|Antiviral Agents|Protein Kinase Inhibitors|Pyrazines|Hydroxychloroquine|Imatinib Mesylate|favipiravir|Telmisartan|NA,"Aged|Aged, 80 and over|Amides|Antihypertensive Agents|Antimalarials|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Tolerance|Feasibility Studies|France|Hospitalization|Humans|Hydroxychloroquine|Imatinib Mesylate|Luxembourg|Outpatients|Pandemics|Pneumonia, Viral|Protein Kinase Inhibitors|Pyrazines|Risk Reduction Behavior|SARS-CoV-2|Telmisartan|Therapies, Investigational|Treatment Outcome|NA",Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).,2020-11-03,Trials,NCT04356495,Abstract,2020-07-29,2021-08-15,Interventional,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Phase 2/Phase 3,"University Hospital, Bordeaux",NA,74,https://pubmed.ncbi.nlm.nih.gov/33050924,https://clinicaltrials.gov/ct2/show/NCT04356495,1,0,1,0,6,0,France,0,vitamins|telmisartan|ciclesonide|interferon î²-1b|interferon î²-1b
33050947,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial",Amides|Antiviral Agents|Biomarkers|Placebos|Pyrazines|favipiravir|NA,"Amides|Antiviral Agents|Australia|Betacoronavirus|Biomarkers|COVID-19|Clinical Protocols|Coronavirus Infections|Female|Hospitalization|Humans|Male|Pandemics|Placebos|Pneumonia, Viral|Pyrazines|SARS-CoV-2|Safety|Treatment Outcome|NA",An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.,2020-11-03,Trials,NCT04445467,Abstract,2020-08-01,2020-11-30,Interventional,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Phase 2,Bayside Health,NA,230,https://pubmed.ncbi.nlm.nih.gov/33050947,https://clinicaltrials.gov/ct2/show/NCT04445467,1,0,1,0,1,0,Australia,0,favipiravir
33053279,"Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|BNT162 vaccine|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Female|Humans|Injections, Intramuscular|Male|Middle Aged|Neutralization Tests|SARS-CoV-2|Single-Blind Method|Spike Glycoprotein, Coronavirus|Young Adult|NA",Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.,2020-12-23,The New England journal of medicine,NCT04368728,Abstract,2020-04-29,2021-08-03,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","Active, not recruiting",Phase 2/Phase 3,BioNTech SE,NA,17,https://pubmed.ncbi.nlm.nih.gov/33053279,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,26,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo
33066761,Clinical Trial Protocol|Journal Article,Cholinesterase Inhibitors|Pyridostigmine Bromide|NA,"Adult|Betacoronavirus|COVID-19|Cholinesterase Inhibitors|Coronavirus Infections|Humans|Inflammation|Lung|Pandemics|Pneumonia, Viral|Pyridostigmine Bromide|Respiration, Artificial|SARS-CoV-2|NA","A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.",2020-10-26,BMC infectious diseases,NCT04343963,Abstract,2020-04-04,2020-09-30,Interventional,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,271,https://pubmed.ncbi.nlm.nih.gov/33066761,https://clinicaltrials.gov/ct2/show/NCT04343963,1,0,1,0,2,0,Mexico,0,pyridostigmine bromide|placebo
33080005,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Receptors, Interleukin-6|C-Reactive Protein|tocilizumab|NA","Aged|Antibodies, Monoclonal, Humanized|Blood Gas Analysis|C-Reactive Protein|COVID-19|Disease Progression|Early Termination of Clinical Trials|Female|Fever|Hospital Mortality|Hospitalization|Humans|Intensive Care Units|Italy|Male|Medical Futility|Middle Aged|Receptors, Interleukin-6|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|NA",Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.,2021-01-15,JAMA internal medicine,NCT04346355,Abstract,2020-03-31,2020-06-06,Interventional,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Phase 2,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,Based on interim analysis for futility and given an enrolment rate almost nil,289,https://pubmed.ncbi.nlm.nih.gov/33080005,https://clinicaltrials.gov/ct2/show/NCT04346355,1,0,1,0,2,0,Italy,0,tocilizumab
33080017,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Adrenal Cortex Hormones|Anti-Bacterial Agents|Antibodies, Monoclonal, Humanized|Anticoagulants|Antiviral Agents|Receptors, Interleukin-6|Vasoconstrictor Agents|tocilizumab|NA","Adrenal Cortex Hormones|Aged|Anti-Bacterial Agents|Antibodies, Monoclonal, Humanized|Anticoagulants|Antiviral Agents|COVID-19|Disease Progression|Female|Hospital Mortality|Hospitalization|Humans|Intubation, Intratracheal|Male|Middle Aged|Mortality|Noninvasive Ventilation|Oxygen Inhalation Therapy|Receptors, Interleukin-6|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Severity of Illness Index|Vasoconstrictor Agents|NA",Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.,2021-01-15,JAMA internal medicine,NCT04331808,Abstract,2020-03-30,2021-03-31,Interventional,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,342,https://pubmed.ncbi.nlm.nih.gov/33080017,https://clinicaltrials.gov/ct2/show/NCT04331808,1,0,1,0,2,0,France,0,tocilizumab
33081817,Journal Article|Multicenter Study|Randomized Controlled Trial,Anti-Bacterial Agents|Antimalarials|Placebos|Hydroxychloroquine|Azithromycin|NA,"Aged|Anti-Bacterial Agents|Antibiotic Prophylaxis|Antimalarials|Azithromycin|Betacoronavirus|COVID-19|Case-Control Studies|Coronavirus Infections|Denmark|Double-Blind Method|Drug Therapy, Combination|Female|Hospital Mortality|Hospitalization|Humans|Hydroxychloroquine|Intensive Care Units|Intention to Treat Analysis|Male|Noninvasive Ventilation|Pandemics|Placebos|Pneumonia, Viral|Risk Reduction Behavior|SARS-CoV-2|NA",Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.,2020-11-03,Trials,NCT04322396,Abstract,2020-04-06,2021-02-02,Interventional,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Completed,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",NA,52,https://pubmed.ncbi.nlm.nih.gov/33081817,https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,0,4,0,Denmark,0,azithromycin|hydroxychloroquine|placebo oral tablet
33082342,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|NA,"Aged|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|Viral Load|NA",A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.,2020-11-02,Nature communications,NCT04316377,Abstract,2020-03-25,2020-05-25,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",NA,303,https://pubmed.ncbi.nlm.nih.gov/33082342,https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,0,3,0,Norway,0,hydroxychloroquine sulfate
33083026,Journal Article, , ,Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.,2020-10-22,NPJ vaccines,NCT04436276,Abstract,2020-07-15,2021-12-03,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,9,https://pubmed.ncbi.nlm.nih.gov/33083026,https://clinicaltrials.gov/ct2/show/NCT04436276,3,0,3,0,9,1,United States|Belgium,0,ad26.cov2.s|placebo
33085857,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|IL6R protein, human|Receptors, Interleukin-6|tocilizumab|NA","Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Boston|COVID-19|Disease Progression|Double-Blind Method|Female|Humans|Intubation|Male|Middle Aged|Receptors, Interleukin-6|Respiratory Therapy|Treatment Failure|Young Adult|NA",Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.,2020-12-17,The New England journal of medicine,NCT04356937,Abstract,2020-04-20,2020-07-13,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,Completed,Phase 3,Massachusetts General Hospital,NA,110,https://pubmed.ncbi.nlm.nih.gov/33085857,https://clinicaltrials.gov/ct2/show/NCT04356937,1,0,1,0,4,1,United States,0,tocilizumab|placebos
33087150,"Clinical Trial, Phase II|Journal Article|Multicenter Study","Antibodies, Monoclonal, Humanized|tocilizumab|NA","Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Betacoronavirus|COVID-19|Cohort Studies|Coronavirus Infections|Female|Humans|Italy|Male|Middle Aged|Mortality|Off-Label Use|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|Validation Studies as Topic|NA",Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.,2020-10-30,Journal of translational medicine,NCT04317092,Abstract,2020-03-19,2021-12-19,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,32,https://pubmed.ncbi.nlm.nih.gov/33087150,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,4,0,Italy,0,tocilizumab injection
33092632,"Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Letter|Randomized Controlled Trial", ,"Aged|Aged, 80 and over|Betacoronavirus|Blood Transfusion|COVID-19|Comorbidity|Coronavirus Infections|Disease Progression|Female|Humans|Immunization, Passive|Informed Consent|Italy|Male|Mortality|Pandemics|Pneumonia|Pneumonia, Viral|SARS-CoV-2|Tomography, X-Ray Computed|Viral Load|NA",&quot;Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial&quot;.,2020-11-03,Trials,NCT04374526,Abstract,2020-05-27,2021-04-30,Interventional,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,180,https://pubmed.ncbi.nlm.nih.gov/33092632,https://clinicaltrials.gov/ct2/show/NCT04374526,1,0,1,0,2,0,Italy,0,covid-19 convalescent plasma
33106167,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial", ,"Bangladesh|Betacoronavirus|Blood Transfusion|COVID-19|Coronavirus Infections|Dose-Response Relationship, Immunologic|Female|Hospital Mortality|Humans|Immunization, Passive|Male|Pandemics|Patient Discharge|Pneumonia, Viral|SARS-CoV-2|Safety|Severity of Illness Index|Time Factors|Treatment Outcome|Ventilators, Mechanical|NA","Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.",2020-11-02,Trials,NCT04403477,Abstract,2020-05-20,2020-07-20,Interventional,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,314,https://pubmed.ncbi.nlm.nih.gov/33106167,https://clinicaltrials.gov/ct2/show/NCT04403477,1,0,1,0,0,0,Bangladesh,0,convalescent plasma
33108622,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial",Anti-Inflammatory Agents|Heparin|NA,"Acute Lung Injury|Adult|Aged|Aged, 80 and over|Anti-Inflammatory Agents|COVID-19|Double-Blind Method|Female|Heparin|Humans|Male|Middle Aged|Respiratory Insufficiency|SARS-CoV-2|Treatment Outcome|NA","Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.",2021-02-22,Advances in therapy,NCT04389840,Abstract,2020-06-03,2021-02-28,Interventional,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Phase 2/Phase 3,Chimerix,NA,46,https://pubmed.ncbi.nlm.nih.gov/33108622,https://clinicaltrials.gov/ct2/show/NCT04389840,1,0,1,0,11,1,United States,0,dociparstat sodium|placebo
33110944,Journal Article, , ,A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.,2020-10-29,Wellcome open research,NCT04328493,Abstract,2020-04-07,2021-04-01,Interventional,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Phase 2,"Oxford University Clinical Research Unit, Vietnam",NA,311,https://pubmed.ncbi.nlm.nih.gov/33110944,https://clinicaltrials.gov/ct2/show/NCT04328493,1,0,1,0,3,0,Vietnam,0,chloroquine phosphate
33113295,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Immunologic Factors|RNA, Viral|bamlanivimab|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|COVID-19|Dose-Response Relationship, Drug|Double-Blind Method|Female|Hospitalization|Humans|Immunologic Factors|Male|Middle Aged|Outpatients|RNA, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Severity of Illness Index|Viral Load|Young Adult|NA",SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.,2021-02-03,The New England journal of medicine,NCT04427501,Abstract,2020-06-17,2020-09-20,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2/Phase 3,Eli Lilly and Company,NA,10,https://pubmed.ncbi.nlm.nih.gov/33113295,https://clinicaltrials.gov/ct2/show/NCT04427501,2,0,2,0,34,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo
33115543,Clinical Trial Protocol|Letter,Protein Kinase Inhibitors|Imatinib Mesylate|NA,"Administration, Oral|Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Care|Dose-Response Relationship, Drug|Double-Blind Method|Drug Monitoring|Female|Humans|Imatinib Mesylate|Male|Pandemics|Pneumonia, Viral|Protein Kinase Inhibitors|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|NA",Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.,2020-11-05,Trials,NCT04394416,Abstract,2020-06-02,2022-06-01,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",NA,305,https://pubmed.ncbi.nlm.nih.gov/33115543,https://clinicaltrials.gov/ct2/show/NCT04394416,2,0,2,0,1,1,United States,0,imatinib|placebo oral tablet
33129363,Clinical Trial Protocol|Letter,Amides|Antiviral Agents|Pyrazines|Hydroxychloroquine|favipiravir|NA,"Amides|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Inpatients|Male|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Pyrazines|Randomized Controlled Trials as Topic|SARS-CoV-2|Saudi Arabia|Time Factors|Treatment Outcome|NA",A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.,2020-11-04,Trials,NCT04392973,Abstract,2020-05-21,2021-11-30,Interventional,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,N/A,King Abdullah International Medical Research Center,NA,251,https://pubmed.ncbi.nlm.nih.gov/33129363,https://clinicaltrials.gov/ct2/show/NCT04392973,1,0,1,0,2,0,Saudi Arabia,0,favipiravir/hydroxychloroquine|favipiravir|hydroxychloroquine
33138848,Clinical Trial Protocol|Letter,Antiviral Agents|Mouthwashes|beta-Cyclodextrins|betadex|NA,"Adult|Antiviral Agents|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Drug Monitoring|Female|Humans|Male|Mouthwashes|Nasal Cavity|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Saliva|Treatment Outcome|Viral Load|beta-Cyclodextrins|NA",Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial.,2020-11-09,Trials,NCT04352959,Abstract,2020-04-27,2020-12-11,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Completed,N/A,Claude Bernard University,NA,52,https://pubmed.ncbi.nlm.nih.gov/33138848,https://clinicaltrials.gov/ct2/show/NCT04352959,2,0,2,0,4,0,France,0,mouthrinse with bãªta-cyclodextrin/citrox|mouthrinse without bãªta-cyclodextrin/citrox|mouthrinse with bãªta-cyclodextrin|citrox|mouthrinse without bãªta-cyclodextrin
33138867,Clinical Trial Protocol|Letter,"Immunoglobulins, Intravenous|Immunologic Factors|NA","Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Female|Humans|Immunization, Passive|Immunoglobulins, Intravenous|Immunologic Factors|Male|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|NA",Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.,2020-11-09,Trials,NCT04521309,Abstract,2020-06-19,2021-01-26,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Completed,Phase 1/Phase 2,Dow University of Health Sciences,NA,13,https://pubmed.ncbi.nlm.nih.gov/33138867,https://clinicaltrials.gov/ct2/show/NCT04521309,2,0,2,0,4,0,Pakistan,0,sars-cov-2 antibody based ivig therapy
33139139,"Journal Article|Research Support, Non-U.S. Gov't","Adjuvants, Immunologic|Antibodies, Neutralizing|COVID-19 Vaccines|Immune Sera|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|recombinant SARS-CoV-2 vaccine NVX-cov2373|spike protein, SARS-CoV-2|ACE2 protein, human|Angiotensin-Converting Enzyme 2|NA","Adjuvants, Immunologic|Adolescent|Adult|Aged|Angiotensin-Converting Enzyme 2|Animals|Antibodies, Neutralizing|COVID-19|COVID-19 Vaccines|Chlorocebus aethiops|Female|Humans|Immune Sera|Macaca fascicularis|Male|Middle Aged|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|Vero Cells|Viral Load|Young Adult|NA",NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.,2020-12-11,Vaccine,NCT04368988,Abstract,2020-05-25,2020-12-01,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,177,https://pubmed.ncbi.nlm.nih.gov/33139139,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,United States|Australia,0,"sars-cov-2 rs - phase 1|sars-cov-2 rs/matrix-m adjuvant - phase 1|normal saline solution (nss), placebo - phase 1|normal saline solution (nss), placebo - phase 2|sars-cov-2 rs/matrix-m adjuvant, day 0 - phase 1|normal saline solution (nss), placebo, day 21 - phase 1|sars-cov-2 rs/matrix-m adjuvant, days 0/21 - phase 2|normal saline solution (nss), placebo, day 189 - phase 2|sars-cov-2 rs/matrix-m adjuvant, day 0 - phase 2|normal saline solution (nss), placebo, day 21 - phase 2|sars-cov-2 rs/matrix-m adjuvant - day 189 - phase 2|sars-cov-2 rs|matrix-m adjuvant - phase 1|matrix-m adjuvant, day 0 - phase 1|matrix-m adjuvant, days 0|21 - phase 2|matrix-m adjuvant, day 0 - phase 2|matrix-m adjuvant - day 189 - phase 2"
33148977,Journal Article|Review, ,"COVID-19|Humans|Immune Tolerance|Kidney Failure, Chronic|Organ Transplantation|SARS-CoV-2|NA",COVID-19 and Solid Organ Transplantation: A Review Article.,2021-01-06,Transplantation,NCT04492475,Abstract,2020-08-05,2020-12-21,Interventional,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,58,https://pubmed.ncbi.nlm.nih.gov/33148977,https://clinicaltrials.gov/ct2/show/NCT04492475,1,0,1,0,29,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,interferon beta-1a|placebo|remdesivir
33148977,Journal Article|Review, ,"COVID-19|Humans|Immune Tolerance|Kidney Failure, Chronic|Organ Transplantation|SARS-CoV-2|NA",COVID-19 and Solid Organ Transplantation: A Review Article.,2021-01-06,Transplantation,NCT04401579,Abstract,2020-05-08,2020-07-31,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,124,https://pubmed.ncbi.nlm.nih.gov/33148977,https://clinicaltrials.gov/ct2/show/NCT04401579,2,0,2,0,15,1,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",0,placebo|remdesivir|baricitinib
33153145,Journal Article|Randomized Controlled Trial, ,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Exercise|Exercise Test|Female|Humans|Male|Masks|Oximetry|Oxygen Consumption|Pandemics|Pneumonia, Viral|SARS-CoV-2|Young Adult|NA",Wearing of Cloth or Disposable Surgical Face Masks has no Effect on Vigorous Exercise Performance in Healthy Individuals.,2020-11-23,International journal of environmental research and public health,NCT04557605,Abstract,2020-09-14,2020-10-15,Interventional,Effects of a Face Mask on Oxygenation During Exercise,Completed,N/A,University of Saskatchewan,NA,169,https://pubmed.ncbi.nlm.nih.gov/33153145,https://clinicaltrials.gov/ct2/show/NCT04557605,1,0,1,0,1,0,Canada,0,progressive cycling exercise test to exhaustion
33153629,"Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Granulocyte-Macrophage Colony-Stimulating Factor|lenzilumab|NA","Aged|Antibodies, Monoclonal, Humanized|COVID-19|Dose-Response Relationship, Drug|Female|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Infusions, Intravenous|Male|Middle Aged|Pandemics|SARS-CoV-2|Treatment Outcome|NA",GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.,2020-12-08,Mayo Clinic proceedings,NCT04351152,Abstract,2020-05-05,2021-03-31,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"Active, not recruiting",Phase 3,"Humanigen, Inc.",NA,33,https://pubmed.ncbi.nlm.nih.gov/33153629,https://clinicaltrials.gov/ct2/show/NCT04351152,2,0,2,0,11,1,United States|Brazil,0,lenzilumab|standard of care
33157937,Clinical Trial Protocol|Journal Article, ,"COVID-19|Cognitive Behavioral Therapy|Coronavirus Infections|Depressive Disorder, Treatment-Resistant|Health Promotion|Healthy Lifestyle|Humans|Mindfulness|Pandemics|Pneumonia, Viral|Pragmatic Clinical Trials as Topic|Quality of Life|Surveys and Questionnaires|Telemedicine|NA",Effectiveness of a healthy lifestyle promotion program as adjunctive teletherapy for treatment-resistant major depression during COVID 19 pandemic: A randomized clinical trial protocol.,2020-11-18,Medicine,NCT04428099,Abstract,2020-01-13,2022-01-12,Interventional,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,N/A,University of the Balearic Islands,NA,297,https://pubmed.ncbi.nlm.nih.gov/33157937,https://clinicaltrials.gov/ct2/show/NCT04428099,1,0,1,0,0,0,Spain,0,lifestyle change promotion program|mindfullness based cognitive program|written information
33165503,Journal Article, , ,"Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.",2020-12-10,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,NCT04412538,Abstract,2020-05-15,2020-09-30,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,305,https://pubmed.ncbi.nlm.nih.gov/33165503,https://clinicaltrials.gov/ct2/show/NCT04412538,1,0,1,1,1,0,China,0,low dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|low dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|high dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|high dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|placebo on a 0-/28-day schedule|placebo on a 0-/14-day schedule|low dosage inactivated sars-cov-2 vaccine on a 0-|28-day schedule|14-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-|high dosage inactivated sars-cov-2 vaccine on a 0-|placebo on a 0-
33165621,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural",Hydroxychloroquine|NA,Adult|Aged|COVID-19|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Treatment Failure|NA,Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.,2020-12-11,JAMA,NCT04332991,Abstract,2020-04-02,2020-06-19,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,NA,22,https://pubmed.ncbi.nlm.nih.gov/33165621,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,0,9,1,United States,1,hydroxychloroquine|placebo
33166179,Journal Article, , ,"Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.",2021-04-02,Annals of the American Thoracic Society,NCT04329832,Abstract,2020-03-30,2020-12-18,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",NA,215,https://pubmed.ncbi.nlm.nih.gov/33166179,https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,0,3,1,United States,0,hydroxychloroquine|azithromycin
33175694,Journal Article, , ,COVID-19 Misinformation Prophylaxis: Protocol for a Randomized Trial of a Brief Informational Intervention.,2020-12-12,JMIR research protocols,NCT04557241,Abstract,2020-01-14,2021-01-14,Interventional,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,N/A,Indiana University,NA,54,https://pubmed.ncbi.nlm.nih.gov/33175694,https://clinicaltrials.gov/ct2/show/NCT04557241,1,0,1,0,1,1,United States,0,brief informational infographic|placebo control (non-behavioral infographic)
33175911,"Journal Article|Research Support, Non-U.S. Gov't","RNA, Viral|NA","Aged|Autopsy|Belgium|Betacoronavirus|COVID-19|Cause of Death|Coronavirus Infections|Female|Humans|Male|Pandemics|Pneumonia, Viral|Prospective Studies|RNA, Viral|SARS-CoV-2|Tomography, X-Ray Computed|NA",The clinical value of minimal invasive autopsy in COVID-19 patients.,2020-11-18,PloS one,NCT04366882,Abstract,2020-04-14,2020-12-31,Interventional,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,N/A,Jessa Hospital,NA,340,https://pubmed.ncbi.nlm.nih.gov/33175911,https://clinicaltrials.gov/ct2/show/NCT04366882,1,0,1,0,0,0,Belgium,0,ct-scan with minimal invasive autopsy
33176886,Clinical Trial Protocol|Letter,Anticoagulants|Fibrin Fibrinogen Degradation Products|Hemoglobins|fibrin fragment D|Heparin|NA,"Acute Kidney Injury|Adult|Anticoagulants|Blood Coagulation|COVID-19|Coronavirus Infections|Drug Monitoring|Female|Fibrin Fibrinogen Degradation Products|Hemoglobins|Hemorrhage|Heparin|Humans|Male|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Renal Dialysis|Risk Adjustment|Thrombocytopenia|Thrombosis|NA",Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.,2020-11-23,Trials,NCT04487990,Abstract,2020-06-29,2020-12-31,Interventional,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,253,https://pubmed.ncbi.nlm.nih.gov/33176886,https://clinicaltrials.gov/ct2/show/NCT04487990,1,0,1,0,0,0,Brazil,0,unfractionated heparin
33177145,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,NCT04347941,Abstract,2020-07-11,2021-06-11,Interventional,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,N/A,University College Hospital Galway,NA,235,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04347941,1,0,1,0,1,0,Ireland,0,prone positioning|standard of care.
33177145,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,NCT04395144,Abstract,2020-05-15,2021-03-15,Interventional,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Completed,N/A,HÃ´pital de Verdun,NA,13,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04395144,1,0,1,0,3,0,Canada,0,awake prone positioning|standard care
33177145,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,NCT04391140,Abstract,2020-05-13,2020-12-31,Interventional,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,232,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04391140,1,0,1,0,2,0,Spain,0,prone position
33177145,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,NCT04358939,Abstract,2020-04-27,2021-11-10,Interventional,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Recruiting,N/A,"University Hospital, Tours",NA,85,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04358939,1,0,1,0,7,0,France,0,prone decubitus
33180097,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Fluvoxamine|NA,Adult|COVID-19|Clinical Deterioration|Double-Blind Method|Female|Fluvoxamine|Humans|Illinois|Male|Middle Aged|Missouri|Outpatients|Treatment Outcome|NA,Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.,2020-12-18,JAMA,NCT04342663,Abstract,2020-04-10,2020-08-20,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,NA,85,https://pubmed.ncbi.nlm.nih.gov/33180097,https://clinicaltrials.gov/ct2/show/NCT04342663,2,0,2,0,5,1,United States,0,fluvoxamine|placebo
33184083,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't",Antiviral Agents|Drug Combinations|lopinavir-ritonavir drug combination|Lopinavir|Ritonavir|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Humans|Lopinavir|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|Switzerland|NA",Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial.,2020-11-19,BMJ open,NCT04364022,Abstract,2020-04-23,2021-03-31,Interventional,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Recruiting,Phase 3,"University Hospital, Geneva",NA,215,https://pubmed.ncbi.nlm.nih.gov/33184083,https://clinicaltrials.gov/ct2/show/NCT04364022,1,0,1,0,1,0,Switzerland,0,lopinavir/ritonavir|lopinavir|ritonavir
33184146,Journal Article, , ,"Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study).",2020-11-13,Postgraduate medical journal,NCT04459247,Abstract,2020-06-15,2020-08-30,Interventional,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",N/A,Postgraduate Institute of Medical Education and Research,NA,221,https://pubmed.ncbi.nlm.nih.gov/33184146,https://clinicaltrials.gov/ct2/show/NCT04459247,1,0,1,0,1,0,India,0,vit d
33186055,"Comparative Study|Journal Article|Research Support, N.I.H., Extramural",Troponin|NA,"Aged|COVID-19|Disease-Free Survival|Female|Heart Injuries|Humans|Male|Middle Aged|Myocardium|Prevalence|Registries|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Severity of Illness Index|Survival Rate|Troponin|NA",Myocardial Injury in Severe COVID-19 Compared With Non-COVID-19 Acute Respiratory Distress Syndrome.,2021-02-15,Circulation,NCT04435184,Abstract,2020-07-09,2020-11-28,Interventional,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,Phase 2,Johns Hopkins University,NA,79,https://pubmed.ncbi.nlm.nih.gov/33186055,https://clinicaltrials.gov/ct2/show/NCT04435184,1,0,1,0,5,1,United States,0,crizanlizumab|0.9% saline
33189161,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Interferon beta-1a|NA,"Administration, Inhalation|Adult|Aged|Antiviral Agents|COVID-19|Double-Blind Method|Female|Humans|Interferon beta-1a|Male|Middle Aged|Nebulizers and Vaporizers|Treatment Outcome|NA","Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.",2021-02-25,The Lancet. Respiratory medicine,NCT04385095,Abstract,2020-03-16,2021-02-17,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,"Active, not recruiting",Phase 2,Synairgen Research Ltd.,NA,15,https://pubmed.ncbi.nlm.nih.gov/33189161,https://clinicaltrials.gov/ct2/show/NCT04385095,2,0,2,0,3,0,United Kingdom,0,sng001|placebo
33190086,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|COVID-19|Critical Illness|Cytokine Release Syndrome|Female|Humans|Male|Middle Aged|Oxygen Inhalation Therapy|Pilot Projects|Plasma Exchange|Prospective Studies|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Severity of Illness Index|NA",Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.,2021-01-11,Respiratory medicine,NCT04374149,Abstract,2020-04-30,2020-09-30,Interventional,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,Completed,Phase 2,Prisma Health-Upstate,NA,10,https://pubmed.ncbi.nlm.nih.gov/33190086,https://clinicaltrials.gov/ct2/show/NCT04374149,1,0,1,0,2,1,United States,0,therapeutic plasma exchange|ruxolitinib
33192504,Journal Article, , ,Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of <i>Glycyrrhiza glabra</i> L. (Licorice).,2020-11-17,Frontiers in pharmacology,NCT04487964,Abstract,2020-01-01,2020-12-01,Interventional,Complementary Intervention for COVID-19,Recruiting,N/A,Egyptian Biomedical Research Network,NA,252,https://pubmed.ncbi.nlm.nih.gov/33192504,https://clinicaltrials.gov/ct2/show/NCT04487964,1,0,1,0,1,0,Egypt,0,licorice extract
33196449,Journal Article, , ,A Self-Administered Multicomponent Web-Based Mental Health Intervention for the Mexican Population During the COVID-19 Pandemic: Protocol for a Randomized Controlled Trial.,2020-12-07,JMIR research protocols,NCT04468893,Abstract,2020-05-20,2020-12-31,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,151,https://pubmed.ncbi.nlm.nih.gov/33196449,https://clinicaltrials.gov/ct2/show/NCT04468893,1,5,6,0,1,0,Mexico,0,online intervention mental health covid-19
33203440,Clinical Trial Protocol|Letter, ,"Adult|Anxiety|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Depression|Eye Movement Desensitization Reprocessing|Feasibility Studies|Female|Home Care Services, Hospital-Based|Humans|Internet-Based Intervention|Male|Pandemics|Pneumonia, Viral|Psychological Techniques|Quality of Life|Randomized Controlled Trials as Topic|SARS-CoV-2|Stress Disorders, Post-Traumatic|NA",CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial.,2020-11-23,Trials,NCT04455360,Abstract,2020-10-01,2021-03-31,Interventional,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,165,https://pubmed.ncbi.nlm.nih.gov/33203440,https://clinicaltrials.gov/ct2/show/NCT04455360,1,0,1,0,1,0,United Kingdom,0,eye movement desensitisation/reprocessing recent traumatic event protocol|eye movement desensitisation|reprocessing recent traumatic event protocol
33204764,Journal Article, , ,Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19.,2020-12-30,Open forum infectious diseases,NCT04328467,Abstract,2020-04-06,2020-08-31,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Phase 3,University of Minnesota,NA,312,https://pubmed.ncbi.nlm.nih.gov/33204764,https://clinicaltrials.gov/ct2/show/NCT04328467,1,0,1,0,5,1,United States,0,hydroxychloroquine|placebo
33205991,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't", ,"Adult|COVID-19|COVID-19 Nucleic Acid Testing|COVID-19 Serological Testing|Denmark|Disease Transmission, Infectious|Humans|Masks|Middle Aged|Pandemics|Physical Distancing|SARS-CoV-2|NA",Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial.,2021-03-23,Annals of internal medicine,NCT04337541,Abstract,2020-04-02,2020-06-02,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,N/A,"Rigshospitalet, Denmark",NA,248,https://pubmed.ncbi.nlm.nih.gov/33205991,https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,0,1,0,Denmark,0,surgical facial mask
33212440,Journal Article, , ,Brief Online Cognitive Behavioural Intervention for Dysfunctional Worry Related to the COVID-19 Pandemic: A Randomised Controlled Trial.,2021-01-14,Psychotherapy and psychosomatics,NCT04341922,Abstract,2020-05-09,2020-08-20,Interventional,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",N/A,Karolinska Institutet,NA,170,https://pubmed.ncbi.nlm.nih.gov/33212440,https://clinicaltrials.gov/ct2/show/NCT04341922,1,0,1,0,5,0,Sweden,0,internet-delivered cognitive behavior therapy (icbt) for dysfunctional worry related to the covid-19 pandemic
33213529,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial",Anti-Bacterial Agents|Complement C5|Ceftriaxone|Oxygen|NA,"Acute Disease|Adult|Anti-Bacterial Agents|Belgium|Betacoronavirus|COVID-19|Case-Control Studies|Ceftriaxone|Complement C5|Coronavirus Infections|Cytokine Release Syndrome|Drug Therapy, Combination|Humans|Hypoxia|Infusions, Intravenous|Injections, Subcutaneous|Oxygen|Pandemics|Pneumonia, Viral|Prospective Studies|Respiratory Insufficiency|SARS-CoV-2|Safety|Treatment Outcome|NA",Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.,2020-11-26,Trials,NCT04382755,Abstract,2020-05-22,2020-12-29,Interventional,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"Active, not recruiting",Phase 2,"University Hospital, Ghent",NA,33,https://pubmed.ncbi.nlm.nih.gov/33213529,https://clinicaltrials.gov/ct2/show/NCT04382755,1,0,1,0,3,0,Belgium,0,zilucoplanâ®|placebo|zilucoplanâ®
33217362,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Immunoglobulin M|Vaccines, Inactivated|NA","Adolescent|Adult|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|China|Female|Healthy Volunteers|Humans|Immunization Schedule|Immunogenicity, Vaccine|Immunoglobulin G|Immunoglobulin M|Male|Middle Aged|SARS-CoV-2|Seroconversion|Vaccination|Vaccines, Inactivated|Young Adult|NA","Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.",2021-02-15,The Lancet. Infectious diseases,NCT04352608,Abstract,2020-04-16,2020-07-10,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,244,https://pubmed.ncbi.nlm.nih.gov/33217362,https://clinicaltrials.gov/ct2/show/NCT04352608,1,0,1,1,3,0,China,0,two doses of placebo at the routine vaccination schedule|two doses of medium dosage inactivated sars-cov-2 vaccine at the emergency vaccination schedule|two doses of high dosage inactivated sars-cov-2 vaccine at the emergency vaccination schedule|two doses of placebo at the emergency vaccination schedule|two doses of medium dosage inactivated sars-cov-2 vaccine at the routine vaccination schedule|two doses of high dosage inactivated sars-cov-2 vaccine at the routine vaccination schedule
33220855,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|Immunoglobulin G|ChAdOx1 COVID-19 vaccine|NA,"Adolescent|Adult|Age Factors|Aged|Aged, 80 and over|COVID-19|COVID-19 Vaccines|Female|Humans|Immunization, Secondary|Immunogenicity, Vaccine|Immunoglobulin G|Male|Middle Aged|SARS-CoV-2|Single-Blind Method|Young Adult|NA","Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.",2020-12-31,"Lancet (London, England)",NCT04400838,Abstract,2020-05-28,2021-09-30,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,116,https://pubmed.ncbi.nlm.nih.gov/33220855,https://clinicaltrials.gov/ct2/show/NCT04400838,4,0,4,1,9,0,United Kingdom,0,chadox1 ncov-19 (abs 260)|menacwy vaccine|chadox1 ncov-19 (abs 260) / 2.2x10^10vp (qpcr) boost|two dose menacwy vaccine|chadox1 ncov-19 (qpcr)|chadox1 ncov-19 0.5ml prime/boost|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|chadox1 ncov-19 0.5ml prime|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml
33225960,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial",Antiviral Agents|Oxygen|Interferon beta-1a|NA,"Adult|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Data Management|Female|Humans|Injections, Subcutaneous|Interferon beta-1a|Italy|Length of Stay|Male|Mortality|Oxygen|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|Viral Load|NA",Interferon Î²-1a (IFNÎ²-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial.,2020-11-26,Trials,NCT04449380,Abstract,2020-11-02,2021-04-30,Interventional,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,Recruiting,Phase 2,IRCCS San Raffaele,NA,148,https://pubmed.ncbi.nlm.nih.gov/33225960,https://clinicaltrials.gov/ct2/show/NCT04449380,1,0,1,0,4,0,Italy,0,interferon-ãÿ-1a|standard of care (soc)|interferon-ãÿ-1a
33225989,Letter|Randomized Controlled Trial,"Fatty Acids, Omega-3|Placebos|NA","Betacoronavirus|COVID-19|Case-Control Studies|Coronavirus Infections|Dietary Supplements|Double-Blind Method|Fatty Acids, Omega-3|Humans|New York|Olfaction Disorders|Pandemics|Placebos|Pneumonia, Viral|SARS-CoV-2|Smell|NA",Letter to the editor: Study Summary - Randomized Control Trial of Omega-3 Fatty Acid Supplementation for the Treatment of COVID-19 Related Olfactory Dysfunction.,2020-11-26,Trials,NCT04495816,Abstract,2020-07-15,2021-08-31,Interventional,COVID-19 Anosmia Study,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,36,https://pubmed.ncbi.nlm.nih.gov/33225989,https://clinicaltrials.gov/ct2/show/NCT04495816,1,0,1,0,3,1,United States,0,omega-3 fatty acid supplement|placebo/control|placebo|control
33225990,Letter|Randomized Controlled Trial,Oxygen|NA,"Acute Disease|Adult|Betacoronavirus|COVID-19|Cannula|Case-Control Studies|Coronavirus Infections|Female|Hospitalization|Humans|Intubation, Intratracheal|Male|Mexico|Oxygen|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Respiratory Insufficiency|SARS-CoV-2|NA","Prone positioning in non-intubated patients with COVID-19 associated acute respiratory failure, the PRO-CARF trial: A structured summary of a study protocol for a randomised controlled trial.",2020-11-26,Trials,NCT04477655,Abstract,2020-05-03,2020-11-30,Interventional,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Recruiting,N/A,Hospital Civil de Guadalajara,NA,244,https://pubmed.ncbi.nlm.nih.gov/33225990,https://clinicaltrials.gov/ct2/show/NCT04477655,1,0,1,0,2,0,Mexico,0,awake prone positioning|standard oxygen therapy
33225995,Comparative Study|Letter|Randomized Controlled Trial, ,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Early Diagnosis|Female|Homeless Persons|Humans|Male|Mass Screening|Ontario|Pandemics|Patient Compliance|Pneumonia, Viral|Program Evaluation|Prospective Studies|SARS-CoV-2|Specimen Handling|Time Factors|NA",Comparison of four COVID-19 screening strategies to facilitate early case identification within the homeless shelter population: A structured summary of a study protocol for a randomised controlled trial.,2020-11-26,Trials,NCT04438070,Abstract,2020-04-10,2020-06-30,Interventional,COVID Screening Strategies in Homeless Shelters,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,290,https://pubmed.ncbi.nlm.nih.gov/33225995,https://clinicaltrials.gov/ct2/show/NCT04438070,1,0,1,0,0,0,Canada,0,covid-19 swab
33232588,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Immunoglobulin G|NA","Aged|Aged, 80 and over|Antibodies, Neutralizing|Blood Component Transfusion|COVID-19|Disease Progression|Double-Blind Method|Female|Hospitalization|Humans|Immunization, Passive|Immunoglobulin G|Kaplan-Meier Estimate|Male|Middle Aged|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|NA",A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.,2021-02-23,The New England journal of medicine,NCT04383535,Abstract,2020-05-15,2020-09-27,Interventional,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,N/A,Hospital Italiano de Buenos Aires,NA,186,https://pubmed.ncbi.nlm.nih.gov/33232588,https://clinicaltrials.gov/ct2/show/NCT04383535,1,1,2,0,4,0,Argentina,0,convalescent sars covid-19 plasma|placebo
33234158,Letter|Randomized Controlled Trial,Antiparasitic Agents|Placebos|Ivermectin|NA,Adult|Antiparasitic Agents|Argentina|COVID-19|Case-Control Studies|Double-Blind Method|Female|Hospitalization|Humans|Ivermectin|Male|Pandemics|Placebos|Prospective Studies|SARS-CoV-2|Time Factors|NA,Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.,2020-12-07,Trials,NCT04529525,Abstract,2020-08-19,2021-02-28,Interventional,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Phase 2/Phase 3,Instituto de CardiologÃ­a de Corrientes,NA,50,https://pubmed.ncbi.nlm.nih.gov/33234158,https://clinicaltrials.gov/ct2/show/NCT04529525,1,11,12,0,5,0,Argentina,0,ivermectin|placebo
33234651,Clinical Study|Journal Article|Multicenter Study,"Antibodies, Viral|NA","Antibodies, Viral|COVID-19|Female|Humans|Male|Mass Screening|Pandemics|Prospective Studies|SARS-CoV-2|Serologic Tests|NA","Assessment of serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric study.",2020-12-10,BMJ open,NCT04341142,Abstract,2020-04-09,2023-04-09,Interventional,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,N/A,Hospices Civils de Lyon,NA,248,https://pubmed.ncbi.nlm.nih.gov/33234651,https://clinicaltrials.gov/ct2/show/NCT04341142,1,0,1,0,5,0,France,0,serological tests will be applied on patients blood sampling
33239100,Letter|Randomized Controlled Trial, ,"Adult|Blood Glucose Self-Monitoring|COVID-19|Denmark|Diabetes Mellitus, Type 2|Female|Glycemic Control|Health Personnel|Hospitalization|Humans|Infectious Disease Transmission, Patient-to-Professional|Male|Quarantine|Remote Consultation|SARS-CoV-2|NA",Remote continuous glucose monitoring during the COVID-19 pandemic in quarantined hospitalized patients in Denmark: A structured summary of a study protocol for a randomized controlled trial.,2020-12-07,Trials,NCT04430608,Abstract,2020-05-25,2021-04-25,Interventional,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,N/A,Nordsjaellands Hospital,NA,296,https://pubmed.ncbi.nlm.nih.gov/33239100,https://clinicaltrials.gov/ct2/show/NCT04430608,1,0,1,0,0,0,Denmark,0,dexcom g6
33240091,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,NCT04348695,Abstract,2020-04-12,2020-05-13,Interventional,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,353,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04348695,1,0,1,0,1,0,Spain,0,ruxolitinib/simvastatin|standard of care|ruxolitinib|simvastatin
33240091,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,NCT04304313,Abstract,2020-02-09,2020-03-01,Interventional,A Pilot Study of Sildenafil in COVID-19,Recruiting,Phase 3,Tongji Hospital,NA,385,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04304313,1,0,1,0,1,0,China,0,sildenafil citrate tablets
33240091,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,NCT04321174,Abstract,2020-04-17,2021-03-31,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,351,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04321174,3,0,3,0,1,0,Canada,0,lopinavir/ritonavir|lopinavir|ritonavir
33240091,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,NCT04244591,Abstract,2020-01-26,2020-04-13,Interventional,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Phase 2/Phase 3,Peking Union Medical College Hospital,NA,294,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04244591,1,0,1,0,6,0,China,0,methylprednisolone therapy|standard care
33240091,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,NCT04280705,Abstract,2020-02-21,2020-05-21,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,119,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04280705,3,0,3,0,24,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir
33240091,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,NCT04359329,Abstract,2020-04-20,2020-11-15,Interventional,Estrogen Patch for COVID-19 Symptoms,Recruiting,Phase 2,Stony Brook University,NA,346,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04359329,1,0,1,0,0,1,United States,0,estradiol patch
33240091,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,NCT04342663,Abstract,2020-04-10,2020-08-20,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,NA,85,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04342663,2,0,2,0,5,1,United States,0,fluvoxamine|placebo
33246499,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial","Antibodies, Viral|NA","Adult|Antibodies, Viral|Belgium|COVID-19|Combined Modality Therapy|Female|Global Burden of Disease|Hospitalization|Humans|Immunization, Passive|Male|Mortality|Respiration, Artificial|SARS-CoV-2|Safety|Standard of Care|Treatment Outcome|NA","A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.",2020-12-07,Trials,NCT04429854,Abstract,2020-05-02,2021-04-30,Interventional,Donated Antibodies Working Against nCoV,"Active, not recruiting",Phase 2,Universitaire Ziekenhuizen Leuven,NA,17,https://pubmed.ncbi.nlm.nih.gov/33246499,https://clinicaltrials.gov/ct2/show/NCT04429854,1,0,1,0,3,0,Belgium,0,convalescent plasma|standard of care
33247380,Journal Article, , ,"Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial.",2020-12-02,Biological trace element research,NCT04447534,Abstract,2020-06-23,2030-10-01,Interventional,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Phase 3,Tanta University,NA,122,https://pubmed.ncbi.nlm.nih.gov/33247380,https://clinicaltrials.gov/ct2/show/NCT04447534,1,0,1,0,3,0,Egypt,0,chloroquine|zinc
33251500,Journal Article, , ,Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.,2020-12-18,EClinicalMedicine,NCT04349592,Abstract,2020-04-14,2020-08-14,Interventional,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,N/A,Hamad Medical Corporation,NA,41,https://pubmed.ncbi.nlm.nih.gov/33251500,https://clinicaltrials.gov/ct2/show/NCT04349592,1,0,1,0,2,0,Qatar,0,hydroxychloroquine|azithromycin|placebo tablet|placebo capsules
33259326,Journal Article, , ,Online and Recovery-Oriented Support Groups Facilitated by Peer Support Workers in Times of COVID-19: Protocol for a Feasibility Pre-Post Study.,2020-12-31,JMIR research protocols,NCT04445324,Abstract,2020-08-25,2020-08-25,Interventional,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting",N/A,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,NA,135,https://pubmed.ncbi.nlm.nih.gov/33259326,https://clinicaltrials.gov/ct2/show/NCT04445324,1,0,1,0,4,0,Canada,0,"transitional online peer support group (n=20)|control group (pharmacotherapy and/or psychotherapy, n=10)|control group (pharmacotherapy and|or psychotherapy, n=10)"
33264556,"Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Lopinavir|remdesivir|Adenosine Monophosphate|Hydroxychloroquine|Alanine|Interferon beta-1a|NA,"Adenosine Monophosphate|Aged|Alanine|Antiviral Agents|COVID-19|Drug Therapy, Combination|Female|Hospital Mortality|Hospitalization|Humans|Hydroxychloroquine|Intention to Treat Analysis|Interferon beta-1a|Kaplan-Meier Estimate|Length of Stay|Lopinavir|Male|Middle Aged|Respiration, Artificial|Treatment Failure|NA",Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.,2021-02-12,The New England journal of medicine,NCT04315948,Abstract,2020-03-22,2023-03-31,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,"Active, not recruiting",Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,61,https://pubmed.ncbi.nlm.nih.gov/33264556,https://clinicaltrials.gov/ct2/show/NCT04315948,3,0,3,0,7,0,Austria|Belgium|France|Luxembourg|Portugal,0,remdesivir|lopinavir/ritonavir|interferon beta-1a|hydroxychloroquine|standard of care|lopinavir|ritonavir
33267662,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",NCT04432987,Abstract,2020-05-25,2020-08-25,Interventional,Dornase Alpha for the Treatment of COVID-19,Recruiting,Phase 2,Acibadem University,NA,292,https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04432987,1,0,1,0,0,0,Turkey,0,pulmozyme
33267662,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",NCT04445285,Abstract,2020-04-28,2020-11-30,Interventional,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,University of South Alabama,NA,227,https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04445285,1,0,1,0,2,1,United States,0,pulmozyme/ recombinant human deoxyribonuclease (rh-dnase)|0.9%sodium chloride|pulmozyme|recombinant human deoxyribonuclease (rh-dnase)
33267662,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",NCT04541979,Abstract,2020-06-04,2021-05-01,Interventional,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Phase 2,Region Skane,NA,38,https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04541979,1,0,1,0,1,0,Sweden,0,aerosolized dnase|nacl
33267662,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",NCT04402944,Abstract,2020-07-05,2021-05-31,Interventional,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Phase 2,Boston Children's Hospital,NA,162,https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04402944,1,0,1,0,2,1,United States,0,pulmozyme|placebo
33267662,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",NCT04402970,Abstract,2020-06-19,2020-12-31,Interventional,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Completed,Phase 3,University of Missouri-Columbia,NA,58,https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04402970,1,0,1,0,5,1,United States,0,dornase alfa inhalation solution
33270471,Journal Article, , ,"Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure.",2020-12-24,Platelets,NCT04343053,Abstract,2020-04-08,2020-06-09,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,NA,298,https://pubmed.ncbi.nlm.nih.gov/33270471,https://clinicaltrials.gov/ct2/show/NCT04343053,3,0,3,0,2,0,Italy,0,sars-cov-2 infection
33272319,Comparative Study|Journal Article|Randomized Controlled Trial, ,"Adult|COVID-19|Cannula|Continuous Positive Airway Pressure|Female|Head Protective Devices|Humans|Hypoxia|Male|Oxygen Inhalation Therapy|Positive-Pressure Respiration|Respiration, Artificial|SARS-CoV-2|Sweden|NA",Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET).,2020-12-14,Trials,NCT04395807,Abstract,2020-06-03,2020-12-31,Interventional,Helmet CPAP Versus HFNC in COVID-19,Recruiting,N/A,Lund University,NA,303,https://pubmed.ncbi.nlm.nih.gov/33272319,https://clinicaltrials.gov/ct2/show/NCT04395807,1,0,1,0,1,0,Sweden,0,helmet cpap|hfnc
33273742,"Journal Article|Research Support, N.I.H., Extramural",Antiviral Agents|Cytokines|Hydroxylamines|remdesivir|Adenosine Monophosphate|Cytidine|Alanine|molnupiravir|NA,"Adenosine Monophosphate|Alanine|Animals|Antiviral Agents|COVID-19|Chlorocebus aethiops|Cytidine|Cytokines|Disease Models, Animal|Disease Transmission, Infectious|Female|Ferrets|Hydroxylamines|Random Allocation|SARS-CoV-2|Vero Cells|NA",Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.,2021-01-13,Nature microbiology,NCT04405739,Abstract,2020-06-16,2021-05-28,Interventional,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",NA,45,https://pubmed.ncbi.nlm.nih.gov/33273742,https://clinicaltrials.gov/ct2/show/NCT04405739,1,0,1,0,15,1,United States,0,eidd-2801|placebo (pb0)
33273742,"Journal Article|Research Support, N.I.H., Extramural",Antiviral Agents|Cytokines|Hydroxylamines|remdesivir|Adenosine Monophosphate|Cytidine|Alanine|molnupiravir|NA,"Adenosine Monophosphate|Alanine|Animals|Antiviral Agents|COVID-19|Chlorocebus aethiops|Cytidine|Cytokines|Disease Models, Animal|Disease Transmission, Infectious|Female|Ferrets|Hydroxylamines|Random Allocation|SARS-CoV-2|Vero Cells|NA",Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.,2021-01-13,Nature microbiology,NCT04405570,Abstract,2020-06-16,2021-02-21,Interventional,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,Phase 2,"Ridgeback Biotherapeutics, LP",NA,40,https://pubmed.ncbi.nlm.nih.gov/33273742,https://clinicaltrials.gov/ct2/show/NCT04405570,1,0,1,0,18,1,United States,0,eidd-2801|placebo (pbo)
33284679,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Antiviral Agents|COVID-19|COVID-19 Nucleic Acid Testing|Double-Blind Method|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Post-Exposure Prophylaxis|SARS-CoV-2|Time Factors|Treatment Outcome|United States|Young Adult|NA",Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.,2021-03-23,Annals of internal medicine,NCT04328961,Abstract,2020-03-31,2020-09-24,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,NA,158,https://pubmed.ncbi.nlm.nih.gov/33284679,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,0,5,1,United States,0,hydroxychloroquine sulfate|ascorbic acid
33287790,Clinical Trial Protocol|Journal Article,"Antibodies, Viral|NA","Adult|Antibodies, Viral|Belgium|COVID-19|Clinical Trials, Phase II as Topic|Humans|Immunization, Passive|Intensive Care Units|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|Respiration, Artificial|Severe Acute Respiratory Syndrome|Time Factors|Treatment Outcome|NA",A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.,2020-12-21,BMC pulmonary medicine,NCT04558476,Abstract,2020-09-01,2022-09-01,Interventional,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Phase 2,University of Liege,NA,194,https://pubmed.ncbi.nlm.nih.gov/33287790,https://clinicaltrials.gov/ct2/show/NCT04558476,1,0,1,0,0,0,Belgium,0,convalescent plasma|standard of care
33289973,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anti-Infective Agents|Hydroxychloroquine|NA,"Adult|Anti-Infective Agents|COVID-19|Disease Transmission, Infectious|Double-Blind Method|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Patient Compliance|SARS-CoV-2|Treatment Failure|Viral Load|NA",A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.,2021-02-09,The New England journal of medicine,NCT04304053,Abstract,2020-03-18,2020-06-15,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,281,https://pubmed.ncbi.nlm.nih.gov/33289973,https://clinicaltrials.gov/ct2/show/NCT04304053,2,0,2,0,9,0,Spain,0,treatment/prophylaxis|standard public health measures|treatment|prophylaxis
33290245,Journal Article, , ,Using the Online Psychotherapy Tool to Address Mental Health Problems in the Context of the COVID-19 Pandemic: Protocol for an Electronically Delivered Cognitive Behavioral Therapy Program.,2020-12-31,JMIR research protocols,NCT04476667,Abstract,2020-06-15,2021-05-31,Interventional,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,N/A,Queen's University,NA,46,https://pubmed.ncbi.nlm.nih.gov/33290245,https://clinicaltrials.gov/ct2/show/NCT04476667,1,0,1,0,1,0,Canada,0,e-psychotherapy
33298117,Letter|Randomized Controlled Trial, ,Adult|Anxiety|COVID-19|Case-Control Studies|Humans|Meditation|Mindfulness|Mobile Applications|SARS-CoV-2|Surveys and Questionnaires|NA,Effectiveness of using a meditation app in reducing anxiety and improving well-being during the COVID-19 pandemic: A structured summary of a study protocol for a randomized controlled trial.,2020-12-21,Trials,NCT04369378,Abstract,2020-08-19,2021-02-28,Interventional,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,N/A,Lake Erie College of Osteopathic Medicine,NA,144,https://pubmed.ncbi.nlm.nih.gov/33298117,https://clinicaltrials.gov/ct2/show/NCT04369378,1,0,1,0,2,1,United States,0,meditation app usage
33301246,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","COVID-19 Vaccines|Vaccines, Synthetic|mRNA Vaccine|BNT162 vaccine|NA","Adolescent|Adult|Aged|COVID-19|COVID-19 Vaccines|Fatigue|Female|Headache|Humans|Immunization, Secondary|Male|Middle Aged|SARS-CoV-2|Single-Blind Method|Treatment Outcome|Vaccines, Synthetic|Young Adult|NA",Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.,2021-01-12,The New England journal of medicine,NCT04368728,Abstract,2020-04-29,2021-08-03,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","Active, not recruiting",Phase 2/Phase 3,BioNTech SE,NA,17,https://pubmed.ncbi.nlm.nih.gov/33301246,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,26,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo
33302976,Letter|Randomized Controlled Trial,Surface-Active Agents|NA,"Adult|COVID-19|Case-Control Studies|Feasibility Studies|Humans|Intensive Care Units|London|Mortality|Nebulizers and Vaporizers|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Safety|Surface-Active Agents|Treatment Outcome|Ventilation|NA",Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.,2020-12-21,Trials,NCT04362059,Abstract,2020-06-18,2021-07-27,Interventional,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,207,https://pubmed.ncbi.nlm.nih.gov/33302976,https://clinicaltrials.gov/ct2/show/NCT04362059,1,14,15,0,3,0,United Kingdom,0,covsurf drug delivery system|standard of care
33303470,Comparative Study|Journal Article|Multicenter Study, ,"COVID-19|Depression, Postpartum|Female|France|Humans|Parturition|Physical Distancing|Postpartum Period|Pregnancy|Prospective Studies|Psychiatric Status Rating Scales|Research Design|Stress Disorders, Post-Traumatic|Surveys and Questionnaires|Time Factors|NA",Birth experience during COVID-19 confinement (CONFINE): protocol for a multicentre prospective study.,2020-12-29,BMJ open,NCT04348929,Abstract,2020-04-16,2021-08-16,Interventional,Birth Experience During COVID-19 Confinement,Recruiting,N/A,"Central Hospital, Nancy, France",NA,183,https://pubmed.ncbi.nlm.nih.gov/33303470,https://clinicaltrials.gov/ct2/show/NCT04348929,1,0,1,0,3,0,France,0,self-administered questionnaires
33304914,Journal Article, , ,Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform to Enhance Lung-Protective Ventilation in Hypercapnic Patients With Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome.,2020-12-12,Frontiers in medicine,NCT04351906,Abstract,2020-05-03,2021-06-01,Interventional,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,N/A,University of Giessen,NA,186,https://pubmed.ncbi.nlm.nih.gov/33304914,https://clinicaltrials.gov/ct2/show/NCT04351906,1,1,2,0,5,0,Germany,0,ecco2r
33306283,"Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Antiviral Agents|Azetidines|Janus Kinase Inhibitors|Purines|Pyrazoles|Sulfonamides|remdesivir|Adenosine Monophosphate|baricitinib|Alanine|NA,"Adenosine Monophosphate|Adult|Aged|Alanine|Antiviral Agents|Azetidines|COVID-19|Double-Blind Method|Drug Therapy, Combination|Female|Hospital Mortality|Hospitalization|Humans|Janus Kinase Inhibitors|Male|Middle Aged|Oxygen Inhalation Therapy|Purines|Pyrazoles|Respiration, Artificial|Sulfonamides|Treatment Outcome|NA",Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.,2021-03-08,The New England journal of medicine,NCT04401579,Abstract,2020-05-08,2020-07-31,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,124,https://pubmed.ncbi.nlm.nih.gov/33306283,https://clinicaltrials.gov/ct2/show/NCT04401579,2,0,2,0,15,1,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",0,placebo|remdesivir|baricitinib
33306989,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,Adolescent|Adult|Aged|Brazil|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Male|Middle Aged|Single-Blind Method|South Africa|Treatment Outcome|United Kingdom|Young Adult|NA,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.",2021-02-01,"Lancet (London, England)",NCT04444674,Abstract,2020-06-24,2020-12-31,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,131,https://pubmed.ncbi.nlm.nih.gov/33306989,https://clinicaltrials.gov/ct2/show/NCT04444674,3,0,3,1,4,0,South Africa,0,chadox1 ncov-19|normal saline 0.9%
33306989,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,Adolescent|Adult|Aged|Brazil|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Male|Middle Aged|Single-Blind Method|South Africa|Treatment Outcome|United Kingdom|Young Adult|NA,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.",2021-02-01,"Lancet (London, England)",NCT04324606,Abstract,2020-04-23,2021-10-31,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,12,https://pubmed.ncbi.nlm.nih.gov/33306989,https://clinicaltrials.gov/ct2/show/NCT04324606,4,0,4,1,13,0,United Kingdom,0,chadox1 ncov-19|menacwy|chadox1 ncov-19 full boost|chadox1 ncov-19 half boost|menacwy boost|paracetamol|chadox1 ncov-19 0.5ml boost|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine (lv)|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine two (lvt)
33306989,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,Adolescent|Adult|Aged|Brazil|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Male|Middle Aged|Single-Blind Method|South Africa|Treatment Outcome|United Kingdom|Young Adult|NA,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.",2021-02-01,"Lancet (London, England)",NCT04400838,Abstract,2020-05-28,2021-09-30,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,116,https://pubmed.ncbi.nlm.nih.gov/33306989,https://clinicaltrials.gov/ct2/show/NCT04400838,4,0,4,1,9,0,United Kingdom,0,chadox1 ncov-19 (abs 260)|menacwy vaccine|chadox1 ncov-19 (abs 260) / 2.2x10^10vp (qpcr) boost|two dose menacwy vaccine|chadox1 ncov-19 (qpcr)|chadox1 ncov-19 0.5ml prime/boost|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|chadox1 ncov-19 0.5ml prime|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml
33307107,"Clinical Trial, Phase II|Journal Article|Multicenter Study","Antibodies, Monoclonal, Humanized|Biomarkers|Circulating MicroRNA|MIRN146 microRNA, human|MicroRNAs|tocilizumab|NA","Adult|Aged|Antibodies, Monoclonal, Humanized|Biomarkers|COVID-19|Circulating MicroRNA|Female|Humans|Inflammation|Male|MicroRNAs|Middle Aged|Pandemics|SARS-CoV-2|NA",Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.,2021-01-12,Mechanisms of ageing and development,NCT04315480,Abstract,2020-03-12,2020-04-09,Interventional,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Phase 2,UniversitÃ  Politecnica delle Marche,NA,359,https://pubmed.ncbi.nlm.nih.gov/33307107,https://clinicaltrials.gov/ct2/show/NCT04315480,1,0,1,0,2,0,Italy,0,tocilizumab
33329103,Journal Article, , ,"Implementation of a Mindfulness-Based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain.",2020-12-18,Frontiers in psychiatry,NCT04555005,Abstract,2020-03-10,2020-04-26,Interventional,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,N/A,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,198,https://pubmed.ncbi.nlm.nih.gov/33329103,https://clinicaltrials.gov/ct2/show/NCT04555005,1,0,1,0,0,0,Spain,0,mindfulness based intervention
33332778,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Drug Combinations|Immunologic Factors|REGN-COV-2|NA","Adult|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|COVID-19|Double-Blind Method|Drug Combinations|Female|Humans|Immunologic Factors|Least-Squares Analysis|Male|Middle Aged|Outpatients|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA","REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.",2021-02-03,The New England journal of medicine,NCT04425629,Abstract,2020-06-16,2021-04-10,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",Recruiting,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,44,https://pubmed.ncbi.nlm.nih.gov/33332778,https://clinicaltrials.gov/ct2/show/NCT04425629,1,0,1,0,17,1,United States|Chile|Mexico|Romania,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987 combination therapy
33332779,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|tocilizumab|NA","Adult|Aged|Antibodies, Monoclonal, Humanized|COVID-19|Disease Progression|Female|Hospitalization|Humans|Intention to Treat Analysis|Male|Middle Aged|Pneumonia, Viral|Respiration, Artificial|Survival Rate|NA",Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.,2021-01-12,The New England journal of medicine,NCT04372186,Abstract,2020-05-14,2020-08-18,Interventional,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Recruiting,Phase 3,"Genentech, Inc.",NA,30,https://pubmed.ncbi.nlm.nih.gov/33332779,https://clinicaltrials.gov/ct2/show/NCT04372186,1,0,1,0,8,1,United States|Brazil|Kenya|Mexico|Peru|South Africa,0,placebo|tocilizumab
33335322,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|ChAdOx1 COVID-19 vaccine|NA","Adolescent|Adult|Antibodies, Neutralizing|Antibody Formation|COVID-19|COVID-19 Vaccines|Dose-Response Relationship, Drug|Genetic Vectors|Humans|Immunization, Secondary|Middle Aged|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Time Factors|Young Adult|NA",Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.,2021-02-23,Nature medicine,NCT04324606,Abstract,2020-04-23,2021-10-31,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,12,https://pubmed.ncbi.nlm.nih.gov/33335322,https://clinicaltrials.gov/ct2/show/NCT04324606,4,0,4,1,13,0,United Kingdom,0,chadox1 ncov-19|menacwy|chadox1 ncov-19 full boost|chadox1 ncov-19 half boost|menacwy boost|paracetamol|chadox1 ncov-19 0.5ml boost|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine (lv)|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine two (lvt)
33335323,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","COVID-19 Vaccines|Immunoglobulin A|Immunoglobulin M|Protein Subunits|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|Interferon-gamma|ChAdOx1 COVID-19 vaccine|NA","Adolescent|Antibody Formation|CD4-Positive T-Lymphocytes|CD8-Positive T-Lymphocytes|COVID-19|COVID-19 Vaccines|Dose-Response Relationship, Immunologic|Female|Humans|Immunity, Cellular|Immunity, Humoral|Immunoglobulin A|Immunoglobulin M|Interferon-gamma|Lymphocyte Activation|Male|Middle Aged|Protein Subunits|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|Vaccination|Young Adult|NA",T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.,2021-02-23,Nature medicine,NCT04400838,Abstract,2020-05-28,2021-09-30,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,116,https://pubmed.ncbi.nlm.nih.gov/33335323,https://clinicaltrials.gov/ct2/show/NCT04400838,4,0,4,1,9,0,United Kingdom,0,chadox1 ncov-19 (abs 260)|menacwy vaccine|chadox1 ncov-19 (abs 260) / 2.2x10^10vp (qpcr) boost|two dose menacwy vaccine|chadox1 ncov-19 (qpcr)|chadox1 ncov-19 0.5ml prime/boost|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|chadox1 ncov-19 0.5ml prime|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml
33347320,Journal Article, , ,Comparison of Knowledge and Information-Seeking Behavior After General COVID-19 Public Health Messages and Messages Tailored for Black and Latinx Communities : A Randomized Controlled Trial.,2021-01-05,Annals of internal medicine,NCT04371419,Abstract,2020-05-13,2020-05-24,Interventional,COVID-19 Health Messaging to Underserved Communities,Completed,N/A,"National Bureau of Economic Research, Inc.",NA,290,https://pubmed.ncbi.nlm.nih.gov/33347320,https://clinicaltrials.gov/ct2/show/NCT04371419,1,0,1,0,2,1,United States,0,messaging
33356051,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|Glucocorticoids|remdesivir|Adenosine Monophosphate|bamlanivimab|Alanine|NA","Adenosine Monophosphate|Adult|Aged|Alanine|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|COVID-19|Double-Blind Method|Drug Therapy, Combination|Female|Glucocorticoids|Hospitalization|Humans|Intention to Treat Analysis|Male|Middle Aged|Treatment Failure|NA",A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.,2021-03-23,The New England journal of medicine,NCT04501978,Abstract,2020-08-04,2022-07-31,Interventional,ACTIV-3: Therapeutics for Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,8,https://pubmed.ncbi.nlm.nih.gov/33356051,https://clinicaltrials.gov/ct2/show/NCT04501978,1,0,1,0,28,1,United States|Denmark|India|Poland|Singapore|Spain|Switzerland|United Kingdom,0,ly3819253|placebo|remdesivir|vir-7831|brii-196/brii-198|azd7442|brii-196|brii-198
33367731,Journal Article, , ,Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.,2021-03-31,The Journal of infectious diseases,NCT04579393,Abstract,2020-01-27,2022-01-31,Interventional,Fostamatinib for Hospitalized Adults With COVID-19,"Active, not recruiting",Phase 2,National Institutes of Health Clinical Center (CC),NA,16,https://pubmed.ncbi.nlm.nih.gov/33367731,https://clinicaltrials.gov/ct2/show/NCT04579393,1,0,1,0,15,1,United States,0,placebo|fostamatinib
33371905,Journal Article|Multicenter Study|Randomized Controlled Trial,Vitamins|Vitamin D|NA,"Aged|COVID-19|Dietary Supplements|Dose-Response Relationship, Drug|Female|Humans|Male|Nutrition Therapy|Pandemics|Risk Factors|SARS-CoV-2|Time Factors|Treatment Outcome|Vitamin D|Vitamins|NA",COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial.,2021-01-06,Trials,NCT04344041,Abstract,2020-04-15,2021-05-31,Interventional,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,Phase 3,"University Hospital, Angers",NA,184,https://pubmed.ncbi.nlm.nih.gov/33371905,https://clinicaltrials.gov/ct2/show/NCT04344041,1,0,1,0,4,0,France,0,"cholecalciferol 200,000 iu|cholecalciferol 50,000 iu"
33377218,Journal Article, , ,INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies.,2021-01-19,British journal of clinical pharmacology,NCT04635241,Abstract,2020-06-01,2021-04-01,Interventional,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Phase 2/Phase 3,Australian National University,NA,111,https://pubmed.ncbi.nlm.nih.gov/33377218,https://clinicaltrials.gov/ct2/show/NCT04635241,1,0,1,0,1,0,Argentina|Egypt,0,unfractionated heparin
33378609,"Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|mRNA-1273 vaccine|NA","Adolescent|Adult|Aged|COVID-19|COVID-19 Vaccines|Female|Humans|Incidence|Male|Middle Aged|Patient Acuity|SARS-CoV-2|Single-Blind Method|Spike Glycoprotein, Coronavirus|Treatment Outcome|Young Adult|NA",Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.,2021-02-09,The New England journal of medicine,NCT04470427,Abstract,2020-07-27,2022-10-27,Interventional,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Phase 3,"ModernaTX, Inc.",NA,39,https://pubmed.ncbi.nlm.nih.gov/33378609,https://clinicaltrials.gov/ct2/show/NCT04470427,1,0,1,1,15,1,United States,0,mrna-1273|placebo
33392485,Journal Article, , ,"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.",2021-01-30,EClinicalMedicine,NCT04336410,Abstract,2020-04-03,2022-01-31,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Phase 1,Inovio Pharmaceuticals,NA,33,https://pubmed.ncbi.nlm.nih.gov/33392485,https://clinicaltrials.gov/ct2/show/NCT04336410,1,0,1,1,9,1,United States,0,ino-4800|cellectraâ® 2000|cellectraâ® 2000
33397432,Clinical Trial Protocol|Letter,"Anti-Infective Agents, Local|Nasal Sprays|Placebos|Povidone-Iodine|NA","Administration, Intranasal|Adolescent|Adult|Aged|Aged, 80 and over|Anti-Infective Agents, Local|Bangladesh|COVID-19|Clinical Trials, Phase II as Topic|Dose-Response Relationship, Drug|Female|Humans|Male|Middle Aged|Nasal Lavage|Nasal Sprays|Nasopharynx|Placebos|Povidone-Iodine|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|Young Adult|NA",Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial.,2021-01-12,Trials,NCT04549376,Abstract,2020-07-01,2020-10-20,Interventional,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Phase 2,"Pi Research Consultancy Center, Bangladesh",NA,203,https://pubmed.ncbi.nlm.nih.gov/33397432,https://clinicaltrials.gov/ct2/show/NCT04549376,1,0,1,0,0,0,Bangladesh,0,povidone-iodine 0.4% ni|povidone-iodine 0.5% ni|povidone-iodine 0.6% ni|povidone-iodine 0.5% ns|povidone-iodine 0.6% ns|placebo comparator: dw-ni|placebo comparator: dw-ns
33397449,Clinical Trial Protocol|Letter,Complement C1 Inhibitor Protein|Recombinant Proteins|conestat alfa|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Brazil|COVID-19|Clinical Trials, Phase II as Topic|Complement C1 Inhibitor Protein|Drug Administration Schedule|Female|Humans|Injections, Intravenous|Male|Mexico|Middle Aged|Multicenter Studies as Topic|Pilot Projects|Randomized Controlled Trials as Topic|Recombinant Proteins|SARS-CoV-2|Severity of Illness Index|Switzerland|Treatment Outcome|Young Adult|NA","Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).",2021-01-12,Trials,NCT04414631,Abstract,2020-08-06,2021-06-30,Interventional,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"University Hospital, Basel, Switzerland",NA,46,https://pubmed.ncbi.nlm.nih.gov/33397449,https://clinicaltrials.gov/ct2/show/NCT04414631,1,0,1,0,5,0,Brazil|Mexico|Switzerland,0,conestat alfa
33397457,Clinical Trial Protocol|Comparative Study|Letter,"Antiviral Agents|Drug Combinations|RNA, Viral|Thiazoles|Atazanavir Sulfate|Ritonavir|nitazoxanide|NA","Administration, Oral|Adolescent|Adult|Aged|Antiviral Agents|Atazanavir Sulfate|COVID-19|COVID-19 Nucleic Acid Testing|Clinical Trials, Phase II as Topic|Drug Administration Schedule|Drug Combinations|Drug Repositioning|Drug Therapy, Combination|Female|Humans|Male|Middle Aged|Multicenter Studies as Topic|Nigeria|Pilot Projects|RNA, Viral|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|Severity of Illness Index|Standard of Care|Thiazoles|Treatment Outcome|Viral Load|Young Adult|NA",Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.,2021-01-12,Trials,NCT04459286,Abstract,2020-10-09,2021-03-31,Interventional,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Phase 2,Obafemi Awolowo University,NA,61,https://pubmed.ncbi.nlm.nih.gov/33397457,https://clinicaltrials.gov/ct2/show/NCT04459286,1,0,1,0,3,0,Nigeria,0,nitazoxanide/atazanavir/ritonavir|standard of care|nitazoxanide|atazanavir|ritonavir
33406353,"Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Immunoglobulin G|NA,"Aged|Aged, 80 and over|Blood Component Transfusion|COVID-19|Disease Progression|Double-Blind Method|Female|Humans|Immunization, Passive|Immunoglobulin G|Intention to Treat Analysis|Kaplan-Meier Estimate|Male|Respiratory Insufficiency|SARS-CoV-2|Severity of Illness Index|NA",Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.,2021-02-23,The New England journal of medicine,NCT04479163,Abstract,2020-06-04,2020-10-25,Interventional,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,N/A,Fundacion Infant,NA,105,https://pubmed.ncbi.nlm.nih.gov/33406353,https://clinicaltrials.gov/ct2/show/NCT04479163,1,0,1,0,3,0,Argentina,0,convalescent plasma|placebo
33407777,Clinical Trial Protocol|Letter,Antiviral Agents|Biomarkers|NA,"Administration, Intravenous|Adult|Antiviral Agents|Biomarkers|COVID-19|Clinical Trials, Phase II as Topic|Combined Modality Therapy|Double-Blind Method|Female|Humans|Male|Mesenchymal Stem Cell Transplantation|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Severity of Illness Index|Spain|Standard of Care|Transplantation, Homologous|NA","Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.",2021-01-12,Trials,NCT04615429,Abstract,2020-09-15,2021-01-04,Interventional,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,"Active, not recruiting",Phase 2,Puerta de Hierro University Hospital,NA,57,https://pubmed.ncbi.nlm.nih.gov/33407777,https://clinicaltrials.gov/ct2/show/NCT04615429,1,0,1,0,2,0,Spain,0,mesenchymal stromal cells|placebo
33422263,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|NA,"Aged|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|COVID-19|Cardiovascular Diseases|Female|Hospitalization|Humans|Male|Middle Aged|Prospective Studies|Respiration, Artificial|SARS-CoV-2|Treatment Outcome|Withholding Treatment|NA","Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.",2021-03-19,The Lancet. Respiratory medicine,NCT04338009,Abstract,2020-03-31,2020-12-31,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Enrolling by invitation,N/A,University of Pennsylvania,NA,346,https://pubmed.ncbi.nlm.nih.gov/33422263,https://clinicaltrials.gov/ct2/show/NCT04338009,1,0,1,0,2,1,United States,0,discontinuation of arb/acei|continuation of arb/acei|discontinuation of arb|acei|continuation of arb
33429174,Journal Article|Randomized Controlled Trial,Anti-Inflammatory Agents|Nasal Sprays|Mometasone Furoate|NA,Adolescent|Adult|Age Factors|Anosmia|Anti-Inflammatory Agents|COVID-19|Diabetes Complications|Female|Humans|Male|Middle Aged|Mometasone Furoate|Nasal Sprays|Prospective Studies|Recovery of Function|Visual Analog Scale|Young Adult|NA,Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.,2021-03-08,American journal of otolaryngology,NCT04484493,Abstract,2020-08-08,2020-10-25,Interventional,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Phase 3,Benha University,NA,143,https://pubmed.ncbi.nlm.nih.gov/33429174,https://clinicaltrials.gov/ct2/show/NCT04484493,1,0,1,0,5,0,Egypt,0,mometasone furoate nasal spray
33430891,Clinical Trial Protocol|Letter,Glucocorticoids|Interleukin-6|C-Reactive Protein|Ferritins|Methylprednisolone|NA,"C-Reactive Protein|COVID-19|Double-Blind Method|Ferritins|Glucocorticoids|Hospitalization|Humans|Infusions, Intravenous|Interleukin-6|Methylprednisolone|Pulse Therapy, Drug|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|NA",Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.,2021-01-18,Trials,NCT04438980,Abstract,2020-05-15,2020-12-31,Interventional,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Phase 3,Fundacion Miguel Servet,NA,289,https://pubmed.ncbi.nlm.nih.gov/33430891,https://clinicaltrials.gov/ct2/show/NCT04438980,1,0,1,0,1,0,Spain,0,methylprednisolone|placebo
33430924,Clinical Trial Protocol|Letter,"Proto-Oncogene Proteins|Receptors, Coronavirus|Receptors, G-Protein-Coupled|Spike Glycoprotein, Coronavirus|proto-oncogene proteins c-mas-1|spike protein, SARS-CoV-2|Ecdysterone|Angiotensin-Converting Enzyme 2|NA","Aged|Aged, 80 and over|Angiotensin-Converting Enzyme 2|COVID-19|Disease Progression|Double-Blind Method|Ecdysterone|Extracorporeal Membrane Oxygenation|Hospitalization|Humans|Hypoxia|Middle Aged|Mortality|Oxygen Inhalation Therapy|Proto-Oncogene Proteins|Randomized Controlled Trials as Topic|Receptors, Coronavirus|Receptors, G-Protein-Coupled|Renin-Angiotensin System|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Tachypnea|Treatment Outcome|NA","Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.",2021-01-18,Trials,NCT04472728,Abstract,2020-06-16,2021-07-31,Interventional,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Biophytis,NA,40,https://pubmed.ncbi.nlm.nih.gov/33430924,https://clinicaltrials.gov/ct2/show/NCT04472728,1,0,1,0,6,1,United States|Belgium|Brazil|France|Puerto Rico,0,bio101|placebo
33440088,Journal Article, , ,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.,2021-01-30,The New England journal of medicine,NCT04436276,Abstract,2020-07-15,2021-12-03,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,9,https://pubmed.ncbi.nlm.nih.gov/33440088,https://clinicaltrials.gov/ct2/show/NCT04436276,3,0,3,0,9,1,United States|Belgium,0,ad26.cov2.s|placebo
33446655,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|Vaccines, Subunit|spike glycoprotein, SARS-CoV|Angiotensin-Converting Enzyme 2|NA","Angiotensin-Converting Enzyme 2|Animals|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Disease Models, Animal|Female|Humans|Male|Mice|Mice, Inbred BALB C|Papio|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|Vaccines, Subunit|NA",SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.,2021-01-19,Nature communications,NCT04368988,Abstract,2020-05-25,2020-12-01,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,177,https://pubmed.ncbi.nlm.nih.gov/33446655,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,United States|Australia,0,"sars-cov-2 rs - phase 1|sars-cov-2 rs/matrix-m adjuvant - phase 1|normal saline solution (nss), placebo - phase 1|normal saline solution (nss), placebo - phase 2|sars-cov-2 rs/matrix-m adjuvant, day 0 - phase 1|normal saline solution (nss), placebo, day 21 - phase 1|sars-cov-2 rs/matrix-m adjuvant, days 0/21 - phase 2|normal saline solution (nss), placebo, day 189 - phase 2|sars-cov-2 rs/matrix-m adjuvant, day 0 - phase 2|normal saline solution (nss), placebo, day 21 - phase 2|sars-cov-2 rs/matrix-m adjuvant - day 189 - phase 2|sars-cov-2 rs|matrix-m adjuvant - phase 1|matrix-m adjuvant, day 0 - phase 1|matrix-m adjuvant, days 0|21 - phase 2|matrix-m adjuvant, day 0 - phase 2|matrix-m adjuvant - day 189 - phase 2"
33464336,Journal Article|Multicenter Study|Pragmatic Clinical Trial|Randomized Controlled Trial,Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|NA,"Aged|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|COVID-19|Disease Progression|Female|Heart Failure|Hospitalization|Humans|Male|Middle Aged|Myocardial Infarction|Odds Ratio|Patient Discharge|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Sample Size|Shock|Time Factors|Treatment Outcome|Withholding Treatment|NA",Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.,2021-01-27,JAMA,NCT04364893,Abstract,2020-04-09,2020-10-01,Interventional,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,N/A,D'Or Institute for Research and Education,NA,276,https://pubmed.ncbi.nlm.nih.gov/33464336,https://clinicaltrials.gov/ct2/show/NCT04364893,1,0,1,0,2,0,Brazil,0,suspension/maintenance of angiotensin receptor blockers/angiotensin-converting enzyme inhibitors|suspension|maintenance of angiotensin receptor blockers|angiotensin-converting enzyme inhibitors
33472681,Clinical Trial Protocol|Journal Article, ,"Adult|COVID-19|Clinical Trials, Phase II as Topic|Female|Hospitalization|Humans|Immunization, Passive|Male|Middle Aged|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|SARS-CoV-2|Severity of Illness Index|Standard of Care|Treatment Outcome|NA","Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.",2021-01-26,Trials,NCT04345523,Abstract,2020-04-03,2021-02-28,Interventional,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,66,https://pubmed.ncbi.nlm.nih.gov/33472681,https://clinicaltrials.gov/ct2/show/NCT04345523,1,0,1,0,2,0,Spain,0,blood/derivatives.|standard of care|blood|derivatives.
33472855,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|tocilizumab|NA","Adolescent|Adult|Aged|Aged, 80 and over|Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|COVID-19|Critical Illness|Female|Follow-Up Studies|Hospitalization|Humans|Infusions, Intravenous|Male|Middle Aged|Respiration, Artificial|Severity of Illness Index|Treatment Outcome|Young Adult|NA",Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.,2021-01-27,BMJ (Clinical research ed.),NCT04403685,Abstract,2020-05-08,2020-07-08,Interventional,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Phase 3,BeneficÃªncia Portuguesa de SÃ£o Paulo,Safety,224,https://pubmed.ncbi.nlm.nih.gov/33472855,https://clinicaltrials.gov/ct2/show/NCT04403685,1,0,1,0,3,0,Brazil,0,tocilizumab
33475701,"Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|bamlanivimab|etesevimab|NA","Adult|Aged|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|COVID-19|Dose-Response Relationship, Drug|Double-Blind Method|Drug Therapy, Combination|Female|Hospitalization|Humans|Infusions, Intravenous|Male|Middle Aged|SARS-CoV-2|Severity of Illness Index|Viral Load|NA",Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.,2021-02-23,JAMA,NCT04427501,Abstract,2020-06-17,2020-09-20,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2/Phase 3,Eli Lilly and Company,NA,10,https://pubmed.ncbi.nlm.nih.gov/33475701,https://clinicaltrials.gov/ct2/show/NCT04427501,2,0,2,0,34,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo
33482902,Clinical Trial|Journal Article,Biomarkers|Inflammation Mediators|NA,Adult|Aged|Amniotic Fluid|Biomarkers|COVID-19|Female|Hospital Mortality|Humans|Inflammation Mediators|Male|Middle Aged|Pilot Projects|Pregnancy|Time Factors|Treatment Outcome|Young Adult|NA,A pilot trial of human amniotic fluid for the treatment of COVID-19.,2021-01-27,BMC research notes,NCT04319731,Abstract,2020-03-20,2021-03-20,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Early Phase 1,University of Utah,NA,353,https://pubmed.ncbi.nlm.nih.gov/33482902,https://clinicaltrials.gov/ct2/show/NCT04319731,1,0,1,0,1,1,United States,0,human amniotic fluid
33485468,Journal Article, , ,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.",2021-02-26,The Lancet. Infectious diseases,NCT04471519,Abstract,2020-07-15,2020-07-31,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,9,https://pubmed.ncbi.nlm.nih.gov/33485468,https://clinicaltrials.gov/ct2/show/NCT04471519,3,0,3,1,3,0,India,0,bbv152a - phase i|bbv152b - phase i|bbv152c - phase i|placebo - phase i|bbv152a - phase ii|bbv152b - phase ii
33486496,Journal Article|Multicenter Study|Randomized Controlled Trial,"Anti-Bacterial Agents|Antiviral Agents|CD3 Complex|Glucocorticoids|RNA, Viral|Methylprednisolone|NA","Adult|Aged|Anti-Bacterial Agents|Antiviral Agents|CD3 Complex|CD8-Positive T-Lymphocytes|COVID-19|COVID-19 Nucleic Acid Testing|Disease Progression|Early Medical Intervention|Extracorporeal Membrane Oxygenation|Female|Glucocorticoids|Hospitalization|Humans|Killer Cells, Natural|Lymphocyte Count|Male|Methylprednisolone|Middle Aged|Oxygen Inhalation Therapy|Patients' Rooms|Pharynx|Proportional Hazards Models|RNA, Viral|Respiration, Artificial|SARS-CoV-2|Single-Blind Method|T-Lymphocyte Subsets|T-Lymphocytes|Time Factors|Treatment Outcome|Virus Shedding|NA","Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial.",2021-03-12,Respiration; international review of thoracic diseases,NCT04273321,Abstract,2020-02-14,2020-04-15,Interventional,Efficacy and Safety of Corticosteroids in COVID-19,Completed,N/A,Beijing Chao Yang Hospital,NA,330,https://pubmed.ncbi.nlm.nih.gov/33486496,https://clinicaltrials.gov/ct2/show/NCT04273321,1,0,1,0,4,0,China,0,methylprednisolone
33492523,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial",Amides|Antiviral Agents|Pyrazines|Chloroquine|favipiravir|NA,"Adult|Amides|Antiviral Agents|COVID-19|Chloroquine|Female|Humans|Length of Stay|Male|Pyrazines|Respiration, Artificial|SARS-CoV-2|Treatment Outcome|NA",Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.,2021-02-22,Archives of virology,NCT04351295,Abstract,2020-04-20,2020-12-01,Interventional,Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,190,https://pubmed.ncbi.nlm.nih.gov/33492523,https://clinicaltrials.gov/ct2/show/NCT04351295,1,0,1,0,2,0,Egypt,0,favipiravir|placebos
33495742,Journal Article|Review, , ,"Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.",2021-01-27,Contemporary clinical trials communications,NCT04341038,Abstract,2020-04-01,2020-06-01,Interventional,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Phase 3,Hospital Universitari de Bellvitge,NA,360,https://pubmed.ncbi.nlm.nih.gov/33495742,https://clinicaltrials.gov/ct2/show/NCT04341038,1,0,1,0,0,0,Spain,0,tacrolimus|methylprednisolone
33495752,Journal Article, , ,"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.",2021-03-01,EClinicalMedicine,NCT04390022,Abstract,2020-07-31,2020-09-17,Interventional,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Completed,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,114,https://pubmed.ncbi.nlm.nih.gov/33495752,https://clinicaltrials.gov/ct2/show/NCT04390022,1,0,1,0,6,0,Spain,1,ivermectin|placebo
33499887,Letter,"RNA, Viral|NA","COVID-19|Critical Care|Hospitalization|Humans|RNA, Viral|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Treatment Outcome|NA",Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial.,2021-02-03,Trials,NCT04451174,Abstract,2020-06-23,2020-11-30,Interventional,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Recruiting,Phase 3,University of Chile,NA,169,https://pubmed.ncbi.nlm.nih.gov/33499887,https://clinicaltrials.gov/ct2/show/NCT04451174,1,0,1,0,3,0,Chile,0,prednisone
33502567,Journal Article, , ,COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): aÂ single institution report of two cases.,2021-01-30,Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],NCT04394182,Abstract,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,322,https://pubmed.ncbi.nlm.nih.gov/33502567,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,ultra-low-dose radiotherapy|ventilatory support with oxygen therapy|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|low molecular weight heparin|corticosteroid injection|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04362085,Abstract,2020-05-11,2022-03-31,Interventional,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,67,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04362085,2,0,2,0,3,0,Canada,0,therapeutic anticoagulation
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04367831,Abstract,2020-05-02,2020-11-30,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Phase 4,Columbia University,NA,321,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04367831,2,0,2,0,2,1,United States,0,enoxaparin prophylactic dose|heparin infusion|heparin sc|enoxaparin/lovenox intermediate dose|enoxaparin|lovenox intermediate dose
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04368377,Abstract,2020-04-06,2020-04-23,Interventional,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Phase 2,University of Milan,NA,340,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04368377,1,0,1,0,0,0,Italy,0,tirofiban injection|clopidogrel|acetylsalicylic acid|fondaparinux
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04373707,Abstract,2020-05-13,2021-11-30,Interventional,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Recruiting,Phase 4,"Central Hospital, Nancy, France",NA,134,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04373707,1,0,1,0,5,0,France,0,enoxaparin
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04366960,Abstract,2020-05-14,2021-08-31,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Phase 3,Niguarda Hospital,NA,82,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04366960,2,0,2,0,3,0,Italy,0,enoxaparin
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04354155,Abstract,2020-06-02,2022-09-30,Interventional,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,Phase 2,Johns Hopkins All Children's Hospital,NA,68,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04354155,1,0,1,0,2,1,United States,0,enoxaparin prefilled syringe [lovenox]
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04359277,Abstract,2020-04-21,2020-09-20,Interventional,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,Phase 3,NYU Langone Health,the PROTECT study is being transitioned to ACTIV4 ACUTE anticoagulation inpatient study,180,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04359277,1,0,1,0,3,1,United States,0,enoxaparin higher dose|lower-dose prophylactic anticoagulation
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04394377,Abstract,2020-06-21,2021-03-31,Interventional,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,"Active, not recruiting",Phase 4,Brazilian Clinical Research Institute,NA,19,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04394377,1,0,1,0,8,0,Brazil,0,group 1: rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|group 2: control group with enoxaparin 40mg/d|group 1: rivaroxaban 20mg|d followed by enoxaparin|unfractionated heparin when needed|group 2: control group with enoxaparin 40mg|d
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04401293,Abstract,2020-04-26,2021-04-26,Interventional,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Recruiting,Phase 3,Northwell Health,NA,123,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04401293,1,0,1,0,2,1,United States,0,enoxaparin|prophylactic/intermediate dose enoxaparin|prophylactic|intermediate dose enoxaparin
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04360824,Abstract,2020-05-06,2021-04-16,Interventional,Covid-19 Associated Coagulopathy,Recruiting,Phase 4,University of Iowa,NA,289,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04360824,1,0,1,0,4,1,United States,0,intermediate dose thromboprophylaxis|standard of care thromboprophylaxis
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04416048,Abstract,2020-11-30,2021-04-30,Interventional,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Recruiting,Phase 3,"Charite University, Berlin, Germany",NA,38,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04416048,1,0,1,0,3,0,Germany,0,rivaroxaban|standard of care (soc)
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04345848,Abstract,2020-04-28,2021-03-31,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Phase 3,"University Hospital, Geneva",NA,103,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04345848,2,0,2,0,3,0,Switzerland,0,enoxaparin
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04397510,Abstract,2020-06-01,2021-12-31,Interventional,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Phase 4,Frederick Health,NA,40,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04397510,1,0,1,0,7,1,United States,0,heparin|0.9% sodium-chloride
33502773,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,NCT04372589,Abstract,2020-05-20,2021-01-31,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Active, not recruiting",Phase 2/Phase 3,University of Manitoba,NA,65,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04372589,3,0,3,1,4,1,United States|Brazil|Canada|Mexico,0,heparin
33505321,Journal Article|Review, , ,Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the <i>COVID-Omega-F</i> Trial.,2021-01-30,Frontiers in physiology,NCT04647604,Abstract,2020-06-23,2021-04-30,Interventional,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Phase 2,Karolinska University Hospital,NA,127,https://pubmed.ncbi.nlm.nih.gov/33505321,https://clinicaltrials.gov/ct2/show/NCT04647604,1,0,1,0,0,0,Sweden,0,omegavenâ®|sodium chloride|omegavenâ®
33519339,Journal Article, , ,Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.,2021-02-02,Saudi journal of medicine &amp; medical sciences,NCT04347681,Abstract,2020-04-18,2020-12-31,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Phase 2,King Fahad Specialist Hospital Dammam,NA,237,https://pubmed.ncbi.nlm.nih.gov/33519339,https://clinicaltrials.gov/ct2/show/NCT04347681,2,0,2,0,3,0,Saudi Arabia,0,convalescent plasma from recovered covid 19 donor
33522946,Clinical Trial Protocol|Letter,Vitamins|Cholecalciferol|NA,"Aged|Aged, 80 and over|Argentina|COVID-19|Cholecalciferol|Double-Blind Method|Female|Humans|Male|Middle Aged|Multicenter Studies as Topic|Pandemics|Patient Admission|Pragmatic Clinical Trials as Topic|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Treatment Outcome|Vitamins|NA",High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).,2021-02-19,Trials,NCT04411446,Abstract,2020-08-11,2020-12-15,Interventional,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Phase 4,Vitamin D Study Group,NA,146,https://pubmed.ncbi.nlm.nih.gov/33522946,https://clinicaltrials.gov/ct2/show/NCT04411446,1,1,2,0,4,0,Argentina,0,vitamin d|placebo
33524311,"Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Adjuvants, Immunologic|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Protein Subunits|Vaccines, Subunit|NA","Adjuvants, Immunologic|Adult|Aged|Antibodies, Neutralizing|Antibodies, Viral|Australia|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Immunogenicity, Vaccine|Immunoglobulin G|Male|Middle Aged|Protein Subunits|SARS-CoV-2|Vaccines, Subunit|NA","Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.",2021-02-26,"Lancet (London, England)",NCT04405908,Abstract,2020-06-19,2020-10-16,Interventional,SCB-2019 as COVID-19 Vaccine,"Active, not recruiting",Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,NA,82,https://pubmed.ncbi.nlm.nih.gov/33524311,https://clinicaltrials.gov/ct2/show/NCT04405908,1,0,1,1,4,0,Australia,0,scb-2019|scb-2019 with as03 adjuvant|scb-2019 with cpg 1018 adjuvant/alum adjuvant|scb-2019 with cpg 1018 adjuvant|alum adjuvant
33524990,Journal Article, , ,BNT162b vaccines protect rhesus macaques from SARS-CoV-2.,2021-02-25,Nature,NCT04380701,Abstract,2020-04-23,2023-04-30,Interventional,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,Recruiting,Phase 1/Phase 2,BioNTech SE,NA,61,https://pubmed.ncbi.nlm.nih.gov/33524990,https://clinicaltrials.gov/ct2/show/NCT04380701,1,0,1,1,4,0,Germany,0,bnt162a1|bnt162b1|bnt162b2|bnt162c2
33524990,Journal Article, , ,BNT162b vaccines protect rhesus macaques from SARS-CoV-2.,2021-02-25,Nature,NCT04368728,Abstract,2020-04-29,2021-08-03,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","Active, not recruiting",Phase 2/Phase 3,BioNTech SE,NA,17,https://pubmed.ncbi.nlm.nih.gov/33524990,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,26,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo
33545094,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|NA","Adult|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Immunization, Secondary|Injections, Intramuscular|Male|Middle Aged|Moscow|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|NA",Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.,2021-02-26,"Lancet (London, England)",NCT04530396,Abstract,2020-09-07,2021-05-01,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,73,https://pubmed.ncbi.nlm.nih.gov/33545094,https://clinicaltrials.gov/ct2/show/NCT04530396,1,0,1,1,8,0,Russian Federation,0,gam-covid-vac|placebo
33547300,"Clinical Trial|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't",Angiogenesis Inhibitors|Bevacizumab|NA,Aged|Angiogenesis Inhibitors|Bevacizumab|Body Temperature|COVID-19|China|Female|Fever|Humans|Italy|Male|Middle Aged|SARS-CoV-2|Treatment Outcome|NA,Efficacy and tolerability of bevacizumab in patients with severe Covid-19.,2021-02-22,Nature communications,NCT04275414,Abstract,2020-02-15,2020-04-05,Interventional,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Completed,Phase 2,Qilu Hospital of Shandong University,NA,205,https://pubmed.ncbi.nlm.nih.gov/33547300,https://clinicaltrials.gov/ct2/show/NCT04275414,1,0,1,0,2,0,China|Italy,0,bevacizumab injection
33548194,Journal Article, , ,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.",2021-02-28,The Lancet. Infectious diseases,NCT04383574,Abstract,2020-05-22,2020-08-28,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,207,https://pubmed.ncbi.nlm.nih.gov/33548194,https://clinicaltrials.gov/ct2/show/NCT04383574,1,0,1,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of high dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of placebo at the schedule of day 0,28"
33555780,"Journal Article|Research Support, U.S. Gov't, Non-P.H.S.",Adrenal Cortex Hormones|Anticoagulants|remdesivir|Adenosine Monophosphate|Hydroxychloroquine|Dexamethasone|Alanine|NA,"Adenosine Monophosphate|Adrenal Cortex Hormones|Alanine|Anticoagulants|COVID-19|Critical Care|Dexamethasone|Disease Management|Evidence-Based Medicine|Hemodynamics|Humans|Hydroxychloroquine|Immunization, Passive|Intensive Care Units|Patient Positioning|Practice Guidelines as Topic|Ventilation|NA",Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update.,2021-03-04,Critical care medicine,NCT04350723,Abstract,2020-06-10,2021-07-30,Interventional,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,166,https://pubmed.ncbi.nlm.nih.gov/33555780,https://clinicaltrials.gov/ct2/show/NCT04350723,1,0,1,0,1,0,Canada|Saudi Arabia,0,awake proning
33556319,Journal Article, , ,"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.",2021-02-28,The Lancet. Respiratory medicine,NCT04354259,Abstract,2020-05-13,2020-08-01,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,325,https://pubmed.ncbi.nlm.nih.gov/33556319,https://clinicaltrials.gov/ct2/show/NCT04354259,3,0,3,0,1,0,Canada,0,peginterferon lambda-1a|placebo
33557591,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Viral|Caprylates|Immunoglobulins, Intravenous|NA","Antibodies, Viral|COVID-19|Caprylates|Chemical Fractionation|Humans|Immunization, Passive|Immunoglobulins, Intravenous|SARS-CoV-2|NA",Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.,2021-02-18,Immunotherapy,NCT04521309,Abstract,2020-06-19,2021-01-26,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Completed,Phase 1/Phase 2,Dow University of Health Sciences,NA,13,https://pubmed.ncbi.nlm.nih.gov/33557591,https://clinicaltrials.gov/ct2/show/NCT04521309,2,0,2,0,4,0,Pakistan,0,sars-cov-2 antibody based ivig therapy
33562419,Journal Article, , ,Passive Microwave Radiometry for the Diagnosis of Coronavirus Disease 2019 Lung Complications in Kyrgyzstan.,2021-03-16,"Diagnostics (Basel, Switzerland)",NCT04568525,Abstract,2020-07-01,2020-07-25,Interventional,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Completed,N/A,Kyrgyz State Medical Academy,NA,187,https://pubmed.ncbi.nlm.nih.gov/33562419,https://clinicaltrials.gov/ct2/show/NCT04568525,1,0,1,0,0,0,Kyrgyzstan,0,passive microwave radiometry
33568226,Clinical Trial Protocol|Letter,Capsules|Iodine Compounds|Oral Sprays|Polymers|NA,Adult|COVID-19|Capsules|Female|Humans|Iodine Compounds|Male|Oral Sprays|Pakistan|Patient Admission|Polymers|Randomized Controlled Trials as Topic|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|NA,A quadruple blinded placebo controlled randomised trial to evaluate the effectiveness of an Iodine complex for patients with mild to moderate COVID-19 in Pakistan (I-COVID-PK): A structured summary of a study protocol for a randomised controlled trial.,2021-02-19,Trials,NCT04473261,Abstract,2020-07-14,2021-07-15,Interventional,Efficacy of Iodine Complex Against COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,86,https://pubmed.ncbi.nlm.nih.gov/33568226,https://clinicaltrials.gov/ct2/show/NCT04473261,1,0,1,0,1,0,Pakistan,0,iodine complex|placebo|idoine complex
33568628,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't", ,Aged|Allografts|COVID-19|Double-Blind Method|Female|Humans|Male|Mesenchymal Stem Cell Transplantation|Mesenchymal Stem Cells|Middle Aged|SARS-CoV-2|Treatment Outcome|Umbilical Cord|NA,"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.",2021-02-22,Signal transduction and targeted therapy,NCT04288102,Abstract,2020-03-05,2020-05-12,Interventional,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Completed,Phase 2,Beijing 302 Hospital,NA,228,https://pubmed.ncbi.nlm.nih.gov/33568628,https://clinicaltrials.gov/ct2/show/NCT04288102,1,0,1,0,5,0,China,0,uc-mscs|saline containing 1% human serum albuminï¼ˆsolution without uc-mscsï¼‰|saline containing 1% human serum albuminï¼ˆsolution without uc-mscsï¼‰
33570583,Journal Article|Systematic Review,Micronutrients|Trace Elements|Vitamin A|Iron|Selenium|Zinc|NA,COVID-19|Diet|Dietary Supplements|Humans|Immune System|Iron|Micronutrients|Nutrition Therapy|Nutritional Status|Selenium|Trace Elements|Vitamin A|Zinc|NA,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-03-01,Nutrition reviews,NCT04318444,Abstract,2020-03-29,2021-03-31,Interventional,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Recruiting,Phase 2/Phase 3,Columbia University,NA,345,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04318444,1,0,1,0,2,1,United States,0,hydroxychloroquine|placebo oral tablet
33570583,Journal Article|Systematic Review,Micronutrients|Trace Elements|Vitamin A|Iron|Selenium|Zinc|NA,COVID-19|Diet|Dietary Supplements|Humans|Immune System|Iron|Micronutrients|Nutrition Therapy|Nutritional Status|Selenium|Trace Elements|Vitamin A|Zinc|NA,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-03-01,Nutrition reviews,NCT04303507,Abstract,2020-04-29,2021-04-30,Interventional,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,Recruiting,N/A,University of Oxford,NA,184,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04303507,1,0,1,0,7,0,Indonesia|Italy|Lao People's Democratic Republic|Pakistan|Thailand|United Kingdom,0,chloroquine/hydroxychloroquine|placebo|chloroquine|hydroxychloroquine
33570583,Journal Article|Systematic Review,Micronutrients|Trace Elements|Vitamin A|Iron|Selenium|Zinc|NA,COVID-19|Diet|Dietary Supplements|Humans|Immune System|Iron|Micronutrients|Nutrition Therapy|Nutritional Status|Selenium|Trace Elements|Vitamin A|Zinc|NA,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-03-01,Nutrition reviews,NCT04312243,Abstract,2020-04-07,2021-04-07,Interventional,NO Prevention of COVID-19 for Healthcare Providers,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,26,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04312243,1,0,1,0,3,1,United States,0,inhaled nitric oxide gas
33570583,Journal Article|Systematic Review,Micronutrients|Trace Elements|Vitamin A|Iron|Selenium|Zinc|NA,COVID-19|Diet|Dietary Supplements|Humans|Immune System|Iron|Micronutrients|Nutrition Therapy|Nutritional Status|Selenium|Trace Elements|Vitamin A|Zinc|NA,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-03-01,Nutrition reviews,NCT04321174,Abstract,2020-04-17,2021-03-31,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,351,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04321174,3,0,3,0,1,0,Canada,0,lopinavir/ritonavir|lopinavir|ritonavir
33570583,Journal Article|Systematic Review,Micronutrients|Trace Elements|Vitamin A|Iron|Selenium|Zinc|NA,COVID-19|Diet|Dietary Supplements|Humans|Immune System|Iron|Micronutrients|Nutrition Therapy|Nutritional Status|Selenium|Trace Elements|Vitamin A|Zinc|NA,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-03-01,Nutrition reviews,NCT04251871,Abstract,2020-01-22,2021-01-22,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,N/A,Beijing 302 Hospital,NA,334,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04251871,2,0,2,0,1,0,China,0,"conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,|lopinavir|ritonavir)|traditional chinese medicines (tcms) granules"
33570583,Journal Article|Systematic Review,Micronutrients|Trace Elements|Vitamin A|Iron|Selenium|Zinc|NA,COVID-19|Diet|Dietary Supplements|Humans|Immune System|Iron|Micronutrients|Nutrition Therapy|Nutritional Status|Selenium|Trace Elements|Vitamin A|Zinc|NA,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-03-01,Nutrition reviews,NCT04304053,Abstract,2020-03-18,2020-06-15,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,281,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04304053,2,0,2,0,9,0,Spain,0,treatment/prophylaxis|standard public health measures|treatment|prophylaxis
33570583,Journal Article|Systematic Review,Micronutrients|Trace Elements|Vitamin A|Iron|Selenium|Zinc|NA,COVID-19|Diet|Dietary Supplements|Humans|Immune System|Iron|Micronutrients|Nutrition Therapy|Nutritional Status|Selenium|Trace Elements|Vitamin A|Zinc|NA,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-03-01,Nutrition reviews,NCT04308668,Abstract,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,262,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,9,1,United States|Canada,0,hydroxychloroquine|placebo
33571450,"Clinical Trial|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't","Antibodies, Viral|Immunoglobulin G|Immunoglobulin M|NA","Adult|Antibodies, Viral|COVID-19|Child Day Care Centers|Child, Preschool|Cross-Sectional Studies|France|Humans|Immunoassay|Immunoglobulin G|Immunoglobulin M|Infant|SARS-CoV-2|Seroepidemiologic Studies|NA","SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.",2021-04-02,The Lancet. Child &amp; adolescent health,NCT04413968,Abstract,2020-06-02,2020-07-02,Interventional,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",Completed,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,162,https://pubmed.ncbi.nlm.nih.gov/33571450,https://clinicaltrials.gov/ct2/show/NCT04413968,1,0,1,0,3,0,France,0,rapid detection test|nasopharyngeal swab|stool collection
33573681,Clinical Trial Protocol|Letter,Voltage-Gated Sodium Channel Blockers|Lidocaine|NA,"Administration, Intravenous|COVID-19|Clinical Trials, Phase III as Topic|Equivalence Trials as Topic|Humans|Inflammation|Lidocaine|Pulmonary Gas Exchange|Randomized Controlled Trials as Topic|Respiratory Distress Syndrome|SARS-CoV-2|Treatment Outcome|Voltage-Gated Sodium Channel Blockers|NA",Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.,2021-02-18,Trials,NCT04609865,Abstract,2020-11-04,2021-12-31,Interventional,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,74,https://pubmed.ncbi.nlm.nih.gov/33573681,https://clinicaltrials.gov/ct2/show/NCT04609865,1,0,1,0,2,0,France,0,lidocaine 2%|control
33574155,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Biological Products|C-Reactive Protein|NA,Amniotic Fluid|Biological Products|C-Reactive Protein|COVID-19|Double-Blind Method|Feasibility Studies|Humans|Inflammation|Pilot Projects|Randomized Controlled Trials as Topic|Treatment Outcome|NA,"Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial.",2021-02-25,BMJ open,NCT04497389,Abstract,2020-10-28,2021-09-15,Interventional,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,Phase 1/Phase 2,University of Utah,NA,150,https://pubmed.ncbi.nlm.nih.gov/33574155,https://clinicaltrials.gov/ct2/show/NCT04497389,1,0,1,0,2,1,United States,0,human amniotic fluid
33576820,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial,Antioxidants|Gluconates|Trace Elements|Zinc|Ascorbic Acid|gluconic acid|NA,Adult|Ambulatory Care|Antioxidants|Ascorbic Acid|COVID-19|Cough|Dietary Supplements|Dyspnea|Fatigue|Female|Fever|Gluconates|Humans|Male|Middle Aged|SARS-CoV-2|Severity of Illness Index|Standard of Care|Trace Elements|Treatment Outcome|Zinc|NA,Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.,2021-02-25,JAMA network open,NCT04342728,Abstract,2020-04-08,2020-12-30,Interventional,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,Completed,N/A,The Cleveland Clinic,NA,50,https://pubmed.ncbi.nlm.nih.gov/33576820,https://clinicaltrials.gov/ct2/show/NCT04342728,1,0,1,0,6,1,United States,0,ascorbic acid|zinc gluconate|ascorbic acid/zinc gluconate|standard of care
33583027,Journal Article, , ,Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis.,2021-04-02,Acta anaesthesiologica Scandinavica,NCT04509973,Abstract,2020-08-27,2021-09-17,Interventional,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Recruiting,Phase 3,Scandinavian Critical Care Trials Group,NA,218,https://pubmed.ncbi.nlm.nih.gov/33583027,https://clinicaltrials.gov/ct2/show/NCT04509973,1,0,1,0,1,0,Denmark|India|Sweden|Switzerland,0,dexamethasone
33585031,Journal Article, , ,"&quot;Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience&quot;, a retrospective study-original article.",2021-03-23,Annals of medicine and surgery (2012),NCT04730323,Abstract,2020-05-12,2020-06-12,Interventional,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,65,https://pubmed.ncbi.nlm.nih.gov/33585031,https://clinicaltrials.gov/ct2/show/NCT04730323,1,0,1,0,0,0,Pakistan,0,tocilizumab
33595634,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Vitamins|Vitamin D|Cholecalciferol|25-hydroxyvitamin D|NA,"Adult|Brazil|COVID-19|Cholecalciferol|Double-Blind Method|Female|Hospital Mortality|Humans|Intensive Care Units|Length of Stay|Male|Middle Aged|Respiration, Artificial|Treatment Failure|Vitamin D|Vitamin D Deficiency|Vitamins|NA",Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.,2021-03-23,JAMA,NCT04449718,Abstract,2020-06-01,2020-10-07,Interventional,Vitamin D Supplementation in Patients With COVID-19,Completed,N/A,University of Sao Paulo,NA,138,https://pubmed.ncbi.nlm.nih.gov/33595634,https://clinicaltrials.gov/ct2/show/NCT04449718,1,0,1,0,1,0,Brazil,0,vitamin d|placebo
33608030,"Journal Article|Research Support, Non-U.S. Gov't","Antigens, Neoplasm|Biomarkers|E-Selectin|ICAM1 protein, human|P-Selectin|SELE protein, human|VCAN protein, human|VPS51 protein, human|Vesicular Transport Proteins|Intercellular Adhesion Molecule-1|Versicans|MOK protein, human|Mitogen-Activated Protein Kinases|NA","Aged|Antigens, Neoplasm|Area Under Curve|Biomarkers|COVID-19|Cohort Studies|E-Selectin|Female|Humans|Intensive Care Units|Intercellular Adhesion Molecule-1|Lung Injury|Male|Middle Aged|Mitogen-Activated Protein Kinases|P-Selectin|Prospective Studies|ROC Curve|Respiration, Artificial|Respiratory Distress Syndrome|Versicans|Vesicular Transport Proteins|NA",Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients.,2021-03-03,"Critical care (London, England)",NCT04343053,Abstract,2020-04-08,2020-06-09,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,NA,298,https://pubmed.ncbi.nlm.nih.gov/33608030,https://clinicaltrials.gov/ct2/show/NCT04343053,3,0,3,0,2,0,Italy,0,sars-cov-2 infection
33617777,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,"Adolescent|Adult|Aged|Antibody Formation|Asymptomatic Infections|COVID-19|COVID-19 Vaccines|Humans|Immunization Schedule|Immunization, Secondary|Middle Aged|Randomized Controlled Trials as Topic|SARS-CoV-2|Young Adult|NA",Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.,2021-03-17,"Lancet (London, England)",NCT04444674,Abstract,2020-06-24,2020-12-31,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,131,https://pubmed.ncbi.nlm.nih.gov/33617777,https://clinicaltrials.gov/ct2/show/NCT04444674,3,0,3,1,4,0,South Africa,0,chadox1 ncov-19|normal saline 0.9%
33617777,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,"Adolescent|Adult|Aged|Antibody Formation|Asymptomatic Infections|COVID-19|COVID-19 Vaccines|Humans|Immunization Schedule|Immunization, Secondary|Middle Aged|Randomized Controlled Trials as Topic|SARS-CoV-2|Young Adult|NA",Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.,2021-03-17,"Lancet (London, England)",NCT04400838,Abstract,2020-05-28,2021-09-30,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,116,https://pubmed.ncbi.nlm.nih.gov/33617777,https://clinicaltrials.gov/ct2/show/NCT04400838,4,0,4,1,9,0,United Kingdom,0,chadox1 ncov-19 (abs 260)|menacwy vaccine|chadox1 ncov-19 (abs 260) / 2.2x10^10vp (qpcr) boost|two dose menacwy vaccine|chadox1 ncov-19 (qpcr)|chadox1 ncov-19 0.5ml prime/boost|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|chadox1 ncov-19 0.5ml prime|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml
33617777,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,"Adolescent|Adult|Aged|Antibody Formation|Asymptomatic Infections|COVID-19|COVID-19 Vaccines|Humans|Immunization Schedule|Immunization, Secondary|Middle Aged|Randomized Controlled Trials as Topic|SARS-CoV-2|Young Adult|NA",Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.,2021-03-17,"Lancet (London, England)",NCT04324606,Abstract,2020-04-23,2021-10-31,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,12,https://pubmed.ncbi.nlm.nih.gov/33617777,https://clinicaltrials.gov/ct2/show/NCT04324606,4,0,4,1,13,0,United Kingdom,0,chadox1 ncov-19|menacwy|chadox1 ncov-19 full boost|chadox1 ncov-19 half boost|menacwy boost|paracetamol|chadox1 ncov-19 0.5ml boost|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine (lv)|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine two (lvt)
33621601,Journal Article, , ,"Progesterone in Addition to Standard of Care vsÂ Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial.",2021-04-01,Chest,NCT04365127,Abstract,2020-04-27,2020-08-20,Interventional,Progesterone for the Treatment of COVID-19 in Hospitalized Men,Completed,Phase 1,Cedars-Sinai Medical Center,NA,68,https://pubmed.ncbi.nlm.nih.gov/33621601,https://clinicaltrials.gov/ct2/show/NCT04365127,1,0,1,0,2,1,United States,0,progesterone 100 mg
33629225,Journal Article, , ,"A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study.",2021-02-28,Infectious diseases and therapy,NCT04557046,Abstract,2020-06-26,2021-11-30,Interventional,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,Recruiting,N/A,LumiraDx UK Limited,NA,65,https://pubmed.ncbi.nlm.nih.gov/33629225,https://clinicaltrials.gov/ct2/show/NCT04557046,1,0,1,0,3,1,United States,0,nasal swab|nasopharyngeal swab|throat swab|fingerstick|saliva specimen
33631066,Journal Article, , ,Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.,2021-03-19,The New England journal of medicine,NCT04320615,Abstract,2020-04-03,2020-06-24,Interventional,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,192,https://pubmed.ncbi.nlm.nih.gov/33631066,https://clinicaltrials.gov/ct2/show/NCT04320615,1,0,1,0,10,1,United States|Canada|Denmark|France|Germany|Italy|Netherlands|Spain|United Kingdom,0,tocilizumab (tcz)|placebo
33631357,Journal Article, , ,"RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19.",2021-04-02,Contemporary clinical trials,NCT04366050,Abstract,2020-05-11,2021-05-31,Interventional,Ramipril for the Treatment of COVID-19,Recruiting,Phase 2,"University of California, San Diego",NA,74,https://pubmed.ncbi.nlm.nih.gov/33631357,https://clinicaltrials.gov/ct2/show/NCT04366050,1,0,1,0,2,1,United States,0,ramipril 2.5 mg oral capsule|placebo oral capsule
33638057,Journal Article, , ,Comparison of lung ultrasonography findings with chest computed tomography results in coronavirus (COVID-19) pneumonia.,2021-03-02,Journal of medical ultrasonics (2001),NCT04719234,Abstract,2020-06-15,2020-12-01,Interventional,Lung Ultrasonography in COVID-19 Pneumonia,Completed,N/A,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,72,https://pubmed.ncbi.nlm.nih.gov/33638057,https://clinicaltrials.gov/ct2/show/NCT04719234,1,0,1,0,0,0,Turkey,0,lung ultrasonography
33647225,Journal Article, , ,Rationale and Design of the Awake Prone Position for Early Hypoxemia in COVID-19 (APPEX-19) Study Protocol.,2021-03-01,Annals of the American Thoracic Society,NCT04344587,Abstract,2020-04-23,2021-04-30,Interventional,Awake Prone Position for Early Hypoxemia in COVID-19,Enrolling by invitation,N/A,Boston University,NA,99,https://pubmed.ncbi.nlm.nih.gov/33647225,https://clinicaltrials.gov/ct2/show/NCT04344587,1,0,1,0,12,1,United States|Spain,0,self-prone position recommendation|usual care
33648555,Clinical Trial Protocol|Journal Article, ,"Anxiety|COVID-19|Depression|Emotional Regulation|Humans|Internet-Based Intervention|Loneliness|Optimism|Patient Health Questionnaire|Patient Satisfaction|Pessimism|Psychological Distress|Quality of Life|Randomized Controlled Trials as Topic|Resilience, Psychological|SARS-CoV-2|Self Care|Self Efficacy|Self-Management|Stress, Psychological|Suicidal Ideation|NA",An internet-based self-help intervention for people with psychological distress due to COVID-19: study protocol for a randomized controlled trial.,2021-03-12,Trials,NCT04380909,Abstract,2020-05-06,2021-04-30,Interventional,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,"Active, not recruiting",N/A,University of Bern,NA,33,https://pubmed.ncbi.nlm.nih.gov/33648555,https://clinicaltrials.gov/ct2/show/NCT04380909,1,0,1,0,1,0,Switzerland,0,internet-based self-help|internet-based self-help after 3 weeks
33648563,Clinical Trial Protocol|Journal Article,"Immunoglobulins, Intravenous|Immunologic Factors|NA","Activities of Daily Living|COVID-19|Clinical Trials, Phase III as Topic|Double-Blind Method|Early Medical Intervention|Functional Status|Humans|Immunoglobulins, Intravenous|Immunologic Factors|Intensive Care Units|Length of Stay|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Survival Rate|NA",Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.,2021-03-12,Trials,NCT04350580,Abstract,2020-04-11,2021-04-30,Interventional,Polyvalent Immunoglobulin in COVID-19 Related ARds,Recruiting,Phase 3,Centre Hospitalier St Anne,NA,197,https://pubmed.ncbi.nlm.nih.gov/33648563,https://clinicaltrials.gov/ct2/show/NCT04350580,1,0,1,0,2,0,France,0,human immunoglobulin|placebo
33648568,Clinical Trial Protocol|Letter,Glucocorticoids|Dexamethasone|NA,"COVID-19|Clinical Trials, Phase II as Topic|Dexamethasone|Disease Progression|Dose-Response Relationship, Drug|Equivalence Trials as Topic|Glucocorticoids|Humans|Length of Stay|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|NA","Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.",2021-03-12,Trials,NCT04663555,Abstract,2021-02-02,2022-03-31,Interventional,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,Recruiting,Phase 4,Brno University Hospital,NA,60,https://pubmed.ncbi.nlm.nih.gov/33648568,https://clinicaltrials.gov/ct2/show/NCT04663555,1,0,1,0,3,0,Czechia,0,dexamethasone
33654090,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|NA","Animals|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Enzyme-Linked Immunosorbent Assay|Female|Immunohistochemistry|Lymphocytes|Macaca mulatta|Male|Pneumonia|SARS-CoV-2|NA","Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.",2021-03-11,Nature communications,NCT04471519,Abstract,2020-07-15,2020-07-31,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,9,https://pubmed.ncbi.nlm.nih.gov/33654090,https://clinicaltrials.gov/ct2/show/NCT04471519,3,0,3,1,3,0,India,0,bbv152a - phase i|bbv152b - phase i|bbv152c - phase i|placebo - phase i|bbv152a - phase ii|bbv152b - phase ii
33657114,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't", ,"Adult|Aged|Aged, 80 and over|COVID-19|Chile|Disease Progression|Early Medical Intervention|Female|Hospital Mortality|Humans|Immunization, Passive|Length of Stay|Male|Middle Aged|Mortality|Respiration, Artificial|Time-to-Treatment|Treatment Outcome|NA",Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.,2021-03-11,PLoS medicine,NCT04375098,Abstract,2020-05-04,2020-08-17,Interventional,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Completed,Phase 2,Pontificia Universidad Catolica de Chile,NA,203,https://pubmed.ncbi.nlm.nih.gov/33657114,https://clinicaltrials.gov/ct2/show/NCT04375098,1,0,1,0,3,0,Chile,0,covid-19 convalescent plasma
33662102,Journal Article, , ,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.,2021-03-20,JAMA,NCT04405843,Abstract,2020-07-14,2020-12-21,Interventional,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),Completed,Phase 2/Phase 3,Centro de Estudios en InfectogÃ­a Pediatrica,NA,100,https://pubmed.ncbi.nlm.nih.gov/33662102,https://clinicaltrials.gov/ct2/show/NCT04405843,1,0,1,0,8,0,Colombia,0,ivermectin oral product|placebo
33665371,Journal Article, , ,Assessment of SARS-CoV-2 infection by Reverse transcription-PCR and serology in the Paris area: a cross-sectional study.,2021-03-06,BMJ paediatrics open,NCT04318431,Abstract,2020-04-14,2020-05-12,Interventional,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,Completed,N/A,Centre Hospitalier Intercommunal Creteil,NA,269,https://pubmed.ncbi.nlm.nih.gov/33665371,https://clinicaltrials.gov/ct2/show/NCT04318431,1,0,1,0,7,0,France,0,data collection/rhinopharyngeal swab|data collection|rhinopharyngeal swab
33673929,Letter|Comment,"Antibodies, Monoclonal, Humanized|Granulocyte-Macrophage Colony-Stimulating Factor|lenzilumab|NA","Antibodies, Monoclonal, Humanized|COVID-19|Cohort Studies|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|SARS-CoV-2|NA",Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.,2021-03-11,Mayo Clinic proceedings,NCT04351152,Abstract,2020-05-05,2021-03-31,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"Active, not recruiting",Phase 3,"Humanigen, Inc.",NA,33,https://pubmed.ncbi.nlm.nih.gov/33673929,https://clinicaltrials.gov/ct2/show/NCT04351152,2,0,2,0,11,1,United States|Brazil,0,lenzilumab|standard of care
33675247,Journal Article, , ,Effect of a mobile-based intervention on mental health in frontline healthcare workers against COVID-19: Protocol for a randomized controlled trial.,2021-03-17,Journal of advanced nursing,NCT04393818,Abstract,2020-05-05,2020-08-24,Interventional,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Completed,Phase 3,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,NA,206,https://pubmed.ncbi.nlm.nih.gov/33675247,https://clinicaltrials.gov/ct2/show/NCT04393818,1,0,1,0,4,0,Spain,0,intervention app
33676590,Journal Article, , ,"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.",2021-03-07,The Lancet. Respiratory medicine,NCT04327388,Abstract,2020-03-28,2020-07-30,Interventional,Sarilumab COVID-19,Completed,Phase 3,Sanofi,NA,187,https://pubmed.ncbi.nlm.nih.gov/33676590,https://clinicaltrials.gov/ct2/show/NCT04327388,1,0,1,0,17,0,Argentina|Brazil|Canada|Chile|France|Germany|Israel|Italy|Japan|Russian Federation|Spain,0,sarilumab sar153191|placebo
33681731,Journal Article, , ,Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.,2021-04-02,EClinicalMedicine,NCT04354428,Abstract,2020-04-16,2020-12-31,Interventional,Treatment for COVID-19 in High-Risk Adult Outpatients,"Active, not recruiting",Phase 2/Phase 3,University of Washington,NA,145,https://pubmed.ncbi.nlm.nih.gov/33681731,https://clinicaltrials.gov/ct2/show/NCT04354428,1,0,1,0,6,1,United States,0,ascorbic acid|hydroxychloroquine sulfate|azithromycin|folic acid|lopinavir 200 mg / ritonavir 50 mg [kaletra]|lopinavir 200 mg|ritonavir 50 mg [kaletra]
33682678,Journal Article, , ,An open label trial of anakinra to prevent respiratory failure in COVID-19.,2021-03-08,eLife,NCT04357366,Abstract,2020-04-15,2022-04-15,Interventional,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),Recruiting,Phase 2,Hellenic Institute for the Study of Sepsis,NA,50,https://pubmed.ncbi.nlm.nih.gov/33682678,https://clinicaltrials.gov/ct2/show/NCT04357366,1,0,1,0,6,0,Greece,0,anakinra
33683342,"Journal Article|Research Support, Non-U.S. Gov't","Biomarkers|Inflammasomes|NLR Family, Pyrin Domain-Containing 3 Protein|NLRP3 protein, human|NA","Biomarkers|COVID-19|Case-Control Studies|Humans|Inflammasomes|Middle Aged|Myeloid Cells|NLR Family, Pyrin Domain-Containing 3 Protein|Prospective Studies|SARS-CoV-2|NA",Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity.,2021-03-16,Blood advances,NCT04385017,Abstract,2020-05-11,2021-06-12,Interventional,Role of Inflammasomes in COVID-19 Disease,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,327,https://pubmed.ncbi.nlm.nih.gov/33683342,https://clinicaltrials.gov/ct2/show/NCT04385017,1,0,1,0,0,0,France,0,covid-19 patients
33685502,Clinical Trial Protocol|Letter,Amides|Antiviral Agents|Drug Combinations|Pyrazines|lopinavir-ritonavir drug combination|Lopinavir|favipiravir|Ritonavir|NA,"Ambulatory Care|Amides|Antiviral Agents|COVID-19|Clinical Trials, Phase II as Topic|Double-Blind Method|Drug Combinations|Drug Therapy, Combination|Early Medical Intervention|Humans|Lopinavir|Pyrazines|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|United Kingdom|Viral Load|NA",Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.,2021-03-18,Trials,NCT04499677,Abstract,2020-09-24,2020-12-11,Interventional,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,Recruiting,Phase 2,"University College, London",NA,157,https://pubmed.ncbi.nlm.nih.gov/33685502,https://clinicaltrials.gov/ct2/show/NCT04499677,1,0,1,0,2,0,United Kingdom,0,favipiravir|lopinavir/ ritonavir|favipiravir placebo|lopinavir/ ritonavir placebo|lopinavir|ritonavir|ritonavir placebo
33688640,Preprint, , ,Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.,2021-03-30,Research square,NCT04362176,Abstract,2020-04-24,2021-04-30,Interventional,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Recruiting,Phase 3,Vanderbilt University Medical Center,NA,115,https://pubmed.ncbi.nlm.nih.gov/33688640,https://clinicaltrials.gov/ct2/show/NCT04362176,2,0,2,0,5,1,United States,0,pathogen reduced sars-cov-2 convalescent plasma|placebo
33691765,Clinical Trial Protocol|Letter,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|Heparin|NA","Anticoagulants|Blood Coagulation Disorders|COVID-19|Clinical Trials, Phase III as Topic|Fibrin Fibrinogen Degradation Products|Heparin|Heparin, Low-Molecular-Weight|Hospitalization|Humans|Intensive Care Units|Noninvasive Ventilation|Pragmatic Clinical Trials as Topic|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|NA",Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.,2021-03-18,Trials,NCT04362085,Abstract,2020-05-11,2022-03-31,Interventional,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,67,https://pubmed.ncbi.nlm.nih.gov/33691765,https://clinicaltrials.gov/ct2/show/NCT04362085,2,0,2,0,3,0,Canada,0,therapeutic anticoagulation
33704352,Journal Article, , ,Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.,2021-03-29,JAMA,NCT04436276,Abstract,2020-07-15,2021-12-03,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,9,https://pubmed.ncbi.nlm.nih.gov/33704352,https://clinicaltrials.gov/ct2/show/NCT04436276,3,0,3,0,9,1,United States|Belgium,0,ad26.cov2.s|placebo
33705727,Journal Article, , ,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.",2021-03-11,The Lancet. Infectious diseases,NCT04471519,Abstract,2020-07-15,2020-07-31,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,9,https://pubmed.ncbi.nlm.nih.gov/33705727,https://clinicaltrials.gov/ct2/show/NCT04471519,3,0,3,1,3,0,India,0,bbv152a - phase i|bbv152b - phase i|bbv152c - phase i|placebo - phase i|bbv152a - phase ii|bbv152b - phase ii
33707061,Journal Article, , ,A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.,2021-03-19,Vaccine,NCT04405076,Abstract,2020-05-29,2021-03-31,Interventional,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",Phase 2,"ModernaTX, Inc.",NA,12,https://pubmed.ncbi.nlm.nih.gov/33707061,https://clinicaltrials.gov/ct2/show/NCT04405076,1,0,1,1,5,1,United States,0,biological: mrna-1273|placebo|mrna-1273.351
33712920,Journal Article, , ,Detraining Effects on Musculoskeletal Parameters in Early Postmenopausal Osteopenic Women: 3-Month Follow-Up of the Randomized Controlled ACTLIFE Study.,2021-03-16,Calcified tissue international,NCT04420806,Abstract,2020-03-14,2020-07-30,Interventional,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Completed,N/A,University of Erlangen-NÃ¼rnberg Medical School,NA,142,https://pubmed.ncbi.nlm.nih.gov/33712920,https://clinicaltrials.gov/ct2/show/NCT04420806,1,0,1,0,3,0,Germany,0,hit-exercise|sham intervention
33715160,Journal Article, , ,Brief report: Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.,2021-03-22,Transfusion,NCT04546581,Abstract,2020-10-08,2021-07-31,Interventional,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),"Active, not recruiting",Phase 3,University of Minnesota,NA,50,https://pubmed.ncbi.nlm.nih.gov/33715160,https://clinicaltrials.gov/ct2/show/NCT04546581,1,0,1,0,4,1,United States|Denmark|Greece|Japan|Nigeria|Spain|United Kingdom,0,hyperimmune immunoglobulin to sars-cov-2 (hivig)|placebo|remdesivir
33716889,Journal Article, , ,Comparison Between Conventional Intervention and Non-immersive Virtual Reality in the Rehabilitation of Individuals in an Inpatient Unit for the Treatment of COVID-19: A Study Protocol for a Randomized Controlled Crossover Trial.,2021-03-16,Frontiers in psychology,NCT04537858,Abstract,2020-06-18,2020-08-20,Interventional,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,"Active, not recruiting",N/A,University of Sao Paulo,NA,214,https://pubmed.ncbi.nlm.nih.gov/33716889,https://clinicaltrials.gov/ct2/show/NCT04537858,1,0,1,0,0,0,Brazil,0,virtual reality therapy first|conventional therapy first
33723507,Journal Article, , ,Use of ivermectin in the treatment of Covid-19: A pilot trial.,2021-03-17,Toxicology reports,NCT04431466,Abstract,2020-07-01,2020-12-01,Interventional,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Recruiting,Phase 2,Universidade Federal de Sao Carlos,NA,215,https://pubmed.ncbi.nlm.nih.gov/33723507,https://clinicaltrials.gov/ct2/show/NCT04431466,1,0,1,0,1,0,Brazil,0,ivermectin|standard treatment for covid-19
33725432,Journal Article, , ,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.,2021-03-16,The New England journal of medicine,NCT04444674,Abstract,2020-06-24,2020-12-31,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,131,https://pubmed.ncbi.nlm.nih.gov/33725432,https://clinicaltrials.gov/ct2/show/NCT04444674,3,0,3,1,4,0,South Africa,0,chadox1 ncov-19|normal saline 0.9%
33726804,Clinical Trial Protocol|Letter,Antiviral Agents|MDV 3100|Phenylthiohydantoin|NA,"Antiviral Agents|COVID-19|Clinical Trials, Phase II as Topic|Female|Host-Pathogen Interactions|Humans|Male|Middle Aged|Multicenter Studies as Topic|Phenylthiohydantoin|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|Sweden|Time Factors|Treatment Outcome|Virus Internalization|NA","COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial.",2021-03-25,Trials,NCT04475601,Abstract,2020-07-15,2021-07-08,Interventional,Enzalutamide Treatment in COVID-19,Recruiting,Phase 2,VÃ¤sterbotten County Council,NA,261,https://pubmed.ncbi.nlm.nih.gov/33726804,https://clinicaltrials.gov/ct2/show/NCT04475601,1,0,1,0,0,0,Sweden,0,enzalutamide pill
33734299,Journal Article, , ,"Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.",2021-03-18,JAMA,NCT04486508,Abstract,2020-07-30,2021-04-07,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Recruiting,Phase 3,Rajaie Cardiovascular Medical and Research Center,NA,58,https://pubmed.ncbi.nlm.nih.gov/33734299,https://clinicaltrials.gov/ct2/show/NCT04486508,1,1,2,0,6,0,"Iran, Islamic Republic of",0,intermediate dose enoxaparin/ unfractionated heparin|standard prophylactic dose enoxaparin/ unfractionated heparin|atorvastatin 20mg|matched placebo|intermediate dose enoxaparin|unfractionated heparin|standard prophylactic dose enoxaparin
33743799,Clinical Trial Protocol|Journal Article, ,"COVID-19|Hospitalization|Host-Pathogen Interactions|Humans|Immunization, Passive|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|SARS-CoV-2|Time Factors|Treatment Outcome|United States|NA",Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.,2021-03-25,Trials,NCT04362176,Abstract,2020-04-24,2021-04-30,Interventional,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Recruiting,Phase 3,Vanderbilt University Medical Center,NA,115,https://pubmed.ncbi.nlm.nih.gov/33743799,https://clinicaltrials.gov/ct2/show/NCT04362176,2,0,2,0,5,1,United States,0,pathogen reduced sars-cov-2 convalescent plasma|placebo
33750432,Clinical Trial Protocol|Journal Article,"Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Immunoglobulin G|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|NA","Animals|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|COVID-19|Clinical Trials, Phase II as Topic|Double-Blind Method|Humans|Immunization, Passive|Immunoglobulin G|Oxygen Inhalation Therapy|Randomized Controlled Trials as Topic|SARS-CoV-2|Severity of Illness Index|Spike Glycoprotein, Coronavirus|Swine|Time Factors|NA","Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.",2021-03-29,Trials,NCT04453384,Abstract,2020-09-01,2020-12-31,Interventional,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,Recruiting,Phase 2,Nantes University Hospital,NA,121,https://pubmed.ncbi.nlm.nih.gov/33750432,https://clinicaltrials.gov/ct2/show/NCT04453384,1,0,1,0,2,0,France,0,xav-19|placebo
33752741,Clinical Trial Protocol|Journal Article,Antiviral Agents|Drug Combinations|lopinavir-ritonavir drug combination|Lopinavir|Ritonavir|NA,Antiviral Agents|COVID-19|Drug Combinations|Hospitalization|Humans|Lopinavir|Post-Exposure Prophylaxis|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|NA,Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.,2021-03-29,Trials,NCT04321174,Abstract,2020-04-17,2021-03-31,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,351,https://pubmed.ncbi.nlm.nih.gov/33752741,https://clinicaltrials.gov/ct2/show/NCT04321174,3,0,3,0,1,0,Canada,0,lopinavir/ritonavir|lopinavir|ritonavir
33754144,Journal Article, , ,"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.",2021-03-24,The Lancet. Rheumatology,NCT04399980,Abstract,2020-05-20,2021-05-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Phase 2,The Cleveland Clinic,NA,182,https://pubmed.ncbi.nlm.nih.gov/33754144,https://clinicaltrials.gov/ct2/show/NCT04399980,1,0,1,0,3,1,United States,0,mavrilimumab|placebos
33754144,Journal Article, , ,"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.",2021-03-24,The Lancet. Rheumatology,NCT04463004,Abstract,2020-09-02,2021-08-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Phase 2,Virginia Commonwealth University,NA,46,https://pubmed.ncbi.nlm.nih.gov/33754144,https://clinicaltrials.gov/ct2/show/NCT04463004,1,0,1,0,4,1,United States,0,mavrilimumab|placebos
33754144,Journal Article, , ,"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.",2021-03-24,The Lancet. Rheumatology,NCT04492514,Abstract,2020-05-20,2021-05-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Recruiting,Phase 2,University of Cincinnati,NA,249,https://pubmed.ncbi.nlm.nih.gov/33754144,https://clinicaltrials.gov/ct2/show/NCT04492514,1,0,1,0,0,1,United States,0,mavrilimumab|placebo
33767713,Journal Article, , ,"Blood Interferon-Î± Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients.",2021-03-30,Frontiers in immunology,NCT04343053,Abstract,2020-04-08,2020-06-09,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,NA,298,https://pubmed.ncbi.nlm.nih.gov/33767713,https://clinicaltrials.gov/ct2/show/NCT04343053,3,0,3,0,2,0,Italy,0,sars-cov-2 infection
33773111,Journal Article, , ,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.",2021-03-29,The Lancet. Infectious diseases,NCT04466085,Abstract,2020-07-12,2020-10-22,Interventional,Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 2,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,123,https://pubmed.ncbi.nlm.nih.gov/33773111,https://clinicaltrials.gov/ct2/show/NCT04466085,1,0,1,1,2,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|recombinant new coronavirus vaccine (cho cells) placebo group
33773111,Journal Article, , ,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.",2021-03-29,The Lancet. Infectious diseases,NCT04445194,Abstract,2020-06-22,2020-10-22,Interventional,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,123,https://pubmed.ncbi.nlm.nih.gov/33773111,https://clinicaltrials.gov/ct2/show/NCT04445194,1,0,1,1,3,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|recombinant new coronavirus vaccine (cho cells) placebo group
33783269,Journal Article, , ,Right Ventricular Strain Is Common in Intubated COVID-19 Patients and Does Not Reflect Severity of Respiratory Illness.,2021-03-30,Journal of intensive care medicine,NCT04306393,Abstract,2020-03-21,2021-03-21,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Phase 2,Massachusetts General Hospital,NA,267,https://pubmed.ncbi.nlm.nih.gov/33783269,https://clinicaltrials.gov/ct2/show/NCT04306393,2,0,2,0,7,1,United States,0,nitric oxide gas
29264361,Journal Article|Review, , ,Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies.,2020-10-01,Annals of translational medicine,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/29264361,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
29619244,Journal Article, , ,Antiviral effects of ferric ammonium citrate.,2020-09-29,Cell discovery,NCT04333550,Registry,2020-04-30,2020-09-30,Interventional,Application of Desferal to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,338,https://pubmed.ncbi.nlm.nih.gov/29619244,https://clinicaltrials.gov/ct2/show/NCT04333550,0,17,17,0,2,0,"Iran, Islamic Republic of",0,deferoxamine
29772761,Journal Article, , ,High Concentrations of Sodium Chloride Improve Microbicidal Activity of Ibuprofen against Common Cystic Fibrosis Pathogens.,2020-10-01,"Pharmaceuticals (Basel, Switzerland)",NCT04382768,Registry,2020-05-01,2021-01-31,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,N/A,QuÃ­mica Luar SRL,NA,297,https://pubmed.ncbi.nlm.nih.gov/29772761,https://clinicaltrials.gov/ct2/show/NCT04382768,0,3,3,0,3,0,Argentina,0,inhaled hypertonic ibuprofen
30206520,Journal Article, , ,The acceptability of an online intervention using positive psychology for depression: A qualitative study.,2020-09-30,Internet interventions,NCT04468893,Registry,2020-05-20,2020-12-31,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,151,https://pubmed.ncbi.nlm.nih.gov/30206520,https://clinicaltrials.gov/ct2/show/NCT04468893,1,5,6,0,1,0,Mexico,0,online intervention mental health covid-19
30505605,Journal Article, , ,Haemodynamic Response to Four Different Laryngoscopes.,2020-10-01,Turkish journal of anaesthesiology and reanimation,NCT04424953,Registry,2020-06-01,2020-09-25,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,Completed,N/A,Singapore General Hospital,NA,18,https://pubmed.ncbi.nlm.nih.gov/30505605,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,3,0,Singapore,0,mcgrath videolaryngoscope|direct laryngoscope
30958989,Journal Article|Review, , ,Optimizing Post-Intensive Care Unit Rehabilitation.,2020-09-28,Turkish thoracic journal,NCT04482634,Registry,2020-09-01,2022-08-31,Interventional,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,N/A,KoÃ§ University,NA,150,https://pubmed.ncbi.nlm.nih.gov/30958989,https://clinicaltrials.gov/ct2/show/NCT04482634,0,10,10,0,1,0,Turkey,0,remote controlled exercise|home exercise
30976418,Journal Article, , ,Clinical characteristics and outcomes of patients with severe acute respiratory infections (SARI): results from the Egyptian surveillance study 2010-2014.,2020-09-30,Multidisciplinary respiratory medicine,NCT04359095,Registry,2020-08-18,2021-02-28,Interventional,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Phase 2/Phase 3,Universidad Nacional de Colombia,NA,58,https://pubmed.ncbi.nlm.nih.gov/30976418,https://clinicaltrials.gov/ct2/show/NCT04359095,0,21,21,0,2,0,Colombia,0,emtricitabine/tenofovir|colchicine pill|rosuvastatin|standard treatment|emtricitabine|tenofovir
31282542,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural",Biomarkers|Phosphodiesterase Inhibitors|Dipyridamole|NA,Adolescent|Adult|Biomarkers|Chronic Disease|Dipyridamole|Double-Blind Method|HIV Infections|HIV-1|Humans|Inflammation|Middle Aged|Phosphodiesterase Inhibitors|Pilot Projects|Young Adult|NA,"A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.",2021-02-05,The Journal of infectious diseases,NCT04410328,Registry,2020-10-21,2021-03-15,Interventional,Aggrenox To Treat Acute Covid-19,Recruiting,Phase 3,"Rutgers, The State University of New Jersey",NA,164,https://pubmed.ncbi.nlm.nih.gov/31282542,https://clinicaltrials.gov/ct2/show/NCT04410328,0,5,5,0,4,1,United States,0,dipyridamole er 200mg/ aspirin 25mg orally/enterally/standard of care|standard of care|dipyridamole er 200mg|aspirin 25mg orally|enterally
31346914,Journal Article, , ,The diagnostic accuracy for ARDS of global versus regional lung ultrasound scores - a post hoc analysis of an observational study in invasively ventilated ICU patients.,2020-09-30,Intensive care medicine experimental,NCT04338568,Registry,2020-04-16,2020-11-30,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,N/A,Hasselt University,NA,232,https://pubmed.ncbi.nlm.nih.gov/31346914,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,0,3,0,Belgium,0,lung ultrasound
31606437,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Aged|Canada|Disease Transmission, Infectious|Female|Graft Survival|Hepacivirus|Hepatitis C|Humans|Lung|Lung Transplantation|Male|Middle Aged|Perfusion|Pilot Projects|Proof of Concept Study|Prospective Studies|Tissue Donors|Transplants|Treatment Outcome|Viremia|NA","Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.",2020-08-24,The Lancet. Respiratory medicine,NCT04642326,Registry,2020-06-26,2020-07-01,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",N/A,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,134,https://pubmed.ncbi.nlm.nih.gov/31606437,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,0,0,0,Turkey,0,test group: experimental - uvc therapy applied
31682582,Journal Article, ,"Adolescent|Aged|Aged, 80 and over|Arizona|Cross-Sectional Studies|Female|Humans|Male|Meditation|Middle Aged|Mobile Applications|Patients|Surveys and Questionnaires|NA","Characteristics and Usage Patterns Among 12,151 Paid Subscribers of the Calm Meditation App: Cross-Sectional Survey.",2020-09-15,JMIR mHealth and uHealth,NCT04374786,Registry,2020-05-15,2020-09-01,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,N/A,University of Arizona,NA,306,https://pubmed.ncbi.nlm.nih.gov/31682582,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,0,2,1,United States,0,calm meditation app
31762329,Journal Article,Indoles|Pyridones|Bleomycin|pirfenidone|nintedanib|NA,"Animals|Bleomycin|Disease Models, Animal|Extracellular Matrix|Female|Idiopathic Pulmonary Fibrosis|Indoles|Lung|Myofibroblasts|Pyridones|Sheep|NA",The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.,2020-05-26,Experimental lung research,NCT04282902,Registry,2020-02-04,2020-04-30,Interventional,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Recruiting,Phase 3,Tongji Hospital,NA,407,https://pubmed.ncbi.nlm.nih.gov/31762329,https://clinicaltrials.gov/ct2/show/NCT04282902,0,4,4,0,0,0,China,0,pirfenidone
31818628,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anticoagulants|Fibrinolytic Agents|Rivaroxaban|NA,Anticoagulants|Colorectal Neoplasms|Fibrinolytic Agents|Humans|Laparoscopy|Rivaroxaban|Venous Thromboembolism|NA,Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY.,2021-02-15,European journal of internal medicine,NCT04673214,Registry,2020-12-16,2021-02-02,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,106,https://pubmed.ncbi.nlm.nih.gov/31818628,https://clinicaltrials.gov/ct2/show/NCT04673214,0,6,6,0,3,0,Mexico,0,azithromycin / ivermectin / ribaroxaban / paracetamol|azithromycin / ribaroxaban / paracetamol|azithromycin|ivermectin|ribaroxaban|paracetamol
31930543,Journal Article,Methylene Blue|NA,"Blood Platelets|Blood Transfusion|Hemorrhagic Fever Virus, Crimean-Congo|Humans|Light|Methylene Blue|Nipah Virus|Plasma|SARS Virus|Ultraviolet Rays|Virus Inactivation|NA","Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.",2020-10-19,Vox sanguinis,NCT04642326,Registry,2020-06-26,2020-07-01,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",N/A,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,134,https://pubmed.ncbi.nlm.nih.gov/31930543,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,0,0,0,Turkey,0,test group: experimental - uvc therapy applied
31933547,Journal Article, , ,Application of Low Doses of Ionizing Radiation in Medical Therapies.,2020-09-30,Dose-response : a publication of International Hormesis Society,NCT04394182,Registry,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,322,https://pubmed.ncbi.nlm.nih.gov/31933547,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,ultra-low-dose radiotherapy|ventilatory support with oxygen therapy|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|low molecular weight heparin|corticosteroid injection|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam
31936284,Journal Article|Review, , ,The Use of Antimalarial Drugs against Viral Infection.,2020-09-30,Microorganisms,NCT04501965,Registry,2020-06-01,2020-08-30,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,241,https://pubmed.ncbi.nlm.nih.gov/31936284,https://clinicaltrials.gov/ct2/show/NCT04501965,0,19,19,0,1,0,Guinea,0,hydroxychloroquine/azithromycine|quinquina-stevia/azythromycin|4plants/azythromycin|hydroxychloroquine|azithromycine|quinquina-stevia|azythromycin|4plants
32031570,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Disease Transmission, Infectious|Female|Hospitalization|Humans|Lung|Male|Middle Aged|Pandemics|Pneumonia, Viral|Real-Time Polymerase Chain Reaction|Retrospective Studies|SARS-CoV-2|Tomography, X-Ray Computed|Vital Signs|Young Adult|NA","Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.",2020-09-22,JAMA,NCT04407689,Registry,2020-06-08,2021-07-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Phase 2,Revimmune,NA,80,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04407689,0,2,2,0,2,0,France,0,interleukin-7|placebo
32031570,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Disease Transmission, Infectious|Female|Hospitalization|Humans|Lung|Male|Middle Aged|Pandemics|Pneumonia, Viral|Real-Time Polymerase Chain Reaction|Retrospective Studies|SARS-CoV-2|Tomography, X-Ray Computed|Vital Signs|Young Adult|NA","Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.",2020-09-22,JAMA,NCT04442178,Registry,2020-09-15,2021-10-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Phase 2,Revimmune,NA,47,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04442178,0,4,4,0,2,1,United States,0,cyt107|placebo
32039812,Journal Article, , ,Cancer Patients' and Survivors' Perceptions of the Calm App: Cross-Sectional Descriptive Study.,2020-09-28,JMIR cancer,NCT04374786,Registry,2020-05-15,2020-09-01,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,N/A,University of Arizona,NA,306,https://pubmed.ncbi.nlm.nih.gov/32039812,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,0,2,1,United States,0,calm meditation app
32043986,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Glucocorticoids|Dexamethasone|NA,"Administration, Intravenous|Adult|Aged|Dexamethasone|Female|Glucocorticoids|Humans|Intensive Care Units|Male|Middle Aged|Respiration, Artificial|Respiratory Distress Syndrome|Severity of Illness Index|Treatment Outcome|NA","Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.",2020-09-30,The Lancet. Respiratory medicine,NCT04325061,Registry,2020-04-03,2020-06-19,Interventional,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,Phase 4,Dr. Negrin University Hospital,Lack of enrollment,60,https://pubmed.ncbi.nlm.nih.gov/32043986,https://clinicaltrials.gov/ct2/show/NCT04325061,1,2,3,0,8,0,Spain,0,dexamethasone
32091533,"Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|China|Communicable Disease Control|Coronavirus Infections|Disease Outbreaks|Humans|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|World Health Organization|NA",Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72â€¯314 Cases From the Chinese Center for Disease Control and Prevention.,2020-09-22,JAMA,NCT04353674,Registry,2020-04-28,2020-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,199,https://pubmed.ncbi.nlm.nih.gov/32091533,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control group|sledd with a l-mod
32091533,"Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|China|Communicable Disease Control|Coronavirus Infections|Disease Outbreaks|Humans|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|World Health Organization|NA",Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72â€¯314 Cases From the Chinese Center for Disease Control and Prevention.,2020-09-22,JAMA,NCT04366232,Registry,2020-08-19,2020-10-02,Interventional,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,Terminated,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,investigator decision,113,https://pubmed.ncbi.nlm.nih.gov/32091533,https://clinicaltrials.gov/ct2/show/NCT04366232,0,3,3,0,5,0,France,0,anakinra alone (stages 2b/3)|anakinra/ruxolitinib (overcome stage 3)|standard of care|anakinra alone (stages 2b|3)|anakinra|ruxolitinib (overcome stage 3)
32102726,Journal Article, , ,Expert Recommendations for Tracheal Intubation in Critically ill Patients with Noval Coronavirus Disease 2019.,2020-07-21,Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,NCT04424953,Registry,2020-06-01,2020-09-25,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,Completed,N/A,Singapore General Hospital,NA,18,https://pubmed.ncbi.nlm.nih.gov/32102726,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,3,0,Singapore,0,mcgrath videolaryngoscope|direct laryngoscope
32107577,Journal Article, ,"Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|COVID-19 Testing|China|Clinical Laboratory Techniques|Coronavirus Infections|Cough|Disease Progression|Female|Fever|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Tomography, X-Ray Computed|Young Adult|NA",Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2.,2020-04-03,European journal of nuclear medicine and molecular imaging,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32107577,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32125452,Letter, ,"Betacoronavirus|COVID-19|China|Coronavirus Infections|Female|Humans|Male|Pandemics|Pneumonia, Viral|Risk Assessment|Risk Factors|SARS-CoV-2|NA","Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.",2020-05-14,Intensive care medicine,NCT04353674,Registry,2020-04-28,2020-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,199,https://pubmed.ncbi.nlm.nih.gov/32125452,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control group|sledd with a l-mod
32125458,Journal Article, ,"COVID-19|Capacity Building|Coronavirus Infections|Health Personnel|Hospital Bed Capacity|Humans|Intensive Care Units|Pandemics|Personal Protective Equipment|Pneumonia, Viral|Surge Capacity|NA",COVID-19: a novel coronavirus and a novel challenge for critical care.,2020-05-14,Intensive care medicine,NCT04344951,Registry,2020-04-06,2021-04-01,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,309,https://pubmed.ncbi.nlm.nih.gov/32125458,https://clinicaltrials.gov/ct2/show/NCT04344951,0,3,3,0,1,0,Greece,0,unikinon (chloroquine phosphate) 200mg tablets
32129478,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural","Antibodies, Neutralizing|Antibodies, Viral|Ficusin|NA","Animals|Antibodies, Neutralizing|Antibodies, Viral|Blood Donors|Chlorocebus aethiops|Convalescence|Ebolavirus|Ficusin|Hemorrhagic Fever, Ebola|Humans|Immunity, Active|Immunization, Passive|Neutralization Tests|Plasma|Seroconversion|United States|Vero Cells|Viral Load|NA",Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.,2020-09-08,Transfusion,NCT04385043,Registry,2020-05-01,2020-10-15,Interventional,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,327,https://pubmed.ncbi.nlm.nih.gov/32129478,https://clinicaltrials.gov/ct2/show/NCT04385043,0,3,3,0,0,0,Italy,0,plasma hyperimmune|standard therapy
32140081,Journal Article|Review, , ,Low-Dose radiation therapy for benign pathologies.,2021-03-02,Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology,NCT04394182,Registry,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,322,https://pubmed.ncbi.nlm.nih.gov/32140081,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,ultra-low-dose radiotherapy|ventilatory support with oxygen therapy|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|low molecular weight heparin|corticosteroid injection|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam
32150618,"Journal Article|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|Chloroquine|NA,"Animals|Antiviral Agents|Betacoronavirus|COVID-19|Cell Line|Chlorocebus aethiops|Chloroquine|Coronavirus Infections|Hydroxychloroquine|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|Vero Cells|NA",In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).,2020-08-10,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32150618,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32159775,"Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't","RNA, Viral|NA","Adolescent|Adult|Aged|Betacoronavirus|Bronchoalveolar Lavage Fluid|Bronchoscopy|COVID-19|Child|Child, Preschool|China|Coronavirus Infections|Feces|Female|Gene Dosage|Genes, Viral|Humans|Male|Middle Aged|Nose|Open Reading Frames|Pandemics|Pharynx|Pneumonia, Viral|RNA, Viral|Real-Time Polymerase Chain Reaction|SARS-CoV-2|Sputum|Viral Load|Young Adult|NA",Detection of SARS-CoV-2 in Different Types of Clinical Specimens.,2020-09-23,JAMA,NCT04517162,Registry,2020-08-19,2021-02-19,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,49,https://pubmed.ncbi.nlm.nih.gov/32159775,https://clinicaltrials.gov/ct2/show/NCT04517162,0,31,31,0,3,0,Mexico,0,collagen-polyvinylpyrrolidone
32167524,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Age Factors|Aged|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Female|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Patient Care Planning|Pneumonia, Viral|Respiratory Distress Syndrome|Retrospective Studies|SARS-CoV-2|NA","Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.",2020-09-30,JAMA internal medicine,NCT04494724,Registry,2020-07-13,2020-12-31,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital System,NA,247,https://pubmed.ncbi.nlm.nih.gov/32167524,https://clinicaltrials.gov/ct2/show/NCT04494724,0,8,8,0,0,1,United States,0,clazakizumab|placebo
32167524,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Age Factors|Aged|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Female|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Patient Care Planning|Pneumonia, Viral|Respiratory Distress Syndrome|Retrospective Studies|SARS-CoV-2|NA","Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.",2020-09-30,JAMA internal medicine,NCT04353674,Registry,2020-04-28,2020-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,199,https://pubmed.ncbi.nlm.nih.gov/32167524,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control group|sledd with a l-mod
32171076,Journal Article,Fibrin Fibrinogen Degradation Products|fibrin fragment D|NA,"Adolescent|Adult|Age Factors|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|COVID-19 Testing|Cardiovascular Diseases|China|Clinical Laboratory Techniques|Cohort Studies|Comorbidity|Coronavirus Infections|Diabetes Complications|Disease Progression|Female|Fibrin Fibrinogen Degradation Products|Humans|Hypertension|Male|Middle Aged|Mortality|Organ Dysfunction Scores|Pandemics|Patient Care Planning|Patient Isolation|Pneumonia, Viral|Prognosis|Retrospective Studies|Risk Assessment|Risk Factors|SARS-CoV-2|Young Adult|NA","Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.",2020-04-03,"Lancet (London, England)",NCT04479202,Registry,2020-02-08,2020-04-18,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,258,https://pubmed.ncbi.nlm.nih.gov/32171076,https://clinicaltrials.gov/ct2/show/NCT04479202,0,3,3,0,0,0,China,0,berberine|montmorrillonite
32171740,Journal Article,Antiviral Agents|Chloroquine|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Drug Evaluation, Preclinical|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,2020-05-28,International journal of antimicrobial agents,NCT04340349,Registry,2020-05-11,2021-03-20,Interventional,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Early Phase 1,Instituto Nacional de Rehabilitacion,NA,81,https://pubmed.ncbi.nlm.nih.gov/32171740,https://clinicaltrials.gov/ct2/show/NCT04340349,0,4,4,0,2,0,Mexico,0,hydroxychloroquine sulfate|bromhexine 8 mg|hydroxychloroquine sulfate placebo|bromhexine 8 mg placebo
32171740,Journal Article,Antiviral Agents|Chloroquine|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Drug Evaluation, Preclinical|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,2020-05-28,International journal of antimicrobial agents,NCT04344951,Registry,2020-04-06,2021-04-01,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,309,https://pubmed.ncbi.nlm.nih.gov/32171740,https://clinicaltrials.gov/ct2/show/NCT04344951,0,3,3,0,1,0,Greece,0,unikinon (chloroquine phosphate) 200mg tablets
32173110,Journal Article|Systematic Review,Antimalarials|Chloroquine|NA,"Antimalarials|Betacoronavirus|COVID-19|China|Chloroquine|Clinical Trials as Topic|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|World Health Organization|NA",A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.,2020-05-22,Journal of critical care,NCT04384380,Registry,2020-04-01,2020-05-31,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,N/A,Taoyuan General Hospital,NA,246,https://pubmed.ncbi.nlm.nih.gov/32173110,https://clinicaltrials.gov/ct2/show/NCT04384380,0,5,5,0,1,0,Taiwan,0,hydroxychloroquine sulfate 200 mg [plaquenil]
32179124,Journal Article|Meta-Analysis|Systematic Review, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Cough|Fever|Hospitalization|Humans|Intensive Care Units|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA","Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.",2020-05-18,Travel medicine and infectious disease,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32179124,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32181795,Journal Article, , ,Coronavirus Disease 2019 (COVID-19) in Italy.,2020-09-16,JAMA,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32181795,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32187459,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Equipment and Supplies, Hospital|Health Care Rationing|Humans|Italy|Pandemics|Pneumonia, Viral|Resource Allocation|SARS-CoV-2|Triage|NA","Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line.",2020-05-18,The New England journal of medicine,NCT04353674,Registry,2020-04-28,2020-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,199,https://pubmed.ncbi.nlm.nih.gov/32187459,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control group|sledd with a l-mod
32190290,Journal Article, , ,SARS-CoV-2 and COVID-19: The most important research questions.,2020-09-28,Cell &amp; bioscience,NCT04516811,Registry,2020-09-21,2021-12-30,Interventional,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,South African National Blood Service,NA,191,https://pubmed.ncbi.nlm.nih.gov/32190290,https://clinicaltrials.gov/ct2/show/NCT04516811,0,1,1,0,2,0,South Africa,0,covid-19 convalescent plasma (ccp)/standard of care (soc)|standard of care (soc)/placebo|covid-19 convalescent plasma (ccp)|standard of care (soc)|placebo
32196083,Journal Article,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Cytokine Release Syndrome|Disease Progression|Humans|Hydroxychloroquine|Lymphocyte Activation|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|T-Lymphocytes|NA",COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.,2020-06-24,The Journal of antimicrobial chemotherapy,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32196083,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32199468,Letter|Comment,Antiviral Agents|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Disease Outbreaks|Feasibility Studies|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Use of antiviral drugs to reduce COVID-19 transmission.,2020-05-05,The Lancet. Global health,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32199468,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32205204,Clinical Trial|Journal Article,Hydroxychloroquine|Azithromycin|NA,"Adult|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA",Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.,2020-08-04,International journal of antimicrobial agents,NCT04344951,Registry,2020-04-06,2021-04-01,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,309,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04344951,0,3,3,0,1,0,Greece,0,unikinon (chloroquine phosphate) 200mg tablets
32205204,Clinical Trial|Journal Article,Hydroxychloroquine|Azithromycin|NA,"Adult|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA",Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.,2020-08-04,International journal of antimicrobial agents,NCT04384380,Registry,2020-04-01,2020-05-31,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,N/A,Taoyuan General Hospital,NA,246,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04384380,0,5,5,0,1,0,Taiwan,0,hydroxychloroquine sulfate 200 mg [plaquenil]
32205204,Clinical Trial|Journal Article,Hydroxychloroquine|Azithromycin|NA,"Adult|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA",Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.,2020-08-04,International journal of antimicrobial agents,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32209890,Journal Article,C-Reactive Protein|Oxygen|NA,"Adult|Aged|Aged, 80 and over|Betacoronavirus|C-Reactive Protein|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Oxygen|Pandemics|Pneumonia, Viral|Retrospective Studies|SARS-CoV-2|NA","Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.",2020-06-16,Chinese medical journal,NCT04353674,Registry,2020-04-28,2020-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,199,https://pubmed.ncbi.nlm.nih.gov/32209890,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control group|sledd with a l-mod
32209891,Journal Article, ,"Betacoronavirus|COVID-19|Clinical Protocols|Coronavirus Infections|Elective Surgical Procedures|Epidemics|Humans|Infectious Disease Transmission, Patient-to-Professional|Pandemics|Pneumonia, Viral|SARS-CoV-2|Surgery Department, Hospital|Surgical Procedures, Operative|United States|NA",Managing COVID-19 in Surgical Systems.,2020-07-01,Annals of surgery,NCT04392323,Registry,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,323,https://pubmed.ncbi.nlm.nih.gov/32209891,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,covid-19 pcr/serology|covid-19 pcr|serology
32213556,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Betacoronavirus|COVID-19|COVID-19 Testing|China|Clinical Laboratory Techniques|Coronavirus Infections|Female|Gastrointestinal Tract|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Risk Factors|SARS-CoV-2|NA","Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.",2020-05-13,Gut,NCT04479202,Registry,2020-02-08,2020-04-18,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,258,https://pubmed.ncbi.nlm.nih.gov/32213556,https://clinicaltrials.gov/ct2/show/NCT04479202,0,3,3,0,0,0,China,0,berberine|montmorrillonite
32215691,Evaluation Study|Journal Article, ,"Adult|Aged|Aged, 80 and over|Area Under Curve|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|ROC Curve|Retrospective Studies|SARS-CoV-2|Thorax|Tomography, X-Ray Computed|Vision, Ocular|NA",CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19).,2020-07-14,European radiology,NCT04338568,Registry,2020-04-16,2020-11-30,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,N/A,Hasselt University,NA,232,https://pubmed.ncbi.nlm.nih.gov/32215691,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,0,3,0,Belgium,0,lung ultrasound
32219428,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Glucocorticoids|Immunoglobulin G|Immunoglobulin M|Methylprednisolone|NA","Adult|Aged|Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Betacoronavirus|Blood Donors|COVID-19|Coronavirus Infections|Critical Illness|Female|Glucocorticoids|Humans|Immunization, Passive|Immunoglobulin G|Immunoglobulin M|Male|Methylprednisolone|Middle Aged|Organ Dysfunction Scores|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA",Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.,2020-09-23,JAMA,NCT04356482,Registry,2020-05-20,2020-11-30,Interventional,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,304,https://pubmed.ncbi.nlm.nih.gov/32219428,https://clinicaltrials.gov/ct2/show/NCT04356482,0,6,6,0,3,0,Mexico,0,convalescent plasma
32219428,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Glucocorticoids|Immunoglobulin G|Immunoglobulin M|Methylprednisolone|NA","Adult|Aged|Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Betacoronavirus|Blood Donors|COVID-19|Coronavirus Infections|Critical Illness|Female|Glucocorticoids|Humans|Immunization, Passive|Immunoglobulin G|Immunoglobulin M|Male|Methylprednisolone|Middle Aged|Organ Dysfunction Scores|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA",Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.,2020-09-23,JAMA,NCT04393727,Registry,2020-05-01,2020-09-30,Interventional,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Phase 2,"Azienda Ospedaliero, Universitaria Pisana","Study was stopped because the Promoter was changed and a new study on convalescent plasma
    promoted by AIFA was started in Italy.",145,https://pubmed.ncbi.nlm.nih.gov/32219428,https://clinicaltrials.gov/ct2/show/NCT04393727,0,1,1,0,2,0,Italy,0,convalescent plasma
32221979,Comparative Study|Letter, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Laryngoscopy|Mouth|Pandemics|Pneumonia, Viral|SARS-CoV-2|Video Recording|NA",Videolaryngoscopy increases 'mouth-to-mouth' distance compared with direct laryngoscopy.,2020-06-24,Anaesthesia,NCT04424953,Registry,2020-06-01,2020-09-25,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,Completed,N/A,Singapore General Hospital,NA,18,https://pubmed.ncbi.nlm.nih.gov/32221979,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,3,0,Singapore,0,mcgrath videolaryngoscope|direct laryngoscope
32222346,Journal Article|Published Erratum, , ,Corrigendum to &quot;Traditional Chinese medicine for COVID-19 treatment&quot; [Pharmacol. Res. 155 (2020) 104743].,2020-06-06,Pharmacological research,NCT04501965,Registry,2020-06-01,2020-08-30,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,241,https://pubmed.ncbi.nlm.nih.gov/32222346,https://clinicaltrials.gov/ct2/show/NCT04501965,0,19,19,0,1,0,Guinea,0,hydroxychloroquine/azithromycine|quinquina-stevia/azythromycin|4plants/azythromycin|hydroxychloroquine|azithromycine|quinquina-stevia|azythromycin|4plants
32223047,"Journal Article|Review|Research Support, Non-U.S. Gov't", , ,"Î²-1,3/1,6-Glucans and Immunity: State of the Art and Future Directions.",2021-01-29,Molecular nutrition &amp; food research,NCT04798677,Registry,2020-10-29,2021-04-30,Interventional,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,Recruiting,N/A,AB Biotek,NA,9,https://pubmed.ncbi.nlm.nih.gov/32223047,https://clinicaltrials.gov/ct2/show/NCT04798677,0,19,19,1,1,0,Spain,0,abbc1 immunoessential|placebo
32224769,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Diagnostic Techniques and Procedures|Humans|Infection Control|Intensive Care Units|Pandemics|Pneumonia, Viral|Practice Guidelines as Topic|Respiration, Artificial|SARS-CoV-2|Shock|NA",Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19).,2020-06-04,Critical care medicine,NCT04353674,Registry,2020-04-28,2020-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,199,https://pubmed.ncbi.nlm.nih.gov/32224769,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control group|sledd with a l-mod
32228825,Editorial,Interleukin-1|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Inflammation|Interleukin-1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.,2020-08-10,Journal of biological regulators and homeostatic agents,NCT04366089,Registry,2020-03-26,2020-10-30,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,NA,341,https://pubmed.ncbi.nlm.nih.gov/32228825,https://clinicaltrials.gov/ct2/show/NCT04366089,0,3,3,0,0,0,Italy,0,"oxygen-ozone therapy, probiotic supplementation/standard of care|sivomixx (200 billion)|azithromycin|hydroxychloroquine|oxygen-ozone therapy, probiotic supplementation|standard of care"
32234250,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't", ,"Adult|Anesthesia, Spinal|Anesthesiologists|Anesthetists|Betacoronavirus|COVID-19|China|Coronavirus Infections|Female|Humans|Male|Pandemics|Personal Protective Equipment|Pneumonia, Viral|Retrospective Studies|Risk|SARS-CoV-2|NA","Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study.",2020-05-20,British journal of anaesthesia,NCT04392323,Registry,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,323,https://pubmed.ncbi.nlm.nih.gov/32234250,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,covid-19 pcr/serology|covid-19 pcr|serology
32250280,"Journal Article|Research Support, N.I.H., Extramural", ,Adult|Aged|Cohort Studies|Communication|Cross-Sectional Studies|Female|Health Literacy|Humans|Information Seeking Behavior|Male|Middle Aged|Multilingualism|Surveys and Questionnaires|Urban Health|NA,The Use of Technology for Communicating With Clinicians or Seeking Health Information in a Multilingual Urban Cohort: Cross-Sectional Survey.,2020-11-05,Journal of medical Internet research,NCT04378738,Registry,2020-05-01,2020-05-07,Interventional,Social Media and Covid19 Pandemic,Enrolling by invitation,N/A,Acibadem University,NA,332,https://pubmed.ncbi.nlm.nih.gov/32250280,https://clinicaltrials.gov/ct2/show/NCT04378738,0,1,1,0,0,0,Turkey,0,survey
32250385,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adolescent|Adult|Age Distribution|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|Comorbidity|Coronavirus Infections|Critical Care|Critical Illness|Female|Hospital Mortality|Hospitalization|Humans|Intensive Care Units|Italy|Male|Middle Aged|Pandemics|Pneumonia, Viral|Positive-Pressure Respiration|Respiration, Artificial|Retrospective Studies|SARS-CoV-2|Sex Distribution|Young Adult|NA","Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.",2020-09-23,JAMA,NCT04360837,Registry,2020-05-06,2021-06-01,Interventional,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,N/A,Szeged University,NA,319,https://pubmed.ncbi.nlm.nih.gov/32250385,https://clinicaltrials.gov/ct2/show/NCT04360837,0,1,1,0,2,0,Hungary,0,alveolar recruitment
32253449,Journal Article|Published Erratum, , ,"Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.",2020-09-30,Intensive care medicine,NCT04494724,Registry,2020-07-13,2020-12-31,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital System,NA,247,https://pubmed.ncbi.nlm.nih.gov/32253449,https://clinicaltrials.gov/ct2/show/NCT04494724,0,8,8,0,0,1,United States,0,clazakizumab|placebo
32257537,Journal Article, , ,Transplantation of ACE2<sup>-</sup> Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.,2021-02-23,Aging and disease,NCT04361942,Registry,2020-05-01,2021-11-30,Interventional,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Phase 2,Red de Terapia Celular,NA,26,https://pubmed.ncbi.nlm.nih.gov/32257537,https://clinicaltrials.gov/ct2/show/NCT04361942,0,4,4,0,3,0,Spain,0,mesenchymal stromal cells|placebo
32257537,Journal Article, , ,Transplantation of ACE2<sup>-</sup> Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.,2021-02-23,Aging and disease,NCT04517162,Registry,2020-08-19,2021-02-19,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,49,https://pubmed.ncbi.nlm.nih.gov/32257537,https://clinicaltrials.gov/ct2/show/NCT04517162,0,31,31,0,3,0,Mexico,0,collagen-polyvinylpyrrolidone
32259322,Journal Article, ,"Adult|Betacoronavirus|COVID-19|China|Coronavirus Infections|Female|Genital Neoplasms, Female|Gynecologic Surgical Procedures|Hospitalization|Humans|Incidence|Male|Mass Screening|Medical Records|Middle Aged|Pandemics|Pneumonia, Viral|Postoperative Complications|Retrospective Studies|SARS-CoV-2|NA",Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records.,2020-06-23,The oncologist,NCT04392323,Registry,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,323,https://pubmed.ncbi.nlm.nih.gov/32259322,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,covid-19 pcr/serology|covid-19 pcr|serology
32259546,Case Reports|Journal Article, ,"Betacoronavirus|COVID-19|Contact Tracing|Coronavirus Infections|Cross Infection|Disease Transmission, Infectious|Female|Hong Kong|Hospitals|Humans|Infection Control|Middle Aged|Pandemics|Patients' Rooms|Pneumonia, Viral|SARS-CoV-2|NA",Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong.,2020-06-16,The Journal of hospital infection,NCT04392323,Registry,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,323,https://pubmed.ncbi.nlm.nih.gov/32259546,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,covid-19 pcr/serology|covid-19 pcr|serology
32282022,Journal Article|Review,Adrenal Cortex Hormones|Amides|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Antiviral Agents|Immunoglobulins|Immunologic Factors|Indoles|Pyrazines|Oseltamivir|Lopinavir|remdesivir|Adenosine Monophosphate|Ribavirin|Hydroxychloroquine|Azithromycin|Chloroquine|umifenovir|favipiravir|Ritonavir|Alanine|NA,"Adenosine Monophosphate|Adrenal Cortex Hormones|Alanine|Amides|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Antiviral Agents|Azithromycin|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Humans|Hydroxychloroquine|Immunoglobulins|Immunologic Factors|Indoles|Lopinavir|Oseltamivir|Pandemics|Pneumonia, Viral|Pyrazines|Ribavirin|Ritonavir|SARS-CoV-2|Withholding Treatment|NA",Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.,2020-09-23,JAMA,NCT04480593,Registry,2020-06-02,2020-08-30,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,187,https://pubmed.ncbi.nlm.nih.gov/32282022,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,0,1,0,Brazil,0,brazilian green propolis extract (epp-af)|standard care
32292899,Journal Article, , ,Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection.,2021-02-09,EClinicalMedicine,NCT04392323,Registry,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,323,https://pubmed.ncbi.nlm.nih.gov/32292899,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,covid-19 pcr/serology|covid-19 pcr|serology
32293834,Journal Article|Review,Amides|Antiviral Agents|Drug Combinations|Pyrazines|Thiazoles|lopinavir-ritonavir drug combination|Lopinavir|remdesivir|Adenosine Monophosphate|Hydroxychloroquine|Ivermectin|Chloroquine|favipiravir|Ritonavir|Alanine|nitazoxanide|NA,"Adenosine Monophosphate|Alanine|Amides|Antiviral Agents|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Drug Combinations|Humans|Hydroxychloroquine|Ivermectin|Lopinavir|Pandemics|Pneumonia, Viral|Pyrazines|Ritonavir|SARS-CoV-2|Thiazoles|NA",Antiviral treatment of COVID-19,2020-04-22,Turkish journal of medical sciences,NCT04392713,Registry,2020-04-15,2020-07-31,Interventional,Efficacy of Ivermectin in COVID-19,Recruiting,N/A,"Combined Military Hospital, Pakistan",NA,321,https://pubmed.ncbi.nlm.nih.gov/32293834,https://clinicaltrials.gov/ct2/show/NCT04392713,0,1,1,0,0,0,Pakistan,0,ivermectin 6 mg oral tablet (2 tablets)
32298251,Published Erratum, , ,"Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.",2021-01-11,MMWR. Morbidity and mortality weekly report,NCT04530617,Registry,2020-10-05,2021-04-30,Interventional,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,52,https://pubmed.ncbi.nlm.nih.gov/32298251,https://clinicaltrials.gov/ct2/show/NCT04530617,0,28,28,0,4,0,Mexico,0,camostat mesilate|artemisia annua leaf
32302438,Journal Article,Biomarkers|Inflammation Mediators|NA,"Adult|Aged|Betacoronavirus|Biomarkers|Blood Coagulation|COVID-19|Case-Control Studies|Coronavirus Infections|Host-Pathogen Interactions|Humans|Inflammation Mediators|Intensive Care Units|Middle Aged|Pandemics|Pneumonia, Viral|Predictive Value of Tests|SARS-CoV-2|Thrombelastography|Thrombophilia|Young Adult|NA",Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.,2020-07-15,Journal of thrombosis and haemostasis : JTH,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32302438,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32302462,Letter|Comment, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment.,2020-08-06,Journal of thrombosis and haemostasis : JTH,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32302462,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32303365,Journal Article,Antioxidants|Ascorbic Acid|NA,"Antioxidants|Ascorbic Acid|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19.,2020-05-21,Revista espanola de anestesiologia y reanimacion,NCT04366089,Registry,2020-03-26,2020-10-30,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,NA,341,https://pubmed.ncbi.nlm.nih.gov/32303365,https://clinicaltrials.gov/ct2/show/NCT04366089,0,3,3,0,0,0,Italy,0,"oxygen-ozone therapy, probiotic supplementation/standard of care|sivomixx (200 billion)|azithromycin|hydroxychloroquine|oxygen-ozone therapy, probiotic supplementation|standard of care"
32312790,Letter,Biomarkers|Leukocyte L1 Antigen Complex|NA,"Adult|Aged|Aged, 80 and over|Betacoronavirus|Biomarkers|COVID-19|Coronavirus Infections|Feces|Female|Humans|Inflammatory Bowel Diseases|Leukocyte L1 Antigen Complex|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Faecal calprotectin indicates intestinal inflammation in COVID-19.,2020-07-16,Gut,NCT04479202,Registry,2020-02-08,2020-04-18,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,258,https://pubmed.ncbi.nlm.nih.gov/32312790,https://clinicaltrials.gov/ct2/show/NCT04479202,0,3,3,0,0,0,China,0,berberine|montmorrillonite
32313880,Journal Article|Review, , ,PAK1-blockers: Potential Therapeutics against COVID-19.,2021-01-10,Medicine in drug discovery,NCT04480593,Registry,2020-06-02,2020-08-30,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,187,https://pubmed.ncbi.nlm.nih.gov/32313880,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,0,1,0,Brazil,0,brazilian green propolis extract (epp-af)|standard care
32314249,Journal Article,Anti-Retroviral Agents|Immunosuppressive Agents|Hydroxychloroquine|NA,"Adult|Anti-Retroviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Cough|Dyspnea|Fatigue|Female|Fever|Gastric Bypass|Humans|Hydroxychloroquine|Immunosuppressive Agents|Iran|Male|Middle Aged|Off-Label Use|Pandemics|Patient Readmission|Pneumonia, Viral|Postoperative Complications|SARS-CoV-2|NA",Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak.,2020-08-10,Obesity surgery,NCT04392323,Registry,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,323,https://pubmed.ncbi.nlm.nih.gov/32314249,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,covid-19 pcr/serology|covid-19 pcr|serology
32315809,Comparative Study|Journal Article, ,"Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|China|Clinical Laboratory Techniques|Coronavirus Infections|Diagnostic Tests, Routine|Female|Humans|Male|Middle Aged|Nasopharynx|Pandemics|Pneumonia, Viral|SARS-CoV-2|Young Adult|NA",Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously.,2020-05-20,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32315809,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32320517,Journal Article|Multicenter Study,Anticoagulants|NA,"Aged|Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Female|France|Host-Parasite Interactions|Humans|Incidence|Male|Middle Aged|Pandemics|Pneumonia, Viral|Pulmonary Embolism|Retrospective Studies|Risk Factors|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|Venous Thromboembolism|Venous Thrombosis|NA",High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.,2020-07-15,Journal of thrombosis and haemostasis : JTH,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32320517,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32322397,Journal Article|Review, , ,"Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.",2021-01-10,New microbes and new infections,NCT04673214,Registry,2020-12-16,2021-02-02,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,106,https://pubmed.ncbi.nlm.nih.gov/32322397,https://clinicaltrials.gov/ct2/show/NCT04673214,0,6,6,0,3,0,Mexico,0,azithromycin / ivermectin / ribaroxaban / paracetamol|azithromycin / ribaroxaban / paracetamol|azithromycin|ivermectin|ribaroxaban|paracetamol
32329246,Journal Article|Review,Fibrinolytic Agents|Tissue Plasminogen Activator|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Drug Repositioning|Fibrinolysis|Fibrinolytic Agents|Host-Pathogen Interactions|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombolytic Therapy|Tissue Plasminogen Activator|Treatment Outcome|NA",Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.,2020-07-15,Journal of thrombosis and haemostasis : JTH,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32329246,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32342871,Editorial|Comment, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?,2020-06-25,Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,NCT04394182,Registry,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,322,https://pubmed.ncbi.nlm.nih.gov/32342871,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,ultra-low-dose radiotherapy|ventilatory support with oxygen therapy|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|low molecular weight heparin|corticosteroid injection|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam
32356900,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Airway Management|Australia|Betacoronavirus|COVID-19|Consensus|Coronavirus Infections|Female|Humans|Infection Control|Intubation, Intratracheal|Male|New Zealand|Pandemics|Pneumonia, Viral|Practice Guidelines as Topic|SARS-CoV-2|NA",Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.,2020-06-12,The Medical journal of Australia,NCT04424953,Registry,2020-06-01,2020-09-25,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,Completed,N/A,Singapore General Hospital,NA,18,https://pubmed.ncbi.nlm.nih.gov/32356900,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,3,0,Singapore,0,mcgrath videolaryngoscope|direct laryngoscope
32356910,Journal Article|Systematic Review,"Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|NA","Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|COVID-19|Humans|Immunization, Passive|NA",Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.,2020-12-16,Journal of medical virology,NCT04488484,Registry,2020-07-01,2021-12-31,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,236,https://pubmed.ncbi.nlm.nih.gov/32356910,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,0,1,0,France,0,serology test follow-up
32360300,Journal Article|Review,Phytochemicals|NA,"Animals|Betacoronavirus|COVID-19|Coronavirus Infections|Coronavirus, Feline|Humans|Infectious bronchitis virus|Middle East Respiratory Syndrome Coronavirus|Pandemics|Phytochemicals|Pneumonia, Viral|Porcine epidemic diarrhea virus|SARS Virus|SARS-CoV-2|NA",Natural product-derived phytochemicals as potential agents against coronaviruses: A review.,2020-06-02,Virus research,NCT04480593,Registry,2020-06-02,2020-08-30,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,187,https://pubmed.ncbi.nlm.nih.gov/32360300,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,0,1,0,Brazil,0,brazilian green propolis extract (epp-af)|standard care
32361099,Letter, , ,The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19.,2021-01-19,Medical hypotheses,NCT04798677,Registry,2020-10-29,2021-04-30,Interventional,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,Recruiting,N/A,AB Biotek,NA,9,https://pubmed.ncbi.nlm.nih.gov/32361099,https://clinicaltrials.gov/ct2/show/NCT04798677,0,19,19,1,1,0,Spain,0,abbc1 immunoessential|placebo
32369666,Comparative Study|Journal Article,Anticoagulants|Biomarkers|Fibrin Fibrinogen Degradation Products|fibrin fragment D|NA,"Aged|Anticoagulants|Betacoronavirus|Biomarkers|COVID-19|Catheterization, Central Venous|Coronavirus Infections|Female|Fibrin Fibrinogen Degradation Products|Humans|Incidence|Intensive Care Units|Male|Middle Aged|Netherlands|Pandemics|Patients' Rooms|Pneumonia, Viral|Pulmonary Embolism|Retrospective Studies|Risk Factors|SARS-CoV-2|Thrombophilia|Thrombophlebitis|Venous Thromboembolism|Venous Thrombosis|NA",Incidence of venous thromboembolism in hospitalized patients with COVID-19.,2020-08-14,Journal of thrombosis and haemostasis : JTH,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32369666,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32373721,Journal Article, , ,Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.,2020-09-28,Clinical and translational radiation oncology,NCT04394182,Registry,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,322,https://pubmed.ncbi.nlm.nih.gov/32373721,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,ultra-low-dose radiotherapy|ventilatory support with oxygen therapy|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|low molecular weight heparin|corticosteroid injection|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam
32381426,Journal Article, ,"Adult|Aged|COVID-19|Coronavirus Infections|Cross Infection|Digestive System Surgical Procedures|Female|Hospital Departments|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Retrospective Studies|NA",Nosocomial infection with SARS-Cov-2Â within Departments of Digestive Surgery.,2020-07-06,Journal of visceral surgery,NCT04392323,Registry,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,323,https://pubmed.ncbi.nlm.nih.gov/32381426,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,covid-19 pcr/serology|covid-19 pcr|serology
32387623,Letter,Anticoagulants|NA,"Anticoagulants|Betacoronavirus|COVID-19|Cardiovascular Diseases|Comorbidity|Coronavirus Infections|Hemorrhage|Hospitalization|Humans|Length of Stay|Mortality|New York City|Outcome and Process Assessment, Health Care|Pandemics|Pneumonia, Viral|Respiration, Artificial|Risk Assessment|SARS-CoV-2|NA",Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.,2020-07-13,Journal of the American College of Cardiology,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32387623,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32395391,Journal Article, , ,Development of a rapid test kit for SARS-CoV-2: an example of product design.,2020-09-28,Bio-design and manufacturing,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32395391,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32396163,"Journal Article|Research Support, Non-U.S. Gov't|Validation Study", ,"Adult|Aged|Betacoronavirus|COVID-19|COVID-19 Testing|China|Clinical Laboratory Techniques|Cohort Studies|Coronavirus Infections|Critical Care|Critical Illness|Female|Hospitalization|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Risk Assessment|SARS-CoV-2|NA",Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19.,2020-10-02,JAMA internal medicine,NCT04517162,Registry,2020-08-19,2021-02-19,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,49,https://pubmed.ncbi.nlm.nih.gov/32396163,https://clinicaltrials.gov/ct2/show/NCT04517162,0,31,31,0,3,0,Mexico,0,collagen-polyvinylpyrrolidone
32401873,Journal Article|Randomized Controlled Trial, ,Anxiety Disorders|Cognitive Behavioral Therapy|Comorbidity|Humans|Trichotillomania|NA,Skin picking treatment with the Rothbaum cognitive behavioral therapy protocol: a randomized clinical trial.,2020-11-09,"Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)",NCT04522492,Registry,2020-08-11,2021-03-31,Interventional,Impact of COVID-19 on Mental Health of Patients With Skin Picking,"Active, not recruiting",N/A,Hospital de Clinicas de Porto Alegre,NA,72,https://pubmed.ncbi.nlm.nih.gov/32401873,https://clinicaltrials.gov/ct2/show/NCT04522492,0,2,2,0,1,0,Brazil,0,internet-based cognitive behavioral therapy|quality of life promotion
32404476,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adolescent|Adult|Aged|Aged, 80 and over|COVID-19|Coronavirus Infections|Cost of Illness|Critical Care|Female|France|Hospitalization|Humans|Immunity|Male|Middle Aged|Pandemics|Pneumonia, Viral|Quarantine|SARS Virus|Young Adult|NA",Estimating the burden of SARS-CoV-2 in France.,2020-07-16,"Science (New York, N.Y.)",NCT04488484,Registry,2020-07-01,2021-12-31,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,236,https://pubmed.ncbi.nlm.nih.gov/32404476,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,0,1,0,France,0,serology test follow-up
32404480,Evaluation Study|Letter,"Antigens, Viral|NA","Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Immunoassay|Nasopharynx|Pandemics|Pneumonia, Viral|Point-of-Care Testing|SARS-CoV-2|Sensitivity and Specificity|NA",Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs.,2020-08-04,Journal of clinical microbiology,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32404480,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32419926,Journal Article,"COVID-19 Vaccines|Receptors, Virus|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|ACE2 protein, human|Angiotensin-Converting Enzyme 2|NA","Angiotensin-Converting Enzyme 2|COVID-19|COVID-19 Vaccines|China|Humans|Receptors, Virus|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Viral Tropism|NA","Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.",2021-01-21,F1000Research,NCT04382768,Registry,2020-05-01,2021-01-31,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,N/A,QuÃ­mica Luar SRL,NA,297,https://pubmed.ncbi.nlm.nih.gov/32419926,https://clinicaltrials.gov/ct2/show/NCT04382768,0,3,3,0,3,0,Argentina,0,inhaled hypertonic ibuprofen
32422057,"Journal Article|Research Support, N.I.H., Extramural|Research Support, N.I.H., Intramural|Review", ,"Bayes Theorem|Betacoronavirus|COVID-19|Coronavirus Infections|False Negative Reactions|Humans|Pandemics|Pneumonia, Viral|Reproducibility of Results|Reverse Transcriptase Polymerase Chain Reaction|Risk Factors|SARS-CoV-2|NA",Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure.,2020-08-27,Annals of internal medicine,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32422057,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32437596,"Comparative Study|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't", ,"Aged|Aged, 80 and over|Autopsy|Betacoronavirus|COVID-19|Coronavirus Infections|Endothelium, Vascular|Female|Humans|Influenza A Virus, H1N1 Subtype|Influenza, Human|Lung|Male|Middle Aged|Neovascularization, Pathologic|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|Respiratory Insufficiency|SARS-CoV-2|Thrombosis|NA","Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.",2020-07-16,The New England journal of medicine,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32437596,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32445064,Journal Article,Anticoagulants|Heparin|NA,"Adult|Aged|Anticoagulants|Betacoronavirus|Blood Coagulation|Blood Coagulation Tests|COVID-19|Coronavirus Infections|Drug Monitoring|Drug Resistance|Female|Heparin|Host-Pathogen Interactions|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Pneumonia, Viral|Retrospective Studies|SARS-CoV-2|Thrombosis|Treatment Outcome|NA",Heparin resistance in COVID-19 patients in the intensive care unit.,2020-07-22,Journal of thrombosis and thrombolysis,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32445064,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32445440,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Adult|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Extracorporeal Membrane Oxygenation|Female|Humans|Kaplan-Meier Estimate|Male|Middle Aged|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Time Factors|Young Adult|NA",Remdesivir for the Treatment of Covid-19 - Final Report.,2020-12-01,The New England journal of medicine,NCT04647695,Registry,2020-11-20,2021-07-31,Interventional,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Phase 2,The University of Hong Kong,NA,115,https://pubmed.ncbi.nlm.nih.gov/32445440,https://clinicaltrials.gov/ct2/show/NCT04647695,0,2,2,0,2,0,Hong Kong,0,interferon beta-1b|remdesivir
32450344,"Clinical Trial, Phase II|Controlled Clinical Trial|Journal Article",Fibrin Fibrinogen Degradation Products|Platelet Aggregation Inhibitors|fibrin fragment D|Clopidogrel|Tirofiban|Aspirin|NA,"Aged|Aspirin|Betacoronavirus|COVID-19|Clopidogrel|Compassionate Use Trials|Coronavirus Infections|Female|Fibrin Fibrinogen Degradation Products|Humans|Hypoxia|Male|Middle Aged|Pandemics|Platelet Aggregation Inhibitors|Pneumonia, Viral|Proof of Concept Study|SARS-CoV-2|Thrombophilia|Tirofiban|NA","Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.",2020-07-20,Pharmacological research,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32450344,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32459672,Journal Article|Observational Study,Anticoagulants|Biomarkers|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Anticoagulants|Betacoronavirus|Biomarkers|COVID-19|Comorbidity|Coronavirus Infections|Critical Illness|Female|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombelastography|Thrombophilia|Venous Thromboembolism|Young Adult|NA",Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.,2020-09-02,Critical care medicine,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32459672,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32461699,Journal Article|Published Erratum, , ,Author Correction: Respiratory virus shedding in exhaled breath and efficacy of face masks.,2020-10-21,Nature medicine,NCT04454606,Registry,2020-05-01,2020-05-15,Interventional,The New Silicone N99 Half-Piece Respirator,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,277,https://pubmed.ncbi.nlm.nih.gov/32461699,https://clinicaltrials.gov/ct2/show/NCT04454606,0,1,1,0,0,0,Thailand,0,fit test|filtration test
32462179,Letter,Anticoagulants|Platelet Aggregation Inhibitors|Protective Agents|NA,"Adult|Aged|Anticoagulants|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Pandemics|Platelet Aggregation Inhibitors|Pneumonia, Viral|Propensity Score|Protective Agents|Protective Factors|Retrospective Studies|SARS-CoV-2|Survival Analysis|NA",Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.,2020-07-14,Blood,NCT04466670,Registry,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,269,https://pubmed.ncbi.nlm.nih.gov/32462179,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,unfractionated heparin|unfractionated heparin nebulized|acetylsalicylic acid|enoxaparin
32485618,Journal Article,"Antigens, Viral|NA","Adolescent|Adult|Aged|Aged, 80 and over|Animals|Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Child|Child, Preschool|Clinical Laboratory Techniques|Coronavirus Infections|Female|Humans|Immunoassay|Infant|Infant, Newborn|Male|Middle Aged|Nasopharynx|Pandemics|Pneumonia, Viral|SARS-CoV-2|Sensitivity and Specificity|Young Adult|NA",Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis.,2020-08-11,Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32485618,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32492293,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Hydroxychloroquine|NA,"Adult|Betacoronavirus|COVID-19|Canada|Coronavirus Infections|Double-Blind Method|Female|Humans|Hydroxychloroquine|Inhalation Exposure|Male|Middle Aged|Occupational Exposure|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|SARS-CoV-2|Treatment Failure|United States|NA",A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,2020-08-12,The New England journal of medicine,NCT04308668,Registry,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,262,https://pubmed.ncbi.nlm.nih.gov/32492293,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,9,1,United States|Canada,0,hydroxychloroquine|placebo
32497809,Evaluation Study|Journal Article, ,"Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|COVID-19 Testing|COVID-19 Vaccines|Child|Child, Preschool|Clinical Laboratory Techniques|Coronavirus Infections|Female|Humans|Infant|Male|Middle Aged|Nasopharynx|Pandemics|Pneumonia, Viral|SARS-CoV-2|Sensitivity and Specificity|Viral Load|Young Adult|NA",Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.,2020-11-02,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32497809,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32504944,Journal Article|Comment, , ,Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital.,2020-08-04,Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32504944,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32541583,Historical Article|Journal Article|Review, ,"COVID-19|China|Coronavirus Infections|Health Personnel|History, 21st Century|Humans|Infectious Disease Transmission, Patient-to-Professional|Pandemics|Pneumonia, Viral|NA","To Protect Health Care Workers Better, To Save More Lives With COVID-19.",2020-06-25,Anesthesia and analgesia,NCT04627467,Registry,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,143,https://pubmed.ncbi.nlm.nih.gov/32541583,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,0,0,Colombia,0,chloroquine
32542934,"Journal Article|Research Support, Non-U.S. Gov't|Review", ,"Adult|COVID-19|COVID-19 Testing|Diagnostic Tests, Routine|Emergency Service, Hospital|Female|Humans|Pandemics|Physical Examination|SARS-CoV-2|Tomography, X-Ray Computed|NA","Diagnosing COVID-19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases.",2020-12-21,Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32542934,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32577640,Preprint, , ,SARS-CoV2 Testing: The Limit of Detection Matters.,2020-09-28,bioRxiv : the preprint server for biology,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32577640,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32585619,Evaluation Study|Journal Article,"Antigens, Viral|NA","Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Immunoassay|Pandemics|Pneumonia, Viral|SARS-CoV-2|Sensitivity and Specificity|NA",Evaluation of rapid antigen test for detection of SARS-CoV-2 virus.,2020-08-11,Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32585619,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32595361,Journal Article, , ,Gut-lung axis and dysbiosis in COVID-19.,2020-09-28,Turkish journal of biology = Turk biyoloji dergisi,NCT04517422,Registry,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,48,https://pubmed.ncbi.nlm.nih.gov/32595361,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,6,0,Mexico,0,probiotics|placebo
32636214,"Journal Article|Research Support, Non-U.S. Gov't","Antigens, Viral|RNA, Viral|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Female|Humans|Immunoassay|Male|Middle Aged|Nucleic Acid Amplification Techniques|Pandemics|Pneumonia, Viral|RNA, Viral|SARS-CoV-2|Saliva|Sensitivity and Specificity|Specimen Handling|Young Adult|NA","Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19.",2020-09-08,Journal of clinical microbiology,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32636214,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32645713,Journal Article, , ,"Microbiota and Covid-19. Which came first, the chicken or the egg?",2020-09-01,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,NCT04517422,Registry,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,48,https://pubmed.ncbi.nlm.nih.gov/32645713,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,6,0,Mexico,0,probiotics|placebo
32646750,Journal Article,"RNA, Viral|NA","Adult|Betacoronavirus|COVID-19|COVID-19 Testing|Child|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Nasopharynx|Pandemics|Pneumonia, Viral|RNA, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|NA",How to perform a nasopharyngeal swab in adults and children in the COVID-19 era.,2020-09-10,"European annals of otorhinolaryngology, head and neck diseases",NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32646750,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32670091,Journal Article|Review, , ,The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?,2020-09-28,Frontiers in physiology,NCT04517422,Registry,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,48,https://pubmed.ncbi.nlm.nih.gov/32670091,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,6,0,Mexico,0,probiotics|placebo
32678530,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial,Anti-Infective Agents|Glucocorticoids|Dexamethasone|NA,"Administration, Oral|Aged|Aged, 80 and over|Anti-Infective Agents|COVID-19|Dexamethasone|Drug Therapy, Combination|Female|Glucocorticoids|Hospitalization|Humans|Injections, Intravenous|Kaplan-Meier Estimate|Length of Stay|Male|Odds Ratio|Oxygen Inhalation Therapy|Respiration, Artificial|United Kingdom|NA",Dexamethasone in Hospitalized Patients with Covid-19.,2021-03-01,The New England journal of medicine,NCT04381936,Registry,2020-03-19,2021-12-31,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,37,https://pubmed.ncbi.nlm.nih.gov/32678530,https://clinicaltrials.gov/ct2/show/NCT04381936,2,2,4,0,8,0,Indonesia|Nepal|United Kingdom,0,lopinavir-ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine|baricitinib|anakinra|dimethyl fumarate
32692185,"Journal Article|Research Support, N.I.H., Extramural",Antiviral Agents|Dideoxynucleosides|Viral Nonstructural Proteins|RNA-Dependent RNA Polymerase|Sofosbuvir|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Dideoxynucleosides|Humans|Pandemics|Pneumonia, Viral|RNA-Dependent RNA Polymerase|SARS-CoV-2|Sofosbuvir|Viral Nonstructural Proteins|NA","Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.",2020-11-30,Journal of proteome research,NCT04685512,Registry,2020-11-18,2021-04-01,Interventional,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Recruiting,Phase 2/Phase 3,"University Hospital, Caen",NA,100,https://pubmed.ncbi.nlm.nih.gov/32692185,https://clinicaltrials.gov/ct2/show/NCT04685512,0,5,5,0,0,0,France,0,tenofovir disoproxil/emtricitabine|tenofovir disoproxil|emtricitabine
32723665,Editorial, ,COVID-19|Humans|Recovery of Function|Respiratory Therapy|SARS-CoV-2|NA,Recovery after COVID-19: The potential role of pulmonary rehabilitation.,2021-01-13,Brazilian journal of physical therapy,NCT04514705,Registry,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,233,https://pubmed.ncbi.nlm.nih.gov/32723665,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise
32728349,Journal Article, , ,Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients.,2020-09-28,Biological procedures online,NCT04517422,Registry,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,48,https://pubmed.ncbi.nlm.nih.gov/32728349,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,6,0,Mexico,0,probiotics|placebo
32732744,Case Reports|Journal Article, ,"Aged|Betacoronavirus|COVID-19|Coronavirus Infections|Drainage, Postural|Exercise Therapy|Humans|Japan|Male|Pandemics|Pneumonia, Viral|Respiration, Artificial|Respiratory Therapy|SARS-CoV-2|Treatment Outcome|NA",Rehabilitation Therapy for a COVID-19 Patient Who Received Mechanical Ventilation in Japan.,2020-09-29,American journal of physical medicine &amp; rehabilitation,NCT04514705,Registry,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,233,https://pubmed.ncbi.nlm.nih.gov/32732744,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise
32733907,Journal Article, , ,Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.,2020-09-28,Frontiers in medicine,NCT04517422,Registry,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,48,https://pubmed.ncbi.nlm.nih.gov/32733907,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,6,0,Mexico,0,probiotics|placebo
32737507,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review", ,"Betacoronavirus|COVID-19|Coronavirus Infections|Exercise|Health Status|Humans|Pandemics|Pneumonia, Viral|Recovery of Function|SARS-CoV-2|NA",Systematic Review of Changes and Recovery in Physical Function and Fitness After Severe Acute Respiratory Syndrome-Related Coronavirus Infection: Implications for COVID-19 Rehabilitation.,2020-10-07,Physical therapy,NCT04514705,Registry,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,233,https://pubmed.ncbi.nlm.nih.gov/32737507,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise
32745548,Journal Article,Antiviral Agents|Protease Inhibitors|Viral Nonstructural Proteins|Quercetin|Cysteine Endopeptidases|Coronavirus 3C Proteases|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Catalytic Domain|Coronavirus 3C Proteases|Coronavirus Infections|Cysteine Endopeptidases|Drug Discovery|Humans|Molecular Docking Simulation|Pandemics|Pneumonia, Viral|Protease Inhibitors|Protein Conformation|Protein Unfolding|Quercetin|SARS-CoV-2|Viral Nonstructural Proteins|NA",Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.,2020-11-23,International journal of biological macromolecules,NCT04578158,Registry,2020-09-29,2021-04-28,Interventional,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Liaquat University of Medical & Health Sciences,NA,63,https://pubmed.ncbi.nlm.nih.gov/32745548,https://clinicaltrials.gov/ct2/show/NCT04578158,0,3,3,0,7,0,Pakistan,0,standard covid-19 care|quercetin phytosome
32747157,Journal Article|Review,Antiviral Agents|BCG Vaccine|Cytokines|NA,"Antiviral Agents|BCG Vaccine|Betacoronavirus|COVID-19|Cardiovascular Diseases|Coronavirus Infections|Cytokine Release Syndrome|Cytokines|Diabetes Mellitus|Humans|Hypertension|Middle East Respiratory Syndrome Coronavirus|Mycobacterium bovis|Pandemics|Pneumonia, Viral|Pulmonary Disease, Chronic Obstructive|Risk Factors|SARS-CoV-2|Severe Acute Respiratory Syndrome|Vaccination|NA",A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization.,2020-09-28,Cytokine &amp; growth factor reviews,NCT04753476,Registry,2020-06-08,2021-06-08,Interventional,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,Recruiting,Phase 2,Stem Cell and Cancer Research Indonesia,NA,47,https://pubmed.ncbi.nlm.nih.gov/32747157,https://clinicaltrials.gov/ct2/show/NCT04753476,0,2,2,0,1,0,Indonesia,0,injection of secretome-mscs|standard treatment of covid-19
32759457,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|England|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",An interdisciplinary approach to the management of critically ill patients during covid-19 pandemic; an experience of a university hospital in England.,2020-08-11,"Wiadomosci lekarskie (Warsaw, Poland : 1960)",NCT04514705,Registry,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,233,https://pubmed.ncbi.nlm.nih.gov/32759457,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise
32766458,Journal Article, , ,Occupational therapy: The key to unlocking locked-up occupations during the COVID-19 pandemic.,2020-09-28,Wellcome open research,NCT04514705,Registry,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,233,https://pubmed.ncbi.nlm.nih.gov/32766458,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise
32780788,Journal Article, , ,Gut microbiota and COVID-19: A superfluous diagnostic biomarker or therapeutic target?,2020-09-01,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,NCT04517422,Registry,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,48,https://pubmed.ncbi.nlm.nih.gov/32780788,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,6,0,Mexico,0,probiotics|placebo
32800855,Comparative Study|Journal Article|Validation Study, ,"Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Immunoenzyme Techniques|Luminescent Measurements|Nasal Cavity|Pandemics|Pneumonia, Viral|Real-Time Polymerase Chain Reaction|SARS-CoV-2|Sensitivity and Specificity|Viral Load|NA","Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients.",2020-10-28,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32800855,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32821939,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Hospitalization|Humans|Male|Middle Aged|Odds Ratio|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.,2020-09-29,JAMA,NCT04292730,Registry,2020-03-15,2020-04-29,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,NA,72,https://pubmed.ncbi.nlm.nih.gov/32821939,https://clinicaltrials.gov/ct2/show/NCT04292730,1,1,2,0,20,1,"Japan|United States|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard of care
32823866,Journal Article, , ,Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2.,2020-09-28,"Diagnostics (Basel, Switzerland)",NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32823866,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32845525,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review","Antigens, Viral|NA","Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|False Negative Reactions|False Positive Reactions|Humans|Pandemics|Pneumonia, Viral|Point-of-Care Systems|SARS-CoV-2|Sensitivity and Specificity|NA","Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.",2020-09-16,The Cochrane database of systematic reviews,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32845525,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32883593,"Clinical Trial, Phase II|Journal Article","Antibodies, Viral|Immunoglobulin G|Immunoglobulin M|NA","Adult|Aged|Antibodies, Viral|COVID-19|Female|Humans|Immunization, Passive|Immunoglobulin G|Immunoglobulin M|Male|Middle Aged|SARS-CoV-2|NA",SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma.,2020-12-21,Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,NCT04343261,Registry,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,193,https://pubmed.ncbi.nlm.nih.gov/32883593,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma
32951151,Journal Article, , ,Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective PhaseÂ II Clinical Trial.,2021-01-29,Infectious diseases and therapy,NCT04343261,Registry,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,193,https://pubmed.ncbi.nlm.nih.gov/32951151,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma
32960881,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Asymptomatic Diseases|Asymptomatic Infections|Betacoronavirus|COVID-19|Coronavirus Infections|Disease Progression|Humans|Mass Screening|Pandemics|Pneumonia, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|NA",Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.,2020-10-01,PLoS medicine,NCT04568356,Registry,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,169,https://pubmed.ncbi.nlm.nih.gov/32960881,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19
32992075,Clinical Trial Protocol|Journal Article,Anticoagulants|Enoxaparin|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Atorvastatin|NA,Anticoagulants|Atorvastatin|COVID-19|Critical Illness|Double-Blind Method|Enoxaparin|Humans|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Iran|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|Thrombosis|Time Factors|Treatment Outcome|Venous Thromboembolism|NA,Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.,2020-12-10,Thrombosis research,NCT04486508,Registry,2020-07-30,2021-04-07,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Recruiting,Phase 3,Rajaie Cardiovascular Medical and Research Center,NA,58,https://pubmed.ncbi.nlm.nih.gov/32992075,https://clinicaltrials.gov/ct2/show/NCT04486508,1,1,2,0,6,0,"Iran, Islamic Republic of",0,intermediate dose enoxaparin/ unfractionated heparin|standard prophylactic dose enoxaparin/ unfractionated heparin|atorvastatin 20mg|matched placebo|intermediate dose enoxaparin|unfractionated heparin|standard prophylactic dose enoxaparin
33001138,Journal Article|Multicenter Study|Randomized Controlled Trial,Hydroxychloroquine|NA,"Adult|COVID-19|Cross Infection|Double-Blind Method|Female|Hospitals, Urban|Humans|Hydroxychloroquine|Incidence|Male|Pennsylvania|Personnel, Hospital|Pre-Exposure Prophylaxis|SARS-CoV-2|NA",Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.,2021-02-05,JAMA internal medicine,NCT04329923,Registry,2020-04-09,2020-11-11,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,"Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
    pre-specificied futility analysis at planned second interim analysis",116,https://pubmed.ncbi.nlm.nih.gov/33001138,https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,0,7,1,United States,1,hydroxychloroquine sulfate 400 mg twice a day|hydroxychloroquine sulfate 600 mg twice a day|hydroxychloroquine sulfate 600 mg once a day|placebo oral tablet
33031652,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial,Antiviral Agents|Hydroxychloroquine|NA,"Aged|Aged, 80 and over|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Treatment Failure|NA",Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.,2020-12-01,The New England journal of medicine,NCT04381936,Registry,2020-03-19,2021-12-31,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,37,https://pubmed.ncbi.nlm.nih.gov/33031652,https://clinicaltrials.gov/ct2/show/NCT04381936,2,2,4,0,8,0,Indonesia|Nepal|United Kingdom,0,lopinavir-ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine|baricitinib|anakinra|dimethyl fumarate
33179911,Journal Article,"Angiotensin-Converting Enzyme Inhibitors|Polyphenols|Recombinant Proteins|Quercetin|Peptidyl-Dipeptidase A|ACE2 protein, human|Angiotensin-Converting Enzyme 2|NA",Angiotensin-Converting Enzyme 2|Angiotensin-Converting Enzyme Inhibitors|Enzyme Assays|Humans|Kinetics|Peptidyl-Dipeptidase A|Polyphenols|Quercetin|Recombinant Proteins|Temperature|NA,Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity.,2020-12-01,Journal of agricultural and food chemistry,NCT04578158,Registry,2020-09-29,2021-04-28,Interventional,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Liaquat University of Medical & Health Sciences,NA,63,https://pubmed.ncbi.nlm.nih.gov/33179911,https://clinicaltrials.gov/ct2/show/NCT04578158,0,3,3,0,7,0,Pakistan,0,standard covid-19 care|quercetin phytosome
33210302,"Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't","Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|Receptors, Interleukin-6|C-Reactive Protein|tocilizumab|NA","Aged|Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|C-Reactive Protein|COVID-19|Dose-Response Relationship, Drug|Drug Monitoring|Female|Fever|Humans|Male|Pneumonia, Viral|Receptors, Interleukin-6|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA",COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.,2021-03-01,Clinical pharmacology and therapeutics,NCT04331795,Registry,2020-04-04,2020-06-05,Interventional,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Completed,Phase 2,University of Chicago,NA,29,https://pubmed.ncbi.nlm.nih.gov/33210302,https://clinicaltrials.gov/ct2/show/NCT04331795,0,1,1,0,7,1,United States,0,tocilizumab
33215159,Journal Article, , ,Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection.,2021-03-17,"Function (Oxford, England)",NCT04721457,Registry,2021-01-03,2021-02-28,Interventional,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,Recruiting,Phase 4,King Abdulaziz University,NA,70,https://pubmed.ncbi.nlm.nih.gov/33215159,https://clinicaltrials.gov/ct2/show/NCT04721457,0,17,17,0,1,0,Saudi Arabia,0,distilled water|1% povidone iodine (pvp-i)|1.5% hydrogen peroxide (h2o2)|0.075% cetylpyridinium chloride (cpc)|0.1% sodium hypochlorite
33274176,Journal Article|Review, ,COVID-19|Coronavirus Infections|Humans|Mesenchymal Stem Cells|Pandemics|Respiratory Distress Syndrome|SARS-CoV-2|NA,Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.,2020-12-14,Analytical cellular pathology (Amsterdam),NCT04753476,Registry,2020-06-08,2021-06-08,Interventional,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,Recruiting,Phase 2,Stem Cell and Cancer Research Indonesia,NA,47,https://pubmed.ncbi.nlm.nih.gov/33274176,https://clinicaltrials.gov/ct2/show/NCT04753476,0,2,2,0,1,0,Indonesia,0,injection of secretome-mscs|standard treatment of covid-19
33301246,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","COVID-19 Vaccines|Vaccines, Synthetic|mRNA Vaccine|BNT162 vaccine|NA","Adolescent|Adult|Aged|COVID-19|COVID-19 Vaccines|Fatigue|Female|Headache|Humans|Immunization, Secondary|Male|Middle Aged|SARS-CoV-2|Single-Blind Method|Treatment Outcome|Vaccines, Synthetic|Young Adult|NA",Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.,2021-01-12,The New England journal of medicine,NCT04798677,Registry,2020-10-29,2021-04-30,Interventional,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,Recruiting,N/A,AB Biotek,NA,9,https://pubmed.ncbi.nlm.nih.gov/33301246,https://clinicaltrials.gov/ct2/show/NCT04798677,0,19,19,1,1,0,Spain,0,abbc1 immunoessential|placebo
33390932,Journal Article|Review, , ,"The Therapeutic Potential of the Essential Oil of <i>Thymbra capitata</i> (L.) Cav., <i>Origanum dictamnus</i> L. and <i>Salvia fruticosa</i> Mill. And a Case of Plant-Based Pharmaceutical Development.",2021-01-05,Frontiers in pharmacology,NCT04705753,Registry,2020-04-01,2020-10-15,Interventional,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Completed,Phase 2/Phase 3,University of Crete,NA,82,https://pubmed.ncbi.nlm.nih.gov/33390932,https://clinicaltrials.gov/ct2/show/NCT04705753,0,4,4,0,0,0,Greece,0,cretan iama
33597143,"Journal Article|Research Support, Non-U.S. Gov't", ,"COVID-19|China|Cities|Cross-Sectional Studies|Humans|Humidity|Models, Theoretical|Retrospective Studies|SARS-CoV-2|Temperature|United States|NA",Impact of temperature and relative humidity on the transmission of COVID-19: a modelling study in China and the United States.,2021-02-25,BMJ open,NCT04798677,Registry,2020-10-29,2021-04-30,Interventional,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,Recruiting,N/A,AB Biotek,NA,9,https://pubmed.ncbi.nlm.nih.gov/33597143,https://clinicaltrials.gov/ct2/show/NCT04798677,0,19,19,1,1,0,Spain,0,abbc1 immunoessential|placebo
